The Recognition and Management of Early Psychosis

A Preventive Approach

Psychotic illness is managed and treated with best results when it is recognized at the earliest stages of a person developing the disorder, or when that person is identified as being at high risk of doing so. Describing a stage-specific model highlighting the risk, the clinical and biological factors present during the development of the illness, and the best treatments available for each of these stages, this new edition will guide practitioners and researchers in the adoption of carefully planned management strategies fully integrating treatment with prevention. Issues such as resistance to drugs and vocational recovery are covered, with related topics such as service organization and community education. This will be essential reading for all those involved in the care of people with early psychotic illness, or those responsible for the organization of services.


 Reviews:

"This is a superb book, and every clinician who encounters patients at risk for psychosis or suffering from first episode psychosis should be familiar with the material it presents."
--Doody's Review Service

'The Recognition and Management of Early Psychosis: A Preventive Approach (Second Edition) presents the field of early detection and early intervention in an interesting and informative format. … It is undoubtedly a comprehensive source of information with many references to guide further reading and may also be a useful teaching tool for college and university courses on this topic. … This book is a clear and approachable presentation of early detection and early intervention, and I recommend it strongly.' The Journal of Psychological Medicine

Reference Title: References

Reference Type: reference-list

International Early Psychosis Association Writing Group (2005). International clinical practice guidelines for early psychosis. British Journal of Psychiatry, 187(Suppl 48), s120–4.
McGorry, P. D. & Jackson, H. J. (eds.) (1999). The Recognition and Management of Early Psychosis: A Preventive Approach. Cambridge, UK: Cambridge University Press.
Mrazek, P. J. & Haggerty, R. J. (eds.) (1994). Reducing Risk for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, DC: National Academic Press.

Reference Title: References

Reference Type: reference-list

Andreasen, N. C. (1997). Linking mind and brain in the study of mental illnesses: a project for a scientific psychopathology. Science, 275, 1586–93.
Andreasen, N. C. (2007). DSM and the death of phenomenology in America: an example of unintended consequences. Schizophrenia Bulletin, 33, 108–12.
APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
APA Steering Committee on Practice Guidelines (eds.) (2002). American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders Compendium 2002. Washington, D.C: American Psychiatric Press.
Berk, M., Hallam, K., Lucas, N. et al. (2007). Early intervention in bipolar disorders: opportunities and pitfalls. Medical Journal of Australia, 187(Suppl), S11–14.
Birchwood, M. & Fiorillo, A. (2000). The critical period for early intervention. Psychiatric Rehabilitation Skills, 4, 182–98.
Birchwood, M., Todd, P. & Jackson, C. (1998). Early intervention in psychosis: the critical period hypothesis. British Journal of Psychiatry, 33(Suppl), s53–9.
Craig, T., Garety, P., Power, P. et al. (2004). Lambeth Early Onset Service: a randomised controlled trial. Schizophrenia Research, 70(Suppl), 145–6.
Eaton, W. W. (2001). The Sociology of Mental Disorders, 3rd edn. Westport, CT: Praeger.
Edwards, J., Francey, S. M., McGorry, P. D. & Jackson, H. J. (1996). Early psychosis prevention and intervention: evolution of a comprehensive community-based specialized service. Behavior Change, 11, 223–33.
Fava, G. A. & Kellner, R. (1993). Staging: a neglected dimension in psychiatric classification. Acta Psychiatrica Scandinavica, 87, 225–30.
Garety, P. A., Craig, T. K., Dunn, G. et al. (2006). Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. British Journal of Psychiatry, 188, 37–45.
Harrison, G., Hopper, K., Craig, T., et al. (2001). Recovery from psychotic illness: a 15-and 25-year international follow-up study. British Journal of Psychiatry, 178, 506–17.
Insel, T. R. & Fenton, W. S. (2005). Psychiatric epidemiology: it's not just about counting anymore. Archives of General Psychiatry, 62, 590–2.
International Early Psychosis Writing Group (2005). International clinical practice guidelines for early psychosis. British Journal of Psychiatry, 187(Suppl 48), s120–4.
Jackson, H. J. & McGorry, P. D. (2008). Psychiatric diagnoses: purposes, limitations and an alternative approach. In S. Wood, N. Allen & C. Pantelis (eds.), Handbook of Neuropsychology in Mental Illness. Cambridge, UK: Cambridge University Press, in press.
Johannessen, J. O., McGlashan, T. H., Larsen, T. K. et al. (2001). Early detection strategies for untreated first-episode psychosis. Schizophrenia Research, 51, 39–46.
Jones, S. E. (1984). The staging of Hodgkin's disease revisited. Medical Oncology and Tumor Pharmacotherapy, 1, 15–17.
Jorm, A. F. (2000). Mental health literacy: public knowledge and beliefs about mental disorders. British Journal of Psychiatry, 177, 396–401.
Kasimir-Bauer, S., Schleucher, N., Weber, R., Neumann, R. & Seeber, S. (2003). Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. Oncology Reports, 10, 475–82.
Kitchener, B. A. & Jorm, A. F. (2002). Mental health first aid training for the public: evaluation of effects on knowledge, attitudes and helping behaviour. BMC Psychiatry, 2, 10. http://www.biomedcentral.com/1471–244X/2/10.
Kraepelin, E. (1919). Dementia Praecox. New York: Churchill Livingstone.
Legorreta, A. P., Chernicoff, H. O., Trinh, J. B. & Parker, R. G. (2004). Diagnosis, clinical staging, and treatment of breast cancer: a retrospective multiyear study of a large controlled population. American Journal of Clinical Oncology, 27, 185–90.
Marshall, M., Lewis, S., Lockwood, A. et al. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry, 62, 975–93.
McCutcheon, L. K., Chanen, A. M., Fraser, R. J., Drew, L. & Brewer, W. (2007). Tips and techniques for engaging and managing the reluctant, resistant or hostile young person. Medical Journal of Australia, 187(Suppl), S64–7.
McGlashan, T. H., Zipursky, R. B., Perkins, D. et al. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry, 163, 790–9.
McGlashan, T. H., Addington, J., Cannon, T. et al. (2007). Recruitment and treatment practices for help-seeking ‘prodromal’ patients. Schizophrenia Bulletin, 33, 715–26.
McGorry, P. D. (2007a). The specialist youth mental health model: strengthening the weakest link in the public mental health system. Medical Journal of Australia, 187(Suppl), S53–6.
McGorry, P. D. (2007b). Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. American Journal of Psychiatry, 164, 859–60.
McGorry, P. D. & Jackson, H. J. (eds.) (1999). The Recognition and Management of Early Psychosis: A Preventive Approach. Cambridge, UK: Cambridge University Press.
McGorry, P. D., Copolov, D. L. & Singh, B. S. (1989). The validity of the assessment of psychopathology in the psychoses. Australian and New Zealand Journal of Psychiatry, 23, 469–82.
McGorry, P. D., Edwards, J., Mihalopoulos, C., Harrigan, S. M. & Jackson, H. J. (1996). EPPIC: an evolving system of early detection and optimal management. Schizophrenia Bulletin, 22, 305–26.
McGorry, P. D., Yung, A. & Phillips, L. (2001). Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophrenia Research, 51, 17–29.
McGorry, P. D., Yung, A. R., Phillips, L. J. et al. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59, 921–8.
McGorry, P., Killackey, E., Lambert, T. & Lambert, M. (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39, 1–30.
McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C. & Jackson, H. J. (2006). Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry, 40, 616–22.
McGorry, P., Killackey, E. & Yung, A. (2007). Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Medical Journal of Australia, 187(Suppl), S8–10.
Melle, I., Larsen, T. K., Haahr, U. et al. (2004). Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Archives of General Psychiatry, 61, 143–50.
Morrison, A. P., French, P., Walford, L. et al. (2004). Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. British Journal of Psychiatry, 185, 291–7.
Mrazek, P. J. & Haggerty, R. J. (eds.) (1994). Reducing Risk for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, DC: National Academic Press.
Nordentoft, M., Thorup, A., Petersen, L. et al. (2006). Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophrenia Research, 83, 29–40.
Patel, V., Flisher, A. J., Hetrick, S. & McGorry, P. (2007). Mental health of young people: a global public-health challenge. Lancet, 369, 1302–13.
Perkins, D. O., Gu, H., Boteva, K. & Lieberman, J. A. (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry, 162, 1785–804.
Petersen, L., Jeppesen, P., Thorup, A. et al. (2005a). A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. British Medical Journal, 331, 602–5.
Petersen, L., Nordentoft, M., Jeppesen, P. et al. (2005b). Improving 1-year outcome in first-episode psychosis: OPUS trial. British Journal of Psychiatry, 187(Suppl), s98–103.
Rice, D. & Barone, S. J. (2000). Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environmental Health Perspectives, 108(Suppl 3), S511–33.
Steinberg, L. (2005). Cognitive and affective development in adolescence. Trends in Cognitive Sciences, 9, 69–74.
van Os, J., Hanssen, M., Bijl, R. V. & Ravelli, A. (2000). Strauss (1969) revisited: a psychosis continuum in the general population? Schizophrenia Research, 45, 11–20.
Warner, R. (2005). Problems with early and very early intervention in psychosis. British Journal of Psychiatry, 187(Suppl), s104–7.
WHO (1992). International Statistical Classification of Diseases and Related Health Problems, Vol. 10 revision. Geneva: World Health Organization.
Wright, A., Harris, M. G., Wiggers, J. H. et al. (2005). Recognition of depression and psychosis by young Australians and their beliefs about treatment. Medical Journal of Australia, 183, 18–23.

Reference Title: References

Reference Type: reference-list

Abi-Dargham, A., Rodenhiser, R. J., Printz, D. et al. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences USA, 97, 8104–9.
Allin, M. & Murray, R. M. (2002). Schizophrenia: a neurodevelopmental or neurodegenerative disorder? Current Opinion in Psychiatry, 15, 9–15.
APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
Avramopoulos, D., Stefanis, N. C., Hantoumi, I. et al. (2002). Higher scores of self reported schizotypy in healthy young males carrying the COMT high activity allele. Molecular Psychiatry, 7, 706–11.
Badner, J. A. & Gershon, E. S. (2002). Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Molecular Psychiatry, 7, 405–11.
Bayer, T. A., Falkai, P. & Maier, W. (1999). Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the ‘two hit hypothesis’. Journal of Psychiatric Research, 33, 543–8.
Berger, G., Wood, S. & McGorry, P. (2003). Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacology Bulletin, 37, 79–101.
Bertolino, A., Caforio, G., Blasi, G. et al. (2004). Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. American Journal of Psychiatry, 161, 1798–805.
Bilder, R. M., Volavka, J., Czobor, P. et al. (2002). Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biological Psychiatry, 52, 701–7.
Blackwood, D. H., Fordyce, A., Walker, M. T. et al. (2001). Schizophrenia and affective disorders: cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. American Journal of Human Genetics, 69, 428–33.
Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S. et al. (2000). Patterns of brain activation in people at risk for Alzheimer's disease. New England Journal of Medicine, 343, 450–6.
Callicott, J. H., Straub, R. E., Pezawas, L. et al. (2005). Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proceedings of the National Academy of Sciences USA, 102, 8627–32.
Cannon, T., Huttunen, M., Lonnqvist, J. et al. (2000). The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. American Journal of Human Genetics, 67, 369–82.
Canoll, P. D., Kraemer, R., Teng, K. K., Marchionni, M. A. & Salzer, J. L. (1999). GGF/neuregulin induces a phenotypic reversion of oligodendrocytes. Molecular and Cellular Neuroscience, 13, 79–94.
Caspi, A., Moffitt, T. E., Cannon, M. et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry, 57, 1117–27.
Cassidy, F., Roche, S., Claffey, E. & McKeon, P. (2006). First family-based test for association of neuregulin with bipolar affective disorder. Molecular Psychiatry, 11, 706–7.
Chen, X., Wang, X., O'Neill, A. F., Walsh, D. & Kendler, K. S. (2004). Variants in the catechol-O-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Molecular Psychiatry, 9, 962–7.
Chowdari, K. V., Mirnics, K., Semwal, P. et al. (2002). Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Human Molecular Genetics, 11, 1373–80.
Chumakov, I., Blumenfeld, M., Guerassimenko, O. et al. (2002). Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proceedings of the National Academy of Sciences USA, 99, 13675–80.
Craddock, N., O'Donovan, M. C. & Owen, M. J. (2006). Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophrenia Bulletin, 32, 9–16.
Davis, K. L., Buchsbaum, M. S., Shihabuddin, L. et al. (1998). Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry, 43, 783–93.
Davis, K. L., Stewart, D. G., Friedman, J. I. et al. (2003). White matter changes in schizophrenia: evidence for myelin-related dysfunction. Archives of General Psychiatry, 60, 443–56.
Delisi, L. E. (1999a). Defining the course of brain structural change and plasticity in schizophrenia. Psychiatry Research, 92, 1–9.
Delisi, L. E. (1999b). Regional brain volume change over the lifetime course of schizophrenia. Journal of Psychiatric Research, 33, 535–41.
Delisi, L. E. (1999c). Structural brain changes in schizophrenia. Archives of General Psychiatry, 56, 195–6.
Detera-Wadleigh, S. D. & McMahon, F. J. (2006). G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biological Psychiatry, 60, 106–14.
Egan, M. F., Goldberg, T. E., Kolachana, B. S. et al. (2001a). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences USA, 98, 6917–22.
Egan, M. F., Goldberg, T. E., Gscheidle, T. et al. (2001b). Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biological Psychiatry, 50, 98–107.
Egan, M. F., Kojima, M., Callicott, J. H. et al. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 112, 257–69.
Egan, M. F., Straub, R. E., Goldberg, T. E. et al. (2004). Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proceedings of the National Academy of Sciences USA, 101, 12604–9.
Ekelund, J., Hovatta, I., Parker, A. et al. (2001). Chromosome 1 loci in Finnish schizophrenia families. Human Molecular Genetics, 10, 1611–17.
Falls, D. L. (2003). Neuregulins: functions, forms, and signaling strategies. Experimental Cell Research, 284, 14–30.
First, M. B., Spitzer, R. L., Gibbon, M. & Williams, J. B. W. (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, research version, patient edn (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.
Fraga, M. F., Ballestar, E., Paz, M. F. et al. (2005). Epigenetic differences arise during the lifetime of monozygotic twins. Proceedings of the National Academy of Sciences USA, 102, 10604–9.
Funke, B., Malhotra, A. K., Finn, C. T. et al. (2005). COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behavioral and Brain Functions, 1, 19–27.
Gallinat, J., Bajbouj, M., Sander, T. et al. (2003). Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biological Psychiatry, 54, 40–8.
Glatt, S. J., Faraone, S. V. & Tsuang, M. T. (2003). Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. American Journal of Psychiatry, 160, 469–76.
Goldberg, T. E., Torrey, E. F., Gold, J. M. et al. (1995). Genetic risk of neuropsychological impairment in schizophrenia: a study of monozygotic twins discordant and concordant for the disorder. Schizophrenia Research, 17, 77–84.
Goldberg, T. E., Egan, M. F., Gscheidle, T. et al. (2003). Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Archives of General Psychiatry, 60, 889–96.
Gottesman, I. I. & Gould, T. D. (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. American Journal of Psychiatry, 160, 1–10.
Gottesman, I. I. & Shields, J. (1967). A polygenic theory of schizophrenia. Proceedings of the National Academy of Sciences USA, 58, 199–205.
Green, E. K., Raybould, R., MacGregor, S. et al. (2005). Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Archives of General Psychiatry, 62, 642–8.
Gur, R. E., Cowell, P., Turetsky, B. I. et al. (1998). A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Archives of General Psychiatry, 55, 145–52.
Hakak, Y., Walker, J. R., Li, C. et al. (2001). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Sciences USA, 98, 4746–51.
Hall, D., Dhilla, A., Charalambous, A., Gogos, J. A. & Karayiorgou, M. (2003). Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. American Journal of Human Genetics, 73, 370–6.
Handoko, H. Y., Nyholt, D. R., Hayward, N. K. et al. (2005). Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Molecular Psychiatry, 10, 589–97.
Harrison, P. J. & Law, A. J. (2006). Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biological Psychiatry, 60, 132–40.
Harrison, P. J. & Weinberger, D. R. (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry, 10, 40–68.
Hashimoto, R., Straub, R. E., Weickert, C. S. et al. (2004). Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Molecular Psychiatry, 9, 299–307.
Hawi, Z., Straub, R. E., O'Neill, A. et al. (1998). No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families. Psychiatry Research, 81, 111–16.
Hennah, W., Varilo, T., Kestila, M. et al. (2003). Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Human Molecular Genetics, 12, 3151–9.
Herken, H. & Erdal, M. E. (2001). Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatric Genetics, 11, 105–9.
Hodgkinson, C. A., Goldman, D., Jaeger, J. et al. (2004). Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. American Journal of Human Genetics, 75, 862–72.
Holliday, E. G., Handoko, H. Y., James, M. R. et al. (2006). Association study of the dystrobrevin-binding gene with schizophrenia in Australian and Indian samples. Twin Research and Human Genetics, 9, 531–9.
Hong, C. J., Yu, Y. W., Lin, C. H. & Tsai, S. J. (2003). An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neuroscience Letters, 349, 206–8.
Hovatta, I., Lichtermann, D., Juvonen, H. et al. (1998). Linkage analysis of putative schizophrenia gene candidate regions on chromosomes 3p, 5q, 6p, 8p, 20p and 22q in a population-based sampled Finnish family set. Molecular Psychiatry, 3, 452–7.
Iritani, S., Niizato, K., Nawa, H., Ikeda, K. & Emson, P. C. (2003). Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 801–7.
Jablensky, A. (1999). The concept of schizophrenia: pro et contra. Epidemiologia e Psichiatria Sociale, 8, 242–7.
Jablonka, E. & Lamb, M. J. (2002). The changing concept of epigenetics. Annals of the New York Academy of Sciences, 981, 82–96.
Jacobsen, L. K., Giedd, J. N., Castellanos, F. X. et al. (1998). Progressive reduction of temporal lobe structures in childhood-onset schizophrenia. American Journal of Psychiatry, 155, 678–85.
Jones, G., Zammit, S., Norton, N. et al. (2001). Aggressive behaviour in patients with schizophrenia is associated with catechol-O-methyltransferase genotype. British Journal of Psychiatry, 179, 351–5.
Kendler, K. S. (2004). Schizophrenia genetics and dysbindin: a corner turned? American Journal of Psychiatry, 161, 1533–6.
Keshavan, M. S. (1999). Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. Journal of Psychiatric Research, 33, 513–21.
Kohn, Y., Danilovich, E., Filon, D. et al. (2004). Linkage disequilibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: findings from identity by descent haplotype sharing analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 128, 65–70.
Krebs, M. O., Guillin, O., Bourdell, M. C. et al. (2000). Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Molecular Psychiatry, 5, 558–62.
Kremer, I., Pinto, M., Murad, I. et al. (2003). Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. American Journal of Medical Genetics, 119B, 35–9.
Law, A. J., Shannon Weickert, C., Hyde, T. M., Kleinman, J. E. & Harrison, P. J. (2004). Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience, 127, 125–36.
Law, A. J., Lipska, B. K., Weickert, C. S. et al. (2006). Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. Proceedings of the National Academy of Sciences USA, 103, 6747–52.
Levinson, D. F., Holmans, P. A., Laurent, C. et al. (2002). No major schizophrenia locus detected on chromosome 1q in a large multicenter sample. Science, 296, 739–41.
Lewis, C. M., Levinson, D. F., Wise, L. H. et al. (2003). Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. American Journal of Human Genetics, 73, 34–48.
Lewis, D. A., Hashimoto, T. & Volk, D. W. (2005). Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience, 6, 312–24.
Lewis, M. A., Hunihan, L., Franco, D. et al. (2006). Identification and characterization of compounds that potentiate NT-3-mediated Trk receptor activity. Molecular Pharmacology, 69, 1396–404.
Li, D., Collier, D. A. & He, L. (2006). Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Human Molecular Genetics, 15, 1995–2002.
Lieberman, J., Chakos, M., Wu, H. et al. (2001). Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry, 49, 487–99.
Lipska, B. K., Mitkus, S., Caruso, M. et al. (2006a). RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity. Human Molecular Genetics, 15, 2804–12.
Lipska, B. K., Peters, T., Hyde, T. M. et al. (2006b). Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Human Molecular Genetics, 15, 1245–58.
Mathalon, D. H., Sullivan, E. V., Lim, K. O. & Pfefferbaum, A. (2001). Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Archives of General Psychiatry, 58, 148–57.
Meyer-Lindenberg, A. & Weinberger, D. R. (2006). Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nature Reviews Neuroscience, 7, 818–27.
Meyer-Lindenberg, A., Nichols, T., Callicott, J. H. et al. (2006a). Impact of complex genetic variation in COMT on human brain function. Molecular Psychiatry, 11, 867–77.
Meyer-Lindenberg, A., Mervis, C. B. & Berman, K. F. (2006b). Neural mechanisms in Williams' syndrome: a unique window to genetic influences on cognition and behaviour. Nature Reviews Neuroscience, 7, 380–93.
Mill, J., Dempster, E., Caspi, A. et al. (2006). Evidence for monozygotic twin (MZ) discordance in methylation level at two CpG sites in the promoter region of the catechol-O-methyltransferase (COMT) gene. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 141, 421–5.
Millar, J. K., Wilson-Annan, J. C., Anderson, S. et al. (2000). Disruption of two novel genes by a translocation co-segregating with schizophrenia. Human Molecular Genetics, 9, 1415–23.
Mirnics, K., Middleton, F. A., Stanwood, G. D., Lewis, D. A. & Levitt, P. (2001). Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Molecular Psychiatry, 6, 293–301.
Muglia, P., Vicente, A. M., Verga, M. et al. (2003). Association between the BDNF gene and schizophrenia. Molecular Psychiatry, 8, 146–7.
Munafo, M. R, Bowes, L., Clark, T. G. & Flint, J. (2005). Lack of association of the COMT (Val(158/108) Met) gene and schizophrenia: a meta–analysis of case–control studies. Molecular Psychiatry, 10, 765–70.
Murray, R. M. & Lewis, S. W. (1987). Is schizophrenia a neurodevelopmental disorder? British Medical Journal (Clinical Research Edition), 295, 681–2.
Murray, R. M., Jones, P. & O'Callaghan, E. (1991). Fetal brain development and later schizophrenia. Ciba Foundation Symposium, 156, 155–70.
Nanko, S., Kunugi, H., Hirasawa, H. et al. (2003). Brain-derived neurotrophic factor gene and schizophrenia: polymorphism screening and association analysis. Schizophrenia Research, 62, 281–3.
Neves-Pereira, M., Mundo, E., Muglia, P. et al. (2002). The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. American Journal of Human Genetics, 71, 651–5.
Nicodemus, K. K., Kolachana, B. S., Vakkalanka, R. et al. (2007). Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Human Genetics, 120, 889–906.
Norton, N., Williams, H. J. & Owen, M. J. (2006). An update on the genetics of schizophrenia. Current Opinion in Psychiatry, 19, 158–64.
Owen, M. J., Holmans, P. & McGuffin, P. (1997). Association studies in psychiatric genetics. Molecular Psychiatry, 2, 270–3.
Owen, M. J., Williams, N. M. & O'Donovan, M. C. (2004). The molecular genetics of schizophrenia: new findings promise new insights. Molecular Psychiatry, 9, 14–27.
Ozeki, Y., Tomoda, T., Kleiderlein, J. et al. (2003). Disrupted-in-schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proceedings of the National Academy of Sciences USA, 100, 289–94.
Pantelis, C., Velakoulis, D., McGorry, P. D. et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 361, 281–8.
Petronis, A., Gottesman, I. I., Kan, P. et al. (2003). Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophrenia Bulletin, 29, 169–78.
Prathikanti, S. & Weinberger, D. R. (2005). Psychiatric genetics – the new era: genetic research and some clinical implications. British Medical Bulletin, 73–74, 107–22.
Rapoport, J. L., Giedd, J., Kumra, S. et al. (1997). Childhood-onset schizophrenia. Progressive ventricular change during adolescence. Archives of General Psychiatry, 54, 897–903.
Raybould, R., Green, E. K., MacGregor, S. et al. (2005). Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biological Psychiatry, 57, 696–701.
Ribases, M., Gratacos, M., Armengol, L. et al. (2003). Met66 in the brain-derived neurotrophic factor (BDNF) precursor is associated with anorexia nervosa restrictive type. Molecular Psychiatry, 8, 745–51.
Risch, N. & Merikangas, K. (1996). The future of genetic studies of complex human diseases. Science, 273, 1516–17.
Rocchi, A., Pellegrini, S., Siciliano, G. & Murri, L. (2003). Causative and susceptibility genes for Alzheimer's disease: a review. Brain Research Bulletin, 61, 1–24.
Rybakowski, J. K., Borkowska, A., Czerski, P. M. & Hauser, J. (2002). Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene. Psychiatry Research, 113, 49–57.
Sanders, A. R., Rusu, I., Duan, J. et al. (2005). Haplotypic association spanning the 22q11.21 genes COMT and ARVCF with schizophrenia. Molecular Psychiatry, 10, 353–65.
Sasaki, T., Dai, X. Y., Kuwata, S. et al. (1997). Brain-derived neurotrophic factor gene and schizophrenia in Japanese subjects. American Journal of Medical Genetics, 74, 443–4.
Schwab, S. G., Knapp, M., Mondabon, S. et al. (2003). Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. American Journal of Human Genetics, 72, 185–90.
Seroogy, K. B., Lundgren, K. H., Tran, T. M. et al. (1994). Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. Journal of Comprehensive Neurology, 342, 321–34.
Shifman, S., Bronstein, M., Sternfeld, M. et al. (2002). A highly significant association between a COMT haplotype and schizophrenia. American Journal of Human Genetics, 71, 1296–302.
Shifman, S., Bronstein, M., Sternfeld, M. et al. (2004). COMT: a common susceptibility gene in bipolar disorder and schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 128, 61–4.
Slager, S. L. & Schaid, D. J. (2001). Evaluation of candidate genes in case–control studies: a statistical method to account for related subjects. American Journal of Human Genetics, 68, 1457–62.
Stefansson, H., Sigurdsson, E., Steinthorsdottir, V. et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics, 71, 877–92.
Stefansson, H., Sarginson, J., Kong, A. et al. (2003). Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. American Journal of Human Genetics, 72, 83–7.
Straub, R. E., Jiang, Y., MacLean, C. J. et al. (2002). Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. American Journal of Human Genetics, 71, 337–48.
Strous, R. D., Nolan, K. A., Lapidus, R. et al. (2003). Aggressive behaviour in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication study. American Journal of Medical Genetics, 120B, 29–34.
Sullivan, P. F., Kendler, K. S. & Neale, M. C. (2003). Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Archives of General Psychiatry, 60, 1187–92.
Szekeres, G., Juhasz, A., Rimanoczy, A., Keri, S. & Janka, Z. (2003). The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophrenia Research, 65, 15–18.
Takahashi, M., Shirakawa, O., Toyooka, K. et al. (2000). Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Molecular Psychiatry, 5, 293–300.
Talbot, K., Eidem, W. L., Tinsley, C. L. et al. (2004). Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 113, 1353–63.
Talkowski, M. E., Seltman, H., Bassett, A. S. et al. (2006). Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples. Biological Psychiatry, 60, 152–62.
Tang, J. X., Chen, W. Y., He, G. et al. (2004). Polymorphisms within 5′ end of the neuregulin 1 gene are genetically associated with schizophrenia in the Chinese population. Molecular Psychiatry, 9, 11–12.
Tochigi, M., Zhang, X., Ohashi, J. et al. (2006). Association study of the dysbindin (DTNBP1) gene in schizophrenia from the Japanese population. Neuroscience Research, 56, 45–7.
Tsai, S. J., Yu, Y. W., Chen, T. J. et al. (2003). Association study of a functional catechol-O-methyltransferase gene polymorphism and cognitive function in healthy females. Neuroscience Letters, 338, 123–6.
Tsuang, M. T., Stone, W. S., Tarbox, S. I. & Faraone, S. V. (2002). An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention. Schizophrenia Research, 54, 169–75.
van Os, J., Gilvarry, C., Bale, R. et al. (2000). Diagnostic value of the DSM and ICD categories of psychosis: an evidence-based approach. UK700 Group. Social Psychiatry and Psychiatric Epidemiology, 35, 305–11.
Velakoulis, D., Wood, S. J., McGorry, P. D. & Pantelis, C. (2000). Evidence for progression of brain structural abnormalities in schizophrenia: beyond the neurodevelopmental model. Australian and New Zealand Journal of Psychiatry, 34, 113–26.
Velakoulis, D., Stuart, G. W., Wood, S. J. et al. (2001). Selective bilateral hippocampal volume loss in chronic schizophrenia. Biological Psychiatry, 50, 531–9.
Ventriglia, M., Bocchio Chiavetto, L., Benussi, L. et al. (2002). Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Molecular Psychiatry, 7, 136–7.
Virgos, C., Martorell, L., Valero, J. et al. (2001). Association study of schizophrenia with polymorphisms at six candidate genes. Schizophrenia Research, 49, 65–71.
Wassink, T. H., Nelson, J. J., Crowe, R. R. & Andreasen, N. C. (1999). Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. American Journal of Medical Genetics, 88, 724–8.
Weickert, C. S., Straub, R. E., McClintock, B. W. et al. (2004). Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Archives of General Psychiatry, 61, 544–55.
Weickert, C. S., Ligons, D. L., Romanczyk, T. et al. (2005). Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Molecular Psychiatry, 10, 637–50.
Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660–9.
Weinberger, D. R. & McClure, R. K. (2002). Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Archives of General Psychiatry, 59, 553–8.
Williams, H. J., Glaser, B., Williams, N. M. et al. (2005). No association between schizophrenia and polymorphisms in COMT in two large samples. American Journal of Psychiatry, 162, 1736–8.
Williams, N. M., Preece, A., Spurlock, G. et al. (2003). Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Molecular Psychiatry, 8, 485–7.
Williams, N. M., Preece, A., Spurlock, G. et al. (2004). Support for RGS4 as a susceptibility gene for schizophrenia. Biological Psychiatry, 55, 192–5.
Winterer, G., Egan, M. F., Kolachana, B. S. et al. (2006). Prefrontal electrophysiologic ‘noise’ and catechol-O-methyltransferase genotype in schizophrenia. Biological Psychiatry, 60, 578–84.
WHO (1992). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Categories. Geneva: World Health Organization.
Yang, J. Z., Si, T. M., Ruan, Y. et al. (2003). Association study of neuregulin 1 gene with schizophrenia. Molecular Psychiatry, 8, 706–9.
Yung, A. R., Yuen, H. P., Berger, G. et al. (2002). Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophrenia Bulletin, 33, 673–81.

Reference Title: References

Reference Type: reference-list

Baron, M. & Gruen, R. (1988). Risk factors in schizophrenia. Season of birth and family history. [See comments.] British Journal of Psychiatry, 152, 460–5.
Byrne, M., Agerbo, E., Ewald, H., Eaton, W. W. & Mortensen, P. B. (2003). Parental age and risk of schizophrenia: a case– control study. Archives of General Psychiatry, 60, 673–8.
Cannon, M. & Clarke, M. C. (2005). Risk for schizophrenia: broadening the concepts, pushing back the boundaries. Schizophrenia Research, 79, 5–13.
Cannon, T. D., Mednick, S. A., Parnas, J. et al. (1993). Developmental brain abnormalities in the offspring of schizophrenic mothers. I. Contributions of genetic and perinatal factors [see comments]. Archives of General Psychiatry, 50, 551–64.
Cannon, T. D., van Erp, T. G., Rosso, I. M. et al. (2002). Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Archives of General Psychiatry, 59, 35–41.
Carter, J. W., Parnas, J., Cannon, T. D., Schulsinger, F. & Mednick, S. A. (1999). MMPI variables predictive of schizophrenia in the Copenhagen High-Risk Project: a 25-year follow-up. Acta Psychiatrica Scandinavica, 99, 432–40.
Carter, J. W., Schulsinger, F., Parnas, J., Cannon, T. & Mednick, S. A. (2002). A multivariate prediction model of schizophrenia. Schizophrenia Bulletin, 28, 649–82.
Caspi, A. & Moffitt, T. E. (2006). Gene–environment interactions in psychiatry: joining forces with neuroscience. Nature Review Neuroscience, 7, 583–90.
Caspi, A., McClay, J., Moffitt, T. E. et al. (2002). Role of genotype in the cycle of violence in maltreated children. Science, 297, 851–4.
Caspi, A., Sugden, K., Moffitt, T. E. et al. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301, 386–9.
Caspi, A., Moffitt, T. E., Cannon, M. et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the COMT gene: longitudinal evidence of a gene × environment interaction. Biological Psychiatry, 57, 1117–27.
Colhoun, H. M., McKeigue, P. M. & Davey-Smith, G. (2003). Problems of reporting genetic associations with complex outcomes. Lancet, 361, 865–72.
Craddock, N., Owen, M. J. & O'Donovan, M. C. (2006). The catechol-O-methyltransferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Molecular Psychiatry, 11, 446–58.
Darroch, J. (1997). Biologic synergism and parallelism. [See comments.] American Journal of Epidemiology, 145, 661–8.
Dassa, D., Sham, P. C., van Os, J. et al. (1996). Relationship of birth season to clinical features, family history, and obstetric complication in schizophrenia. Psychiatry Research, 64, 11–17.
Davis, J. O. & Phelps, J. A. (1995). Twins with schizophrenia: genes or germs? Schizophrenia Bulletin, 21, 13–18.
Fergusson, D. M., Poulton, R., Smith, P. F. & Boden, J. M. (2006). Cannabis and psychosis. British Medical Journal, 332, 172–5.
Fischer, M. (1971). Psychoses in the offspring of schizophrenic monozygotic twins and their normal co-twins. British Journal of Psychiatry, 118, 43–52.
Flint, J. (1992). Implications of genomic imprinting for psychiatric genetics. Psychological Medicine, 22, 5–10.
Gottesman, I. I. & Bertelsen, A. (1989). Confirming unexpressed genotypes for schizophrenia. Risks in the offspring of Fischer's Danish identical and fraternal discordant twins. [See comments.] Archives of General Psychiatry, 46, 867–72.
Gottesman, I. I. &, Shields, J. (1976). A critical review of recent adoption, twin, and family studies of schizophrenia: behavioral genetics perspectives. Schizophrenia Bulletin, 2, 360–401.
Hamer, D. (2002). Genetics. Rethinking behavior genetics. Science, 298, 71–2.
Hanssen, M., Krabbendam, L., Vollema, M., Delespaul, P. & van Os, J. (2006). Evidence for instrument and family-specific variation of subclinical psychosis dimensions in the general population. Journal of Abnormal Psychology, 115, 5–14.
Harrison, G., Glazebrook, C., Brewin, J. et al. (1997). Increased incidence of psychotic disorders in migrants from the Caribbean to the United Kingdom. Psychological Medicine, 27, 799–806.
Harrison, P. J. & Weinberger, D. R. (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry, 10, 40–68.
Henquet, C., Krabbendam, L., Spauwen, J. et al. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal, 330, 11–14.
Henquet, C., Rosa, A., Krabbendam, L. et al. (2006). An experimental study of catechol-O-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology, 31, 2748–57.
Hutchinson, G., Takei, N., Fahy, T. A. et al. (1996). Morbid risk of schizophrenia in first-degree relatives of white and African-Caribbean patients with psychosis. British Journal of Psychiatry, 169, 776–80.
Jacobs, N., Myin-Germeys, I., Derom, C., Vlietinck, R & van Os, J. (2005). Deconstructing the familiality of the emotive component of psychotic experiences in the general population. Acta Psychiatrica Scandinavica, 112, 394–401.
Kendler, K. S. (2005). ‘A gene for …’: the nature of gene action in psychiatric disorders. American Journal of Psychiatry, 162, 1243–52.
Kendler, K. S. (2006). Reflections on the relationship between psychiatric genetics and psychiatric nosology. American Journal of Psychiatry, 163, 1138–46.
Khoury, M. J., Millikan, R., Little, J. & Gwinn, M. (2004). The emergence of epidemiology in the genomics age. International Journal of Epidemiology, 33, 936–44.
Kirkbride, J. B., Fearon, P., Morgan, C. et al. (2006). Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Archives of General Psychiatry, 63, 250–8.
Kringlen, E. & Cramer, G. (1989). Offspring of monozygotic twins discordant for schizophrenia. Archives of General Psychiatry, 46, 873–7.
Kunugi, H., Nanko, S., Takei, N. et al. (1996). Perinatal complications and schizophrenia. Data from the Maternal and Child Health Handbook in Japan. Journal of Nervous and Mental Disease, 184, 542–6.
Linney, Y. M., Peters, E. R. & Ayton, P. (1998). Reasoning biases in delusion-prone individuals. British Journal of Clinical Psychology, 37(Pt 3), 285–302.
Linney, Y. M., Murray, R. M., Peters, E. R. et al. (2003). A quantitative genetic analysis of schizotypal personality traits. Psychological Medicine, 33, 803–16.
Malaspina, D., Harlap, S., Fennig, S. et al. (2001). Advancing paternal age and the risk of schizophrenia. Archives of General Psychiatry, 58, 361–7.
Marcelis, M., van Os, J., Sham, P. et al. (1998). Obstetric complications and familial morbid risk of psychiatric disorders. American Journal of Medical Genetics, 81, 29–36.
McGrath, J., Saha, S., Welham, J. et al. (2004). A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine, 2, 13.
Meaney, M. J. & Szyf, M. (2005). Environmental programming of stress responses through DNA methylation: life at the interface between a dynamic environment and a fixed genome. Dialogues in Clinical Neuroscience, 7, 103–23.
Moffitt, T. E., Caspi, A. & Rutter, M. (2005). Strategy for investigating interactions between measured genes and measured environments. Archives of General Psychiatry, 62, 473–81.
Mortensen, P. B., Pedersen, C. B., Westergaard, T. et al. (1999). Effects of family history and place and season of birth on the risk of schizophrenia. [See comments.] New England Journal of Medicine, 340, 603–8.
Nimgaonkar, V. L., Wessely, S. & Murray, R. M. (1988). Prevalence of familiality, obstetric complications, and structural brain damage in schizophrenic patients. British Journal of Psychiatry, 153, 191–7.
Norton, N., Williams, H. J. & Owen, M. J. (2006). An update on the genetics of schizophrenia. Current Opinion in Psychiatry, 19, 158–64.
O'Callaghan, E., Gibson, T., Colohan, H. A. et al. (1992). Risk of schizophrenia in adults born after obstetric complications and their association with early onset of illness: a controlled study. [See comments.] British Medical Journal, 305, 1256–9.
Plomin, R., DeFries, J. C. & Loehlin, J. C. (1977). Genotype–environment interaction and correlation in the analysis of human behavior. Psychological Bulletin, 84, 309–22.
Pulver, A. E., Liang, K. Y., Brown, C. H. et al. (1992). Risk factors in schizophrenia. Season of birth, gender, and familial risk [see comments]. British Journal of Psychiatry, 160, 65–71.
Rutter, M. (2006). Genes and Behavior: Nature–Nurture Interplay Explained. Malden, MA: Blackwell.
Rutter, M., Moffitt, T. E. & Caspi, A. (2006). Gene–environment interplay and psychopathology: multiple varieties but real effects. Journal of Child Psychology and Psychiatry, 47, 226–61.
Shur, E. (1982). Season of birth in high and low genetic risk schizophrenics. British Journal of Psychiatry, 140, 410–15.
Sipos, A., Rasmussen, F., Harrison, G. et al. (2004). Paternal age and schizophrenia: a population based cohort study. British Medical Journal, 329, 1070–3.
Spauwen, J., Krabbendam, L., Lieb, R., Wittchen, H. U. & van Os, J. (2006a). Evidence that the outcome of developmental expression of psychosis is worse for adolescents growing up in an urban environment. Psychological Medicine, 36, 407–15.
Spauwen, J., Krabbendam, L., Lieb, R., Wittchen, H. U. & van Os, J. (2006b). Impact of psychological trauma on the development of psychotic symptoms: relationship with psychosis proneness. British Journal of Psychiatry, 188, 527–33.
Stefanis, N. C., Henquet, C., Avramopoulos, D. et al. (2007). COMT Val158Met moderation of stress-induced psychosis. Psychological Medicine, 37, 1–6.
Straub, R. E. & Weinberger, D. R. (2006). Schizophrenia genes; famine to feast. Biological Psychiatry, 60, 81–3.
Sugarman, P. A. & Craufurd, D. (1994). Schizophrenia in the Afro-Caribbean community. British Journal of Psychiatry, 164, 474–80.
Tienari, P., Wynne, L. C., Moring, J. et al. (1994). The Finnish adoptive family study of schizophrenia. Implications for family research [see comments]. British Journal of Psychiatry, 164(Suppl), s20–6.
Tienari, P., Wynne, L. C., Sorri, A. et al. (2004). Genotype–environment interaction in schizophrenia-spectrum disorder. Long-term follow-up study of Finnish adoptees. British Journal of Psychiatry, 184, 216–22.
Tunbridge, E. M., Harrison, P. J. & Weinberger, D. R. (2006). Catechol-O-methyltransferase, cognition, and psychosis: val(158)met and beyond. Biological Psychiatry, 60, 141–51.
van Os, J. & Delespaul, P. (2005). Toward a world consensus on prevention of schizophrenia. Dialogues in Clinical Neuroscience, 7, 53–67.
van Os, J. & Sham, P. (2003). Gene–environment correlation and interaction in schizophrenia. In R. M.. Murray, P. B. Jones, E. Susser, J. van Os & M. Cannon (eds.), The Epidemiology of Schizophrenia. Cambridge, UK: Cambridge University Press, pp. 235–53.
van Os, J., Hanssen, M., Bak, M., Bijl, R. V. & Vollebergh, W. (2003). Do urbanicity and familial liability coparticipate in causing psychosis? American Journal of Psychiatry, 160, 477–82.
van Os, J., Pedersen, C. B. & Mortensen, P. B. (2004). Confirmation of synergy between urbanicity and familial liability in the causation of psychosis. American Journal of Psychiatry, 161, 2312–14.
van Os, J., Krabbendam, L., Myin-Germeys, I. & Delespaul, P. (2005). The schizophrenia environment and its genomic impact. Current Opinion in Psychiatry, 18, 141–5.
Verdoux, H., Gindre, C., Sorbara, F., Tournier, M. & Swendsen, J. D. (2003). Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychological Medicine, 33, 23–32.
Wahlberg, K. E., Wynne, L. C., Oja, H. et al. (1997). Gene–environment interaction in vulnerability to schizophrenia: findings from the Finnish Adoptive Family Study of Schizophrenia. American Journal of Psychiatry, 154, 355–62.
Wahlberg, K. E., Wynne, L. C., Hakko, H. et al. (2004). Interaction of genetic risk and adoptive parent communication deviance: longitudinal prediction of adoptee psychiatric disorders. Psychological Medicine, 34, 1531–41.
Walker, E. (1981). Attentional and neuromotor functions of schizophrenics, schizoaffectives, and patients with other affective disorders. Archives of General Psychiatry, 38, 1355–8.
Weaver, I. C., Cervoni, N., Champagne, F. A. et al. (2004). Epigenetic programming by maternal behavior. Nature Neuroscience, 7, 847–54.
Wong, M. Y., Day, N. E., Luan, J. A., Chan, K. P. & Wareham, N. J. (2003). The detection of gene–environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement? International Journal of Epidemiology, 32, 51–7.
Zammit, S., Allebeck, P., Dalman, C. et al. (2003). Paternal age and risk for schizophrenia. British Journal of Psychiatry, 183, 405–8.

Reference Title: References

Reference Type: reference-list

Addington, A. M., Gornick, M., Duckworth, J. et al. (2005). GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD(67)), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Molecular Psychiatry, 10, 581–8.
Armstrong, E., Schleicher, A., Omran, H., Curtis, M. & Zilles, K. (1995). The ontogeny of human gyrification. Cerebral Cortex, 5, 56–63.
Asato, M. R., Sweeney, J. A. & Luna, B. (2006). Cognitive processes in the development of TOL performance. Neuropsychologia, 44, 2259–69.
Baaré, W. F., van Oel, C. J., Hulshoff Pol, H. E. et al. (2001). Volumes of brain structures in twins discordant for schizophrenia. Archives of General Psychiatry, 58, 33–40.
Benes, F. M. (2007). Searching for unique endophenotypes for schizophrenia and bipolar disorder within neural circuits and their molecular regulatory mechanisms. Schizophrenia Bulletin, 33, 932–6.
Bertolino, A., Callicott, J. H., Elman, I. et al. (1998). Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry, 43, 641–8.
Bilder, R. M., Goldman, R. S., Robinson, D. et al. (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. American Journal of Psychiatry, 157, 549–59.
Blackwood, D. H., St Clair, D. M., Muir, W. J. & Duffy, J. C. (1991). Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Archives of General Psychiatry, 48, 899–909.
Blackwood, D. H., Fordyce, A., Walker, M. T. et al. (2001). Schizophrenia and affective disorders – cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. American Journal of Human Genetics, 69, 428–33.
Bonnici, H. M., William, T., Moorhead, J. et al. (2007). Pre-frontal lobe gyrification index in schizophrenia, mental retardation and comorbid groups: an automated study. Neuroimage, 53, 648–54.
Boos, H. B., Aleman, A., Cahn, W., Pol, H. H. & Kahn, R. S. (2007). Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Archives of General Psychiatry, 64, 297–304.
Braff, D. L., Freedman, R., Schork, N. J. & Gottesman, II. (2007). Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophrenia Bulletin, 33, 21–32.
Bramon, E., Shaikh, M., Broome, M. et al. (2008). Abnormal P300 in people with high risk of developing psychosis. Neuroimage, 41, 553–60.
Brewer, W. J., Wood, S. J., McGorry, P. D. et al. (2003). Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. American Journal of Psychiatry, 160, 1790–4.
Brewer, W. J., Francey, S. M., Wood, S. J. et al. (2005). Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. American Journal of Psychiatry, 162, 71–8.
Brewer, W. J., Wood, S. J., Phillips, L. J. et al. (2006a). Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophrenia Bulletin, 32, 538–55.
Brewer, W. J., Pantelis, C., De Luca, C. R. & Wood, S. J. (2006b). Olfactory processing and brain maturation. In W. J. Brewer, D. J. Castle & C. Pantelis (eds.), Olfaction and the Brain. Cambridge, UK: Cambridge University Press, pp. 103–18.
Brewer, W. J., Yucel, M., Harrison, B. J. et al. (2007). Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Australian and New Zealand Journal of Psychiatry, 41, 129–35.
Brockhaus-Dumke, A., Tendolkar, I., Pukrop, R. et al. (2005). Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophrenia Research, 73, 297–310.
Byrne, M., Hodges, A., Grant, E., Owens, D. G. & Johnstone, E. C. (1999). Neuropsychological assessment of young people at high genetic risk for developing schizophrenia compared with controls: preliminary findings of the Edinburgh High Risk Study (EHRS). Psychological Medicine, 29, 1161–73.
Cachia, A., Paillere-Martinot, M. L., Galinowski, A. et al. (2008). Cortical folding abnormalities in schizophrenia patients with resistant auditory hallucinations. Neuroimage, 39, 927–35.
Cadenhead, K. S., Light, G. A., Geyer, M. A. & Braff, D. L. (2000). Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. American Journal of Psychiatry, 157, 55–9.
Cadenhead, K. S., Light, G. A., Shafer, K. M. & Braff, D. L. (2005). P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biological Psychiatry, 57, 1504–9.
Callicott, J. H., Straub, R. E., Pezawas, L. et al. (2005). Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proceedings of the National Academy of Sciences USA, 102, 8627–32.
Camargo, L. M., Collura, V., Rain, J. C. et al. (2007). Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Molecular Psychiatry, 12, 74–86.
Cannon, M., Jones, P., Gilvarry, C. et al. (1997). Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. American Journal of Psychiatry, 154, 1544–50.
Cannon, T. D. (2005a). Clinical and genetic high-risk strategies in understanding vulnerability to psychosis. Schizophrenia Research, 79, 35–44.
Cannon, T. D. (2005b). The inheritance of intermediate phenotypes for schizophrenia. Current Opinion in Psychiatry, 18, 135–40.
Cannon, T. D. & Mednick, S. A. (1993). The schizophrenia high-risk project in Copenhagen: three decades of progress. Acta Psychiatrica Scandinavica, 370(Suppl), 33–47.
Cannon, T. D., Bearden, C. E., Hollister, J. M. et al. (2000). Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophrenia Bulletin, 26, 379–93.
Cannon, T. D., Thompson, P. M., van Erp, T. G. et al. (2002). Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proceedings of the National Academy of Sciences, USA, 99, 3228–33.
Cannon, T. D., van Erp, T. G., Bearden, C. E. et al. (2003). Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophrenia Bulletin, 29, 653–69.
Cannon, T. D., Hennah, W., van Erp, T. G. et al. (2005). Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Archives of General Psychiatry, 62, 1205–13.
Carter, C. S., Perlstein, W., Ganguli, R. et al. (1998). Functional hypofrontality and working memory dysfunction in schizophrenia. American Journal of Psychiatry, 155, 1285–7.
Catts, S. V., Shelley, A. M., Ward, P. B. et al. (1995). Brain potential evidence for an auditory sensory memory deficit in schizophrenia. American Journal of Psychiatry, 152, 213–19.
Chi, J., Dooling, E. & Gilles, F. (1977). Gyral development of the human brain. Annals of Neurology, 1, 86–93.
Cornblatt, B. A. & Keilp, J. G. (1994). Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophrenia Bulletin, 20, 31–46.
Cosway, R., Byrne, M., Clafferty, R. et al. (2000). Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychological Medicine, 30, 1111–21.
Cosway, R., Byrne, M., Clafferty, R. et al. (2002). Sustained attention in young people at high risk for schizophrenia. Psychological Medicine, 32, 277–86.
David, A. S., Malmberg, A., Brandt, L., Allebeck, P. & Lewis, G. (1997). IQ and risk for schizophrenia: a population-based cohort study. Psychological Medicine, 27, 1311–23.
Davidson, L. L. & Heinrichs, R. W. (2003). Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Research, 122, 69–87.
Davidson, M., Reichenberg, A., Rabinowitz, J. et al. (1999). Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. American Journal of Psychiatry, 156, 1328–35.
De Luca, C. R., Wood, S. J., Anderson, V. et al. (2003). Normative data from the CANTAB. I: development of executive function over the lifespan. Journal of Clinical and Experimental Neuropsychology, 25, 242–54.
de Wilde, O. M., Bour, L. J., Dingemans, P. M., Koelman, J. H. & Linszen, D. H. (2007). Failure to find p50 suppression deficits in young first-episode patients with schizophrenia and clinically unaffected siblings. Schizophrenia Bulletin, 33, 1319–23.
Dickinson, D., Ramsey, M. E. & Gold, J. M. (2007). Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Archives of General Psychiatry, 64, 532–42.
Egan, M. F., Goldberg, T. E., Kolachana, B. S. et al. (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences, USA, 98, 6917–22.
Erlenmeyer-Kimling, L., Rock, D., Roberts, S. A. et al. (2000). Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-risk Project. American Journal of Psychiatry, 157, 1416–22.
Ettinger, U., Picchioni, M., Hall, M. H. et al. (2006). Antisaccade performance in monozygotic twins discordant for schizophrenia: the Maudsley twin study. American Journal of Psychiatry, 163, 543–5.
Faux, S. F., McCarley, R. W., Nestor, P. G. et al. (1993). P300 topographic asymmetries are present in unmedicated schizophrenics. Electroencephalography and Clinical Neurophysiology, 88, 32–41.
Feinberg, I. (1982). Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? Journal of Psychiatric Research, 17, 319–34.
Ford, J. M., White, P. M., Csernansky, J. G. et al. (1994). ERPs in schizophrenia: effects of antipsychotic medication. Biological Psychiatry, 36, 153–70.
Fornito, A., Yücel, M., Wood, S. J. et al. (2006). Morphology of the paracingulate sulcus and executive cognition in schizophrenia. Schizophrenia Research, 88, 192–7.
Fornito, A., Yücel, M., Wood, S. J. et al. (2008). Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Human Brain Mapping, 29, 478–89.
Francey, S. M., Jackson, H. J., Phillips, L. J. et al. (2005). Sustained attention in young people at high risk of psychosis does not predict transition to psychosis. Schizophrenia Research, 79, 127–36.
Frangou, S., Sharma, T., Alarcon, G. et al. (1997). The Maudsley Family Study, II: Endogenous event-related potentials in familial schizophrenia. Schizophrenia Research, 23, 45–53.
Freedman, R., Adams, C. E., Adler, L. E. et al. (2000). Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. American Journal of Medical Genetics, 97, 58–64.
Friedman, D. & Squires-Wheeler, E. (1994). Event-related potentials (ERPs) as indicators of risk for schizophrenia. Schizophrenia Bulletin, 20, 63–74.
Fusar-Poli, P., Perez, J., Broome, M. et al. (2007a). Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosciences and Biobehavioral Reviews, 31, 465–84.
Fusar-Poli, P., Broome, M. R., Matthiasson, P. et al. (2007b). Effects of acute antipsychotic treatment on brain activation in first episode psychosis: an fMRI study. European Neuropsychopharmacology, 17, 492–500.
Garner, B., Pariante, C. M., Wood, S. J. et al. (2005). Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biological Psychiatry, 58, 417–23.
Giedd, J. N. (2004). Structural magnetic resonance imaging of the adolescent brain. Annals of the New York Academy of Science, 1021, 77–85.
Glahn, D. C., Thompson, P. M. & Blangero, J. (2007). Neuroimaging endophenotypes: strategies for finding genes influencing brain structure and function. Human Brain Mapping, 28, 488–501.
Gornick, M. C., Addington, A. M., Sporn, A. et al. (2005). Dysbindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS). Journal of Autism and Developmental Disorders, 35, 831–8.
Gottesman, I. I. & Gould, T. D. (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. American Journal of Psychiatry, 160, 636–45.
Gur, R. E., Keshavan, M. S. & Lawrie, S. M. (2007a). Deconstructing psychosis with human brain imaging. Schizophrenia Bulletin, 33, 921–31.
Gur, R. E., Calkins, M. E., Gur, R. C. et al. (2007b). The consortium on the genetics of schizophrenia: neurocognitive endophenotypes. Schizophrenia Bulletin, 33, 49–68.
Hall, J., Whalley, H. C., Job, D. E. et al. (2006). A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nature Neurosciences, 9, 1477–8.
Harris, J. M., Yates, S., Miller, P. et al. (2004). Gyrification in first-episode schizophrenia: a morphometric study. Biological Psychiatry, 55, 141–7.
Harris, J. M., Moorhead, T. W., Miller, P. et al. (2007). Increased prefrontal gyrification in a large high-risk cohort characterizes those who develop schizophrenia and reflects abnormal prefrontal development. Biological Psychiatry, 62, 722–9.
Harrison, B. J., Yücel, M., Shaw, M. et al. (2006). Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naive schizophreniform psychosis. Psychiatry Research, 148, 23–31.
Harrison, P. J. & Lewis, D. A. (2003). Neuropathology of schizophrenia. In S. R. Hirsch & D. R. Weinberger (eds.), Schizophrenia. Oxford: Blackwell Science, pp. 310–25.
Harrison, P. J. & Weinberger, D. R. (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry, 10, 40–68; image 5.
Heckers, S. (2001). Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus, 11, 520–8.
Heinrichs, R. W. (2005). The primacy of cognition in schizophrenia. American Psychologist, 60, 229–42.
Hennah, W., Tuulio-Henriksson, A., Paunio, T. et al. (2005). A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. Molecular Psychiatry, 10, 1097–103.
Hirayasu, Y., Asato, N., Ohta, H. et al. (1998). Abnormalities of auditory event-related potentials in schizophrenia prior to treatment. Biological Psychiatry, 43, 244–53.
Hirayasu, Y., Tanaka, S., Shenton, M. E. et al. (2001). Prefrontal gray matter volume reduction in first episode schizophrenia. Cerebral Cortex, 11, 374–81.
Hoff, A. L., Svetina, C., Shields, G., Stewart, J. & DeLisi, L. E. (2005). Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophrenia Research, 78, 27–34.
Hulshoff Pol, H. E., Schnack, H. G., Mandl, R. C. et al. (2006). Gray and white matter density changes in monozygotic and same-sex dizygotic twins discordant for schizophrenia using voxel-based morphometry. Neuroimage, 31, 482–8.
Huttenlocher, P. (1984). Synapse elimination and plasticity in developing human cerebral cortex. American Journal of Mental Deficiency, 88, 488–96.
Ingraham, L. J., Kugelmass, S., Frenkel, E., Nathan, M. & Mirsky, A. F. (1995). Twenty-five-year followup of the Israeli High-Risk Study: current and lifetime psychopathology. Schizophrenia Bulletin, 21, 183–92.
Javitt, D. C., Shelley, A. & Ritter, W. (2000). Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clinical Neurophysiology, 111, 1733–7.
Jeon, Y. W. & Polich, J. (2001). P300 asymmetry in schizophrenia: a meta-analysis. Psychiatry Research, 104, 61–74.
Jessen, F., Scherk, H., Träber, F. et al. (2006). Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophrenia Research, 87, 81–8.
Jin, Y., Bunney, W. E., Jr, Sandman, C. A. et al. (1998). Is p50 suppression a measure of sensory gating in schizophrenia? Biological Psychiatry, 43, 873–8.
Job, D. E., Whalley, H. C., Johnstone, E. C. & Lawrie, S. M. (2005). Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage, 25, 1023–30.
Johnstone, E. C., Ebmeier, K. P., Miller, P., Owens, D. G. & Lawrie, S. M. (2005). Predicting schizophrenia: findings from the Edinburgh High-Risk Study. British Journal of Psychiatry, 186, 18–25.
Jones, H. M., Brammer, M. J., O'Toole, M. et al. (2004). Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study. Biological Psychiatry, 56, 938–42.
Jones, P., Rodgers, B., Murray, R. & Marmot, M. (1994). Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet, 344, 1398–402.
Keefe, R. S., Bilder, R. M., Harvey, P. D. et al. (2006). Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology, 31, 2033–46.
Keshavan, M. S., Berger, G., Zipursky, R. B., Wood, S. J. & Pantelis, C. (2005). Neurobiology of early psychosis. British Journal of Psychiatry Supplement, 48, s8–18.
Keshavan, M. S., Prasad, K. M. & Pearlson, G. (2007). Are brain structural abnormalities useful as endophenotypes in schizophrenia? International Review of Psychiatry, 19, 397–406.
Kimble, M., Lyons, M., O'Donnell, B. et al. (2000). The effect of family status and schizotypy on electrophysiologic measures of attention and semantic processing. Biological Psychiatry, 47, 402–12.
Klosterkötter, J., Hellmich, M., Steinmeyer, E. M. & Schultze-Lutter, F. (2001). Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry, 58, 158–64.
Kremen, W. S., Buka, S. L., Seidman, L. J. et al. (1998). IQ decline during childhood and adult psychotic symptoms in a community sample: a 19-year longitudinal study. American Journal of Psychiatry, 155, 672–7.
Kuroki, N., Shenton, M. E., Salisbury, D. F. et al. (2006). Middle and inferior temporal gyrus gray matter volume abnormalities in first-episode schizophrenia: an MRI study. American Journal of Psychiatry, 163, 2103–10.
Law, A. J., Kleinman, J. E., Weinberger, D. R. & Weickert, C. S. (2007). Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Human Molecular Genetics, 16, 129–41.
Lawrie, S. M. (2004). Premoribid strucutral abnormalities in schizophrenia. In M. S. Keshavan, J. L. Kennedy & R. M. Murray (eds.), Neurodevelopment and Schizophrenia. Cambridge, UK: Cambridge University Press, pp. 347–72.
Lawrie, S. M. & Abukmeil, S. S. (1998). Brain abnormality in schizophrenia: a systematic and quantitative review of volumetric magnetic resonance imaging studies. British Journal of Psychiatry, 172, 110–20.
Lencz, T., Smith, C. W., Auther, A., Correll, C. U. & Cornblatt, B. (2004). Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophrenia Research, 68, 37–48.
Lencz, T., Smith, C. W., McLaughlin, D. et al. (2006). Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biological Psychiatry, 59, 863–71.
Liddle, P. F. & Pantelis, C. (2003). Brain imaging in schizophrenia. In S. R. Hirsch & D. R. Weinberger (eds.), Schizophrenia. Oxford, UK: Blackwell Science, pp. 403–17.
Luna, B. & Sweeney, J. A. (2001). Studies of brain and cognitive maturation through childhood and adolescence: a strategy for testing neurodevelopmental hypotheses. Schizophrenia Bulletin, 27, 443–55.
Luna, B. & Sweeney, J. A. (2004). The emergence of collaborative brain function: fMRI studies of the development of response inhibition. Annals of the New York Academy of Science, 1021, 296–309.
MacDonald, A. W., III, Carter, C. S., Kerns, J. G. et al. (2005). Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. American Journal of Psychiatry, 162, 475–84.
Manoach, D. S., Press, D. Z., Thangaraj, V. et al. (1999). Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biological Psychiatry, 45, 1128–37.
Manoach, D. S., Gollub, R. L., Benson, E. S. et al. (2000). Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biological Psychiatry, 48, 99–109.
Marjoram, D., Job, D. E., Whalley, H. C. et al. (2006). A visual joke fMRI investigation into theory of mind and enhanced risk of schizophrenia. Neuroimage, 31, 1850–8.
Mathalon, D. H., Ford, J. M. & Pfefferbaum, A. (2000). Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biological Psychiatry, 47, 434–49.
McCarley, R. W., Shenton, M. E., O'Donnell, B. F. et al. (1993). Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia. Archives of General Psychiatry, 50, 190–7.
McCarley, R. W., Salisbury, D. F., Hirayasu, Y. et al. (2002). Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Archives of General Psychiatry, 59, 321–31.
McDonald, C., Zanelli, J., Rabe-Hesketh, S. et al. (2004a). Meta-analysis of magnetic resonance imaging brain morphometry studies in bipolar disorder. Biological Psychiatry, 56, 411–17.
McDonald, C., Bullmore, E. T., Sham, P. C. et al. (2004b). Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Archives of General Psychiatry, 61, 974–84.
Miller, B. L., Chang, L., Booth, R. et al. (1996). In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sciences, 58, 1929–35.
Mirsky, A. F. (1995). Israeli High Risk Study: editor's introduction. Schizophrenia Bulletin, 21, 179–82.
Molina, V., Sanz, J., Reig, S. et al. (2005). Hypofrontality in men with first-episode psychosis. British Journal of Psychiatry, 186, 203–8.
Morey, R. A., Inan, S., Mitchell, T. V. et al. (2005). Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Archives of General Psychiatry, 62, 254–62.
Murray, G. K., Jones, P. B., Moilanen, K. et al. (2006). Infant motor development and adult cognitive functions in schizophrenia. Schizophrenia Research, 81, 65–74.
Murray, G. K., Jones, P. B., Kuh, D. & Richards, M. (2007). Infant developmental milestones and subsequent cognitive function. Annals of Neurology, 62, 128–36.
Murray, R. M. & Lewis, S. W. (1987). Is schizophrenia a neurodevelopmental disorder? British Medical Journal (Clinical Research Edition), 295, 681–2.
Myles-Worsley, M., Ord, L., Blailes, F., Ngiralmau, H. & Freedman, R. (2004). P50 sensory gating in adolescents from a Pacific island isolate with elevated risk for schizophrenia. Biological Psychiatry, 55, 663–7.
Nakamura, M., Salisbury, D. F., Hirayasu, Y. et al. (2007). Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biological Psychiatry, 62, 773–83.
Narr, K. L., Bilder, R. M., Kim, S. et al. (2004). Abnormal gyral complexity in first-episode schizophrenia. Biological Psychiatry, 55, 859–67.
Nelson, M. D., Saykin, A. J., Flashman, L. A. & Riordan, H. J. (1998). Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Archives of General Psychiatry, 55, 433–40.
Nieman, D., Becker, H., van de Fliert, R. et al. (2007). Antisaccade task performance in patients at ultra high risk for developing psychosis. Schizophrenia Research, 95, 54–60.
Pantelis, C. & Maruff, P. (2002). The cognitive neuropsychiatric approach to investigating the neurobiology of schizophrenia and other disorders. Journal of Psychosomatic Research, 53, 655–64.
Pantelis, C., Stuart, G. W., Nelson, H. E., Robbins, T. W. & Barnes, T. R. E. (2001). Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. American Journal of Psychiatry, 158, 1276–85.
Pantelis, C., Velakoulis, D., McGorry, P. D. et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 361, 281–8.
Pantelis, C., Yücel, M., Wood, S. J. et al. (2005). Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin, 31, 672–96.
Pantelis, C., Velakoulis, D., Wood, S. J. et al. (2007). Neuroimaging and emerging psychotic disorders: the Melbourne Ultra-High Risk Studies. International Review of Psychiatry, 19, 371–9.
Pariante, C. M., Vassilopoulou, K., Velakoulis, D. et al. (2004). Pituitary volume in psychosis. British Journal of Psychiatry, 185, 5–10.
Pariante, C. M., Dazzan, P., Danese, A. et al. (2005). Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology, 30, 1923–31.
Paus, T. (2005). Mapping brain maturation and cognitive development during adolescence. Trends in Cognitive Science, 9, 60–8.
Petrides, M. (1995). Impairments on nonspatial self-ordered and externally ordered working memory tasks after lesions of the mid-dorsal part of the lateral frontal cortex in the monkey. Journal of Neuroscience, 15(Pt 1), 359–75.
Phillips, L. J., McGorry, P. D., Garner, B. et al. (2006). Stress, the hippocampus and the hypothalamic–pituitary–adrenal axis: implications for the development of psychotic disorders. Australian and New Zealand Journal of Psychiatry, 40, 725–41.
Poulton, R., Caspi, A., Moffitt, T. E. et al. (2000). Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Archives of General Psychiatry, 57, 1053–8.
Pukrop, R., Schultze-Lutter, F., Ruhrmann, S. et al. (2006). Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episode schizophrenia. Journal of Clinical and Experimental Neuropsychology, 28, 1388–407.
Pukrop, R., Ruhrmann, S., Schultze-Lutter, F. et al. (2007). Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophrenia Research, 92, 116–25.
Rapoport, J. L., Addington, A. M., Frangou, S. & Psych, M. R. (2005). The neurodevelopmental model of schizophrenia: update 2005. Molecular Psychiatry, 10, 434–49.
Reichenberg, A., Weiser, M., Rapp, M. A. et al. (2005). Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Archives of General Psychiatry, 62, 1297–304.
Renoult, L., Prevost, M., Brodeur, M. et al. (2007). P300 asymmetry and positive symptom severity: a study in the early stage of a first episode of psychosis. Schizophrenia Research, 93, 366–73.
Rhinewine, J. P., Lencz, T., Thaden, E. P. et al. (2005). Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biological Psychiatry, 58, 705–12.
Rutschmann, J., Cornblatt, B. & Erlenmeyer-Kimling, L. (1977). Sustained attention in children at risk for schizophrenia. Report on a continuous performance test. Archives of General Psychiatry, 34, 571–5.
Salisbury, D. F., Shenton, M. E., Griggs, C. B., Bonner-Jackson, A. & McCarley, R. W. (2002). Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Archives of General Psychiatry, 59, 686–94.
Salisbury, D. F., Krljes, S. & McCarley, R. W. (2003). Electrophysiology of schizophrenia. In S. R. Hirsch & D. R. Weinberger (eds.), Schizophrenia. Oxford: Blackwell Science, pp. 298–309.
Salisbury, D. F., Kuroki, N., Kasai, K., Shenton, M. E. & McCarley, R. W. (2007). Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Archives of General Psychiatry, 64, 521–9.
Seidman, L. J., Pantelis, C., Keshavan, M. S. et al. (2003). A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophrenia Bulletin, 29, 803–30.
Silberberg, G., Darvasi, A., Pinkas-Kramarski, R. & Navon, R. (2006). The involvement of ErbB4 with schizophrenia: association and expression studies. American Journal of Medical Genetics Part B: Neuropsychiatry Genetics, 141, 142–8.
Smyrnis, N., Evdokimidis, I., Stefanis, N. C. et al. (2003). Antisaccade performance of 1273 men: effects of schizotypy, anxiety, and depression. Journal of Abnormal Psychology, 112, 403–14.
Snitz, B. E., MacDonald, A., III, Cohen, J. D. et al. (2005). Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. American Journal of Psychiatry, 162, 2322–9.
Snitz, B. E., Macdonald, A. W., III, & Carter, C. S. (2006). Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophrenia Bulletin, 32, 179–94.
Sponheim, S. R., McGuire, K. A. & Stanwyck, J. J. (2006). Neural anomalies during sustained attention in first-degree biological relatives of schizophrenia patients. Biological Psychiatry, 60, 242–52.
Stanfield, A. C., Moorhead, T. W., Harris, J. M. et al. (2007). Increased right prefrontal cortical folding in adolescents at risk of schizophrenia for cognitive reasons. Biological Psychiatry, 63, 80–5.
Steen, R. G., Mull, C., McClure, R., Hamer, R. M. & Lieberman, J. A. (2006). Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. British Journal of Psychiatry, 188, 510–18.
Stefansson, H., Sigurdsson, E., Steinthorsdottir, V. et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics, 71, 877–92.
Stone, W. S., Faraone, S. V., Seidman, L. J., Olson, E. A. & Tsuang, M. T. (2005). Searching for the liability to schizophrenia: concepts and methods underlying genetic high-risk studies of adolescents. Journal of Child and Adolescent Psychopharmacology, 15, 403–17.
Straub, R. E., Lipska, B. K., Egan, M. F. et al. (2007). Allelic variation in GAD1 (GAD(67)) is associated with schizophrenia and influences cortical function and gene expression. Molecular Psychiatry, 12, 854–69.
Sun, D.-Q., Phillips, L. J., Velakoulis, D. et al. (2008). Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals. Schizophrenia Research, epub PMID 18262769.
Swerdlow, N. R., Light, G. A., Cadenhead, K. S. et al. (2006). Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Archives of General Psychiatry, 63, 1325–35.
Taanila, A., Murray, G. K., Jokelainen, J., Isohanni, M. & Rantakallio, P. (2005). Infant developmental milestones: a 31-year follow-up. Developmental Medicine and Child Neurology, 47, 581–6.
Testa, R. & Pantelis, C. (2007). The role of executive functions in psychiatric disorders. In S. J. Wood, N. Allen & C. Pantelis, (eds.), Neuropsychology of Mental Disorders. Cambridge, UK: Cambridge University Press
Thompson, P. M., Woods, R. P., Mega, M. S. & Toga, A. W. (2000). Mathematical/computational challenges in creating deformable and probabilistic atlases of the human brain. Human Brain Mapping, 9, 81–92.
Turetsky, B. I., Cannon, T. D. & Gur, R. E. (2000). P300 subcomponent abnormalities in schizophrenia: III. Deficits in unaffected siblings of schizophrenic probands. Biological Psychiatry, 47, 380–90.
Turetsky, B. I., Calkins, M. E., Light, G. A. et al. (2007). Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophrenia Bulletin, 33, 69–94.
van Erp, T. G., Saleh, P. A., Huttunen, M. et al. (2004). Hippocampal volumes in schizophrenic twins. Archives of General Psychiatry, 61, 346–53.
van Haren, N. E., Picchioni, M. M., McDonald, C. et al. (2004). A controlled study of brain structure in monozygotic twins concordant and discordant for schizophrenia. Biological Psychiatry, 56, 454–61.
Van Horn, J. D. & McManus, I. C. (1992). Ventricular enlargement in schizophrenia. A meta-analysis of studies of the ventricle:brain ratio (VBR). British Journal of Psychiatry, 160, 687–97.
Velakoulis, D. & Pantelis, C. (1996). What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas. Australian and New Zealand Journal of Psychiatry, 30, 195–209.
Velakoulis, D., Wood, S. J., Wong, M. T. et al. (2006). Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Archives of General Psychiatry, 63, 139–49.
Vidal, C. N., Rapoport, J. L., Hayashi, K. M. et al. (2006). Dynamically spreading frontal and cingulate deficits mapped in adolescents with schizophrenia. Archives of General Psychiatry, 63, 25–34.
Vita, A., de Peri, L., Silenzi, C. & Dieci, M. (2006). Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophrenia Research, 82, 75–88.
Vogeley, K., Schneider-Axmann, T., Pfeiffer, U. et al. (2000). Disturbed gyrification of the prefrontal region in male schizophrenic patients: a morphometric postmortem study. American Journal of Psychiatry, 157, 34–9.
Vogeley, K., Tepest, R., Pfeiffer, U. et al. (2001). Right frontal hypergyria differentiation in affected and unaffected siblings from families multiply affected with schizophrenia: a morphometric MRI study. American Journal of Psychiatry, 158, 494–6.
Walker, E. & Bollini, A. M. (2002). Pubertal neurodevelopment and the emergence of psychotic symptoms. Schizophrenia Research, 54, 17–23.
Walterfang, M., Wood, A., Reutens, D. C. et al. (2008). Morphology of the corpus callosum at different stages of schizophrenia: a cross-sectional study in first-episode and chronic illness. British Journal of Psychiatry, 192, 429–34.
Wang, J., Hirayasu, Y., Hokama, H. et al. (2005). Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia. Psychiatry and Clinical Neuroscience, 59, 209–14.
Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660–9.
Weinberger, D. R. (2002). Biological phenotypes and genetic research on schizophrenia. World Psychiatry, 1, 2–6.
Weintraub, S. (1987). Risk factors in schizophrenia: the Stony Brook High-Risk Project. Schizophrenia Bulletin, 13, 439–50.
Whalley, H. C., Simonotto, E., Moorhead, W. et al. (2006). Functional imaging as a predictor of schizophrenia. Biological Psychiatry, 60, 454–62.
Whalley, H. C., Harris, J. C. & Lawrie, S. M. (2007). The neurobiological underpinnings of risk and conversion in relatives of patients with schizophrenia. International Review of Psychiatry, 19, 383–97.
Whyte, M. C., Brett, C., Harrison, L. K. et al. (2006). Neuropsychological performance over time in people at high risk of developing schizophrenia and controls. Biological Psychiatry, 59, 730–9.
Wiegand, L. C., Warfield, S. K., Levitt, J. J. et al. (2005). An in vivo MRI study of prefrontal cortical complexity in first-episode psychosis. American Journal of Psychiatry, 162, 65–70.
Wisco, J. J., Kuperberg, G., Manoach, D. et al. (2007). Abnormal cortical folding patterns within Broca's area in schizophrenia: evidence from structural MRI. Schizophrenia Research, 94, 317–27.
Wolf, L. E. & Cornblatt, B. A. (1996). Neuropsychological functioning in children at risk for schizophrenia. In C. Pantelis, H. E. Nelson & T. R. E. Barnes (eds.), Schizophrenia: A Neuropsychological Perspective. London: John Wiley, pp. 161–179.
Wolf, L. E., Cornblatt, B. A., Roberts, S. A., Shapiro, B. M. & Erlenmeyer-Kimling, L. (2002). Wisconsin card sorting deficits in the offspring of schizophrenics in the New York High-Risk Project. Schizophrenia Research, 57, 173–82.
Wood, S. J., Pantelis, C., Proffitt, T. et al. (2003a). Spatial working memory ability is a marker of risk-for-psychosis. Psychological Medicine, 33, 1239–47.
Wood, S. J., Berger, G., Velakoulis, D. et al. (2003b). Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophrenia Bulletin, 29, 831–43.
Wood, S. J., De Luca, C. R., Anderson, V. & Pantelis, C. (2004). Cognitive development in adolescence: cerebral underpinnings, neural trajectories and the impact of aberrations. In M. S. Keshavan, J. L. Kennedy & R. M. Murray, (eds.), Neurodevelopment and Schizophrenia. Cambridge, UK: Cambridge University Press, pp. 69–88.
Wood, S. J., Yücel, M., Velakoulis, D. et al. (2005). Hippocampal and anterior cingulate morphology in subjects at ultra-high-risk for psychosis: the role of family history of psychotic illness. Schizophrenia Research, 75, 295–301.
Wood, S. J., Brewer, W. J., Koutsouradis, P. et al. (2007). Cognitive decline following psychosis onset: Data from the PACE clinic. British Journal of Psychiatry, 191(Suppl 51), s52–7.
Wood, S. J., Pantelis, C., Velakoulis, D. et al. (2008). Progressive changes in the development towards schizophrenia: studies in subjects at increased symptomatic risk. Schizophrenia Bulletin, 34, 322–9.
Woods, B. T., Ward, K. E. & Johnson, E. H. (2005). Meta-analysis of the time-course of brain volume reduction in schizophrenia: implications for pathogenesis and early treatment. Schizophrenia Research, 73, 221–8.
Wright, I. C., Rabe-Hesketh, S., Woodruff, P. W. et al. (2000). Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry, 157, 16–25.
Yücel, M., Stuart, G. W., Maruff, P. et al. (2001). Hemispheric and gender-related differences in the gross morphology of the anterior cingulate/paracingulate cortex in normal volunteers: an MRI morphometric study. Cerebral Cortex, 11, 17–25.
Yücel, M., Stuart, G. W., Maruff, P. et al. (2002). Paracingulate morphological differences in males with established schizophrenia: a magnetic resonance imaging morphometric study. Biological Psychiatry, 52, 15–23.
Yücel, M., Wood, S. J., Phillips, L. J. et al. (2003). Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. British Journal of Psychiatry, 182, 518–24.
Yung, A. R. & McGorry, P. D. (1996). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophrenia Bulletin, 22, 353–70.

Reference Title: References

Reference Type: reference-list

Altamura, C., Guercetti, G. & Percudani, M. (1989). Dexamethasone suppression test in positive and negative schizophrenia. Psychiatry Research, 30, 69–75.
APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
Andreasen, N. C. (1983). The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
Andreasen, N. C. (1987). The Comprehensive Assessment of Symptoms and History (CASH) Interview. Iowa City: University of Iowa.
Asnis, G. M., Halbreich, U., Ryan, N. D. et al. (1987). The relationship of the dexamethasone suppression test (1-mg and 2-mg) to basal plasma cortisol levels in endogenous depression. Psychoneuroendocrinology, 12, 295–301.
Bak, M., Myin-Germeys, I., Hanssen, M. et al. (2003). When does experience of psychosis result in a need for care? A prospective general population study. Schizophrenia Bulletin, 29, 349–58.
Bebbington, P., Wilkins, S., Jones, P. et al. (1993). Life events and psychosis: initial results from the Camberwell Collaborative Psychosis Study. British Journal of Psychiatry, 162, 72–9.
Bechdolf, A., Ruhrmann, S., Wagner, M. et al. (2005a). Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. British Journal of Psychiatry, 187, s45–8. [Special Issue: Early Psychosis: A Bridge to the Future.]
Bechdolf, A., Kohn, D., Knost, B., Pukrop, R. & Klosterkötter, J. (2005b). A randomized comparison of group cognitive–behavioural therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months. Acta Psychiatrica Scandinavica, 112, 173–9.
Bechdolf, A., Veith, V., Schwarzer, D. et al. (2005c). Cognitive– behavioral therapy in the pre-psychotic phase: an exploratory study. Psychiatry Research, 136, 251–5.
Bechdolf, A., Phillips, L. J., Francey, S. M. et al. (2006). Recent approaches to psychological interventions for people at risk of psychosis. European Archives of Psychiatry and Clinical Neuroscience, 256, 159–73.
Bell, R. Q. (1992). Multiple-risk cohorts and segmenting risk as solutions to the problem of false positives in risk for the major psychoses. Psychiatry, 55, 370–81.
Bentall, R. P. & Morrison, A. P. (2002). More harm than good: the case against using antipsychotic drugs to prevent severe mental illness. Journal of Mental Health, 11, 351–6.
Bogerts, B., Ashtari, M., Degreef, G. et al. (1990). Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Research, 35, 1–13.
Bogerts, B., Lieberman, J. A., Ashtari, M. et al. (1993). Hippocampus–amygdala volumes and psychopathology in chronic schizophrenia. Biological Psychiatry, 33, 236–46.
Brewer, W. J., Pantelis, C., Anderson, V. et al. (2001). Stability of olfactory identification deficits in neuroleptic-naive patients with first-episode psychosis. American Journal of Psychiatry, 158, 107–15.
Brewer, W. J., Francey, S. M., Wood, S. J. et al. (2005). Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. American Journal of Psychiatry, 162, 71–8.
Brewer, W. J., Wood, S. J., Phillips, L. J. et al. (2006). Generalised and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophrenia Bulletin, 32, 538–55.
Brockhaus-Dumke, A., Schultze-Lutter, F., Müller, R. et al. (2008). Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode and chronic patients. Biological Psychiatry, Epub: 10.1016/j.biopsych.2008.02.006.
Broome, M. R., Woolley, J. B., Tabraham, P. et al. (2005). What causes the onset of psychosis? Schizophrenia Research, 79, 23–34.
Brown, G. & Birley, J. (1968). Crises and life changes and the onset of schizophrenia. Journal of Health and Social Behaviour, 9, 203–14.
Canton, G. & Fraccon, I. G. (1985). Life events and schizophrenia: a replication. Acta Psychiatrica Scandanivica, 71, 211–16.
Carroll, B. J. (1985). Dexamethasone suppression test: a review of contemporary confusion. Journal of Clinical Psychiatry, 46, 13–24.
Chung, R. K., Langeluddecke, P. & Tennant, C. (1986). Threatening life events in the onset of schizophrenia, schizophreniform psychosis and hypomania. British Journal of Psychiatry, 148, 680–5.
Conrad, K. (1958). Die Beginnende Schizophrenie. Stuttgart: Georg Thieme.
Corcoran, C., Malaspina, D. & Hercher, L. (2005). Prodromal interventions for schizophrenia vulnerability: the risks of being ‘at risk’. Schizophrenia Research, 73, 173–84.
Cornblatt, B. A. (2002). The New York High Risk Project to the Hillside Recognition and Prevention (RAP) program. American Journal of Medical Genetics, 114, 956–66.
Cornblatt, B. A., Lencz, T. & Kane, J. M. (2001). Treatment of the schizophrenia prodrome: it is presently ethical? Schizophrenia Research, 51, 31–8.
Cornblatt, B. A., Lencz, T., Correll, C., Auther, A. & Smith, C. (2002). Treating the prodrome: naturalistic findings from the RAP program. Acta Psychiatrica Scandinavica, 106, 44.
Cornblatt, B. A., Lencz, T., Smith, C. W. et al. (2003). The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophrenia Bulletin, 29, 633–51.
Day, R., Nielsen, J. A., Korten, A. et al. (1987). Stressful life events preceding the acute onset of schizophrenia: a cross-national study from the World Health Organization. Culture, Medicine and Psychiatry, 11, 123–205.
Docherty, J. P., van Kammen, D. P., Siris, S. G. & Marder, S. R. (1978). Stages of onset of schizophrenic psychosis. American Journal of Psychiatry, 135, 420–6.
Donlon, P. T. & Blacker, K. H. (1973). Stages of schizophrenic decompensation and reintegration. Journal of Nervous and Mental Disease, 157, 200–9.
Escher, S., Romme, M., Buiks, A., Delespaul, P. & van Os, J. (2002). Formation of delusional ideation in adolescents hearing voices: a prospective study. American Journal of Medical Genetics, 114, 913–20.
Falloon, I. R. H. (1992). Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry, 55, 4–15.
Francey, S. M., Jackson, H. J., Phillips, L. J. et al. (2005). Sustained attention in young people at high risk of psychosis does not predict transition to psychosis. Schizophrenia Research, 79, 127–36.
Freeman, D. & Garety, P. A. (2003). Connecting neurosis and psychosis: the direct influence of emotion on delusions and hallucinations. Behaviour Research and Therapy, 41, 923–47.
Garner, B., Pariante, C. M., Wood, S. J. et al. (2005). Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biological Psychiatry, 58, 417–23.
Goldman-Rakic, P. S. (1994). Working memory in schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 6, 348–57.
Graf von Reventlow, H., Ruhrmann, S., Klosterkötter, J. et al. (2004). Comparison of inclusion criteria for an early detection of psychosis study across different countries: first results from the European Prediction of Psychosis Study, EPOS. Schizophrenia Research, 67(Suppl 1), 37.
Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321–30.
Gross, G. (1989). The ‘basic’ symptoms of schizophrenia. British Journal of Psychiatry, 155(Suppl 7), s21–5.
Häfner, H., Riecher, R. A., Hambrecht, M. et al. (1992). IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research, 6, 209–23.
Häfner, H., Maurer, K., Loffler, W. & Riecher-Rossler, A. (1993). The influence of age and sex on the onset and early course of schizophrenia. British Journal of Psychiatry, 162, 80–6.
Häfner, H., Maurer, W., Loffler, B. et al. (1995). Onset and early course of schizophrenia. In H. Häfner & W. F. Gattaz (eds.), Search for the Causes of Schizophrenia. New York: Springer, pp. 43–66.
Häfner, H., Loffler, W., Maurer, K., Hambrecht, M. & van der Heiden, W. (1999). Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatrica Scandinavica, 100, 105–18.
Häfner, H., Maurer, K., Ruhrmann, S. et al. (2004). Early detection and secondary prevention of psychosis: facts and visions. European Archives of Psychiatry and Clinical Neuroscience, 254, 117–28.
Häfner, H., Maurer, K., Trendler, G., van der Heiden, W. & Schmidt, M. (2005). The early course of schizophrenia and depression. European Archives of Psychiatry and Clinical Neuroscience, 255, 167–73.
Haroun, N., Dunn, L., Haroun, A. & Cadenhead, K. (2006). Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophrenia Bulletin, 32, 166–78.
Hawkins, K. A., Addington, J., Keefe, R. S. E. et al. (2004). Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research, 67, 115–22.
Heinrichs, R. W. & Zakzanis, K. K. (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology, 12, 426–45.
Heinssen, R. K., Perkins, D. O., Appelbaum, P. S. & Fenton, W. S. (2001). Informed consent in early psychosis research: National Institute of Mental Health Workshop, November 15, 2000. Schizophrenia Bulletin, 27, 571–84.
Hirsch, S., Bowen, J., Emmani, J. et al. (1996). A one year prospective study of the effects of life events and medication in the aetiology of schizophrenic relapse. British Journal of Psychiatry, 168, 49–56.
Hubain, P. P., Simonnet, M. P. & Mendlewicz, J. (1986). The dexamethasone suppression test in affective illnesses and schizophrenia: relationship with psychotic symptoms. Neuropsychobiology, 16, 57–60.
Johns, L. C., Cannon, M., Singleton, N. et al. (2004). Prevalence and correlates of self-reported psychotic symptoms in the British population. British Journal of Psychiatry, 185, 298–305.
Johnstone, E. C., Ebmeier, K. P., Miller, P., Owens, D. G. & Lawrie, S. M. (2005). Predicting schizophrenia: findings from the Edinburgh High-Risk Study. British Journal of Psychiatry, 186, 18–25.
Jou, R. J., Hardan, A. Y. & Keshavan, M. S. (2005). Reduced cortical folding in individuals at high risk for schizophrenia: a pilot study. Schizophrenia Research, 75, 309–13.
Kaneko, M., Yokoyama, F., Hoshino, Y. et al. (1992). Hypothalamic–pituitary–adrenal axis function in chronic schizophrenia: association with clinical features. Neuropsychobiology, 25, 1–7.
Kanner, A. D., Coyne, J. C., Scharfer, C. & Lazarus, R. (1981). Comparison of two modes of stress measurement: daily hassles and uplifts vs major life events. Journal of Behavioural Medicine, 4, 1–39.
Klosterkötter, J., Schultze-Lutter, F., Gross, G., Huber, G. & Steinmeyer, E. M. (1997a). Early self-experienced neuropsychological deficits and subsequent schizophrenic diseases: an 8-year average follow-up prospective study. Acta Psychiatrica Scandinavica, 95, 396–404.
Klosterkötter, J., Gross, G., Huber, G. et al. (1997b). Evaluation of the ‘Bonn Scale for the Assessment of Basic Symptoms – BSABS’ as an instrument for the assessment of schizophrenia proneness: a review of recent findings. Neurology, Psychiatry and Brain Research, 5, 137–50.
Klosterkötter, J., Hellmich, M., Steinmeyer, E. M. & Schultze-Lutter, F. (2001) Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry, 58, 158–64.
Klosterkötter, J., Birchwood, M., Linszen, D. et al. (2005). Overview on the recruitment, sample characteristics, and distribution of inclusion criteria of the European Prediction of Psychosis Study (EPOS). European Psychiatry, 20(Suppl 1), s48.
Krabbendam, L., Myin-Germeys, I., Hanssen, M. et al. (2005). Development of depressed mood predicts onset of psychotic disorder in individuals who report hallucinatory experiences. British Journal of Clinical Psychology, 44, 113–25.
Kraepelin, E. (1919). Dementia Praecox. New York: Churchill Livingstone.
Kulynych, J. J., Luevano, L. F., Jones, D. W. & Weinberger, D. R. (1997). Cortical abnormality in schizophrenia: an in vivo application of the gyrification index. Biological Psychiatry, 41, 995–9.
Larsen, T. K. (2002). The transition from premorbid period to psychosis: how can it be described? Acta Psychiatrica Scandinavica, 106(Suppl), S10–11.
Lawrie, S. M., Whalley, H., Abukmeil, S. S. et al. (2002). Temporal lobe volume changes in people at high risk of schizophrenia with psychotic symptoms. British Journal of Psychiatry, 181, 138–43.
Leff, J., Kuipers, L., Berkowitz, R., Vaughn, L. & Sturgeon, D. (1983). Life events, relatives expressed emotion and maintenance neuroleptics in schizophrenic relapse. Psychological Medicine, 13, 799–806.
Lencz, T., Smith, C. W., Auther, A. M., Correll, C. U. & Cornblatt, B. A. (2003). The assessment of ‘prodromal schizophrenia’: unresolved issues and future directions. Schizophrenia Bulletin, 29, 717–28.
Lencz, T., Smith, C. W., Auther, A., Correll, C. U. & Cornblatt, B. (2004). Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophrenia Research, 68, 37–48.
Lencz, T., Smith, C. W., McLaughlin, D. et al. (2006). Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biological Psychiatry, 59, 863–71.
Linszen, D. & van Amelsvoort, T. (2007). Cannabis and psychosis: an update on course and biological plausible mechanisms. Current Opinion in Psychiatry, 20, 116–20.
Loranger, A. W., Sartorius, N., Andreoli, A. et al. (1994). The International Personality Disorder Examination. The World Health Organization Alcohol, Drug Abuse and Mental Health Administration pilot study of personality disorders. Archives of General Psychiatry, 51, 215–24.
Malla, A. K. & Norman, R. M. G. (1992). Relationship of life events and daily stressors to symptomatology in schizophrenia. Journal of Nervous and Mental Disease, 180, 664–7.
Malla, A. K., Cortese, L., Shaw, T. S. & Ginsberg, B. (1990). Life events and relapse in schizophrenia: a one year prospective study. Social Psychiatry and Psychiatric Epidemiology, 25, 221–4.
Mason, O., Startup, M., Halpin, S. et al. (2004). State and trait predictors of transition to first episode psychosis among individuals with at risk mental states. Schizophrenia Research, 71, 227–37.
McGlashan, T. H. (2001). Psychosis treatment prior to psychosis onset: ethical issues. Schizophrenia Research, 51, 47–54.
McGlashan, T. H., Zipursky, R. B., Perkins, D. et al. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry, 163, 790–9.
McGorry, P. D., Yung, A. & Phillips, L. (2001). Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophrenia Research, 51, 17–29.
McGorry, P. D., Yung, A. R., Phillips, L. J. et al. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59, 921–8.
McGorry, P. D., Yung, A. R. & Phillips, L. J. (2003). The ‘close-in’ or ultra high risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophrenia Bulletin, 29, 771–90.
Mednick, S. A., Parnas, J., Schulsinger, F. & Mednick, B. (1987). The Copenhagen High-Risk Project, 1962–1986. Schizophrenia Bulletin, 13, 485–96.
Miller, T. J., McGlashan, T. H., Rosen, J. L. et al. (2002). Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry, 159, 863–5.
Miller, T. J., McGlashan, T. H., Rosen, J. L. et al. (2003a). Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin, 29, 703–15.
Miller, T. J., Zipursky, R. B., Perkins, D. et al. (2003b). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the ‘prodromal’ sample. Schizophrenia Research, 61, 19–30.
Morrison, A. P., Bentall, R. P., French, P. et al. (2002). Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals: study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry, 181(Suppl), s78–84.
Morrison, A. P., French, P., Walford, L. et al. (2004). Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. British Journal of Psychiatry, 185, 291–7.
Niendam, T. A., Bearden, C. E., Johnson, J. K. et al. (2006). Neurocognitive performance and functional disability in the psychosis prodrome. Schizophrenia Research, 84, 100–11.
Nuechterlein, K. H., Dawson, M. E., Ventura, J. et al. (1994). The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatrica Scandanivica, 89, 58–64.
Olsen, K. A. & Rosenbaum, B. (2006). Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatrica Scandinavica, 113, 247–72.
Overall, J. E. & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.
Pantelis, C., Barnes, T. R., Nelson, H. E. et al. (1997). Frontal – striatal cognitive deficits in patients with chronic schizophrenia. Brain, 120, 1823–43.
Pantelis, C., Wood, S. J. & Maruff, P. (2002). Schizophrenia. In A. M. Owen & J. Harrison (eds.), Cognitive Deficits in Brain Disorders. London: Martin Dunitz, pp. 217–48.
Pantelis, C., Velakoulis, D., McGorry, P. D. et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 361, 281–8.
Pariante, C. M., Vassilopoulou, K., Velakoulis, D. et al. (2004). Abnormal pituitary volume in psychosis. British Journal of Psychiatry, 185, 5–10.
Park, S., Püschel, J., Sauter, B. H., Rentsch, M. & Hell, D. (1999). Spatial working memory deficits and clinical symptoms in schizophrenia: a 4-month follow-up study. Biological Psychiatry, 46, 392–400.
Phillips, L., Curry, C., Yung, A. et al. (2002a). Cannabis use is not associated with the development of psychosis in an ‘ultra’ high-risk group. Australian and New Zealand Journal of Psychiatry, 36, 800–6.
Phillips, L. J., Velakoulis, D., Pantelis, C. et al. (2002b). Non-reduction in hippocampal volume is associated with risk for psychosis. Schizophrenia Research, 58, 145–58.
Ruhrmann, S., Schultze-Lutter, F. & Klosterkötter, J. (2003). Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry, 36(Suppl), s162–7.
Ruhrmann, S., Schultze-Lutter, F., Maier, W. & Klosterkötter, J. (2005). Pharmacological intervention in the initial prodromal phase of psychosis. European Psychiatry, 20, 1–6.
Ruhrmann, S., Bechdolf, A., Kühn, K. et al. (2007). Acute effects of treatment for prodromal symptoms in persons putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry, 191(Suppl 51), s88–95.
Schultze-Lutter, F. (2001). Früherkennung der Schizophrenie anhand subjektiver Beschwerdeschilderungen: ein methodenkritischer Vergleich der Vorhersageleistung nonparametrischer statistischer und alternativer Verfahren zur Generierung von Vorhersagemodellen. Ph.D. thesis, University of Cologne (http://www.ub.uni-koeln.de/ediss/archiv/2001/11w1210.pdf).
Schultze-Lutter, F. (2004). Prediction of psychosis is necessary and possible. In C. McDonald, K. Schultz, R. Murray & P. Wright (eds.), Schizophrenia: Challenging the Orthodox. London: Taylor & Francis, pp. 81–90.
Schultze-Lutter, F., Wieneke, A., Picker, H. et al. (2004). The Schizophrenia Prediction Instrument, Adult Version (SPI-A). Schizophrenia Research, 70(Suppl 1), s76–7.
Schultze-Lutter, F., Ruhrmann, S. & Klosterkötter, J. (2006). Can schizophrenia be predicted phenomenologically? In J. O. Johannessen, B. V. Martindale & J. Cullberg (eds.), Evolving Psychosis. New York: Routledge/Taylor & Francis, pp. 104–23.
Schultze-Lutter, F., Addington, J., Klosterkötter, J. & Ruhrmann, S. (2007a). Schizophrenia Proneness Instrument, Adult version (SPI-A). Rome: Giovanni Fioriti Editore s.r.l.
Schultze-Lutter, F., Klosterkötter, J., Picker, H., Steinmeyer, E. M. & Ruhrmann, S. (2007b). Predicting first-episode psychosis by basic symptom criteria. Clinical Neuropsychiatry, 4, 11–22.
Schultze-Lutter, F., Ruhrmann, S., Picker, H. et al. (2007c). Basic symptoms in early psychotic and depressive disorders. British Journal of Psychiatry, 191(Suppl 51), s31–7.
Seidman, L. J., Giuliano, A. J., Smith, C. W. et al. (2006). Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. Schizophrenia Bulletin, 32, 507–24.
Snitz, B. E., Macdonald, A. W. III, & Carter, C. S. (2006). Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophrenia Bulletin, 32, 179–94.
Strauss, J. S. (1969). Hallucinations and delusions as points on continua function. Archives of General Psychiatry, 21, 581–6.
Sullivan, H. S. (1994). The onset of schizophrenia. American Journal of Psychiatry, 151, 135–9.
Tien, A. Y. (1991). Distributions of hallucinations in the population. Social Psychiatry and Psychiatric Epidemiology, 26, 287–92.
van Os, J., Hanssen, M., Bijl, R. V. & Vollebergh, W. (2001). Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Archives of General Psychiatry, 58, 663–8.
Velakoulis, D., Pantelis, C., McGorry, P. D. et al. (1999). Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high resolution magnetic resonance imaging study. Archives of General Psychiatry, 56, 133–41.
Ventura, J., Nuechterlein, K. H., Lukoff, D. & Hardesty, J. P. (1989). A prospective study of stressful life events and schizophrenic relapse. Journal of Abnormal Psychology, 98, 407–11.
Verdoux, H., van Os, J., Maurice-Tison, S. et al. (1998). Is early adulthood a critical developmental stage for psychosis proneness? A survey of delusional ideation in normal subjects. Schizophrenia Research, 29, 24.
Verdoux, H., van Os, J., Maurice-Tison, S. et al. (1999). Increased occurrence of depression in psychosis-prone subjects: a follow-up study in primary care settings. Comprehensive Psychiatry, 40, 462–8.
Warner, R. (2005). Problems with early and very early intervention in psychosis. British Journal of Psychiatry, 48(Suppl), s104–7.
Webster, M. J., Knable, M. B., O'Grady, J., Orthmann, J. & Weickert, C. S. (2002). Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry, 7, 985–94.
Wölwer, W., Buchkremer, G., Häfner, H. et al. (2003). German research network on schizophrenia. Bridging the gap between research and care. European Archives of Psychiatry and Clinical Neuroscience, 253, 321–9.
Wood, S. J., Pantelis, C., Proffitt, T. et al. (2003). Spatial working memory ability is a marker of risk-for-psychosis. Psychological Medicine, 33, 1239–47.
Woods, S. W., Brier, A., Zipursky, R. B. et al. (2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 54, 453–64.
Yung, A. R. (2003). Commentary: the schizophrenia prodrome: a high-risk concept. Schizophrenia Bulletin, 29, 859–65.
Yung, A. R. & McGorry, P. D. (1996). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophrenia Bulletin, 22, 353–70.
Yung, A. R. & McGorry, P. D. (1997). Is pre-psychotic intervention realistic in schizophrenia and related disorders? Australian and New Zealand Journal of Psychiatry, 31, 799–805.
Yung, A. R. & McGorry, P. (2003). Keeping an open mind: investigating options for treatment of the pre-psychotic phase. Journal of Mental Health, 12, 341–3.
Yung, A. R., McGorry, P. D., McFarlane, C. A. & Patton, G. (1995). The PACE Clinic: development of a clinical service for young people at high risk of psychosis. Australasian Psychiatry, 3, 345–9.
Yung, A. R., McGorry, P. D., McFarlane, C. A. et al. (1996). Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin, 22, 283–303.
Yung, A. R., Phillips, L. J., McGorry, P. D. et al. (1998). The prediction of psychosis: a step towards indicated prevention of schizophrenia? British Journal of Psychiatry, 173(Suppl 33), 14–20.
Yung, A. R., Phillips, L. J., Yuen, H. P. et al. (2003). Psychosis prediction: 12-month follow up of a high-risk (‘prodromal’) group. Schizophrenia Research, 60, 21–32.
Yung, A. R., Phillips, L. J. & McGorry, P. D. (2004a). Treating Schizophrenia in the Pre-Psychotic Phase. London: Dunitz.
Yung, A. R., Phillips, L. J., Yuen, H. P. & McGorry, P. D. (2004b). Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research, 67, 131–42.
Yung, A. R., Yuen, H. P., McGorry, P. D. et al. (2005). Mapping the onset of psychosis: the Comprehensive Assessment of At Risk Mental States (CAARMS). Australian and New Zealand Journal of Psychiatry, 39, 964–71.
Yung, A. R., Stanford, C., Cosgrave, E. et al. (2006a). Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophrenia Research, 84, 57–66.
Yung, A. R., Buckby, J. A., Cotton, S. M. et al. (2006b). Psychotic-like experiences in non-psychotic help-seekers: associations with distress, depression and disability. Schizophrenia Bulletin, 32, 352–9.
Yung, A. R., Yuen, H. P., Berger, G. et al. (2007). Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophrenia Bulletin, 33, 673–81.

Reference Title: References

Reference Type: reference-list

Addington, J. & Addington, D. (2005). Clinical trials during the prodromal stage of schizophrenia. [Letter to the editor.] American Journal of Psychiatry, 162, 1387.
Addington, J. & Burnett, P. (2004). Working with families in the early stages of psychosis. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis. Chichester, UK: John Wiley, pp. 99–116.
Addington, J., Francey, S. M. & Morrison, A. P. (2006). Working With People at High Risk of Developing Psychosis: A Treatment Handbook. Chichester, UK: John Wiley.
Agerbo, E., Byrne, M., Eaton, W. W. & Mortensen, P. B. (2003). Schizophrenia, marital status and employment: a forty year study. Schizophrenia Research, 60(Suppl 1), 32.
Andreasen, N. C. (1987). Creativity and mental illness: prevalence rates in writers and their first-degree relatives. American Journal of Psychiatry, 144, 1288–92.
APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
Barrowclough, C., Haddock, G., Tarrier, N. et al. (2001). Randomized controlled trial of motivational interviewing, cognitive behaviour therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry, 158, 1706–13.
Bechdolf, A., Phillips, L. J., Francey, S. et al. (2006). Recent approaches to psychological interventions for people at risk of psychosis. European Archives of Psychiatry and Neuroscience, 256, 159–73.
Beck, A. T. (1976). Cognitive Therapy and the Emotional Disorders. New York: International Universities Press.
Beck, A. T., Rush, A. J., Shaw, B. F. & Emery, G. (1979). Cognitive Therapy of Depression. New York: Guilford Press.
Bentall, R. P. & Morrison, A. P. (2002). More harm than good: the case against using antipsychotic drugs to prevent severe mental illness. Journal of Mental Health, 11, 351–6.
Bernstein, D. A. & Borkovec, T. D. (1973). Progressive Relaxation Training: A Manual for the Health Professionals. Campaign, IL: Research Press.
Broome, M. R., Woolley, J. B., Johns, L. C. et al. (2005). Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. European Psychiatry, 20, 372–8.
Cadenhead, K. (2002). Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics and the identification of the schizophrenia prodrome. Psychiatric Clinics of North America, 25, 837–53.
Carbone, S., Harrigan, S., McGorry, P. D., Curry, C. & Elkins, K. (1999). Duration of untreated psychosis and 12 month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatrica Scandinavica, 100, 96–104.
Caroff, S. N., Mann, S. C., Campbell, E. C. & Sullivan, K. A. (2002). Movement disorders associated with atypical antipsychotic drugs. Journal of Clinical Psychiatry, 63(Suppl 4), 12–19.
Chadwick, P., Birchwood, M. & Trower, P. (1996). Cognitive Therapy for Delusions, Voices and Paranoia. Chichester, UK: John Wiley.
Corcoran, C., Malaspina, D. & Hercher, L. (2005). Prodromal interventions for schizophrenia vulnerability: the risks of being ‘at risk’. Schizophrenia Research, 73, 173–84.
Cornblatt, B. A., Lencz, T. & Kane, J. M. (2001). Treatment of the schizophrenia prodrome: is it presently ethical? Schizophrenia Research, 51, 31–8.
Deegan, P. E. (1988). Recovery: the lived experience of rehabilitation. Psychosocial Rehabilitation Journal, 11, 11–19.
Deffenbacher, J. L. & McKay, M. (2000). Overcoming Situational and General Anger: A Protocol for the Treatment of Anger Based on Relaxation, Cognitive Restructuring, and Coping Skills Training. Oakland, CA: New Harbinger.
Eder-Ischia, U., Ebenbichler, C. & Fleischhacker, W. W. (2005). Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism. Essential Psychopharmacology, 6, 112–17.
Elkins, K., Hinton, M. & Edwards, J. (2004). Cannabis and psychosis: a psychological intervention. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis. Chichester, UK: John Wiley, pp. 137–56.
Falzer, P. R., Stayner, D. A. & Davidson, L. (2004). Principles and strategies for developing psychosocial treatments for negative symptoms in early course psychosis. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis. Chichester, UK: John Wiley, pp. 229–43.
Fowler, D., Garety, P. & Kuipers, E. (1995). Cognitive Behaviour Therapy for Psychosis: Theory and Practice. Chichester, UK: John Wiley.
French, P. & Morrison, A. P. (2004). Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis: A Treatment Approach. New York: John Wiley.
Germer, C. K., (2005). Anxiety disorders: befriending fear. In C. K. Germer, R. D. Siegel & P. R. Fulton (eds.), Mindfulness and Psychotherapy. New York: Guilford Press, pp. 152–72.
Häfner, H., Nowotny, B., Löffler, W., van der Heiden, W. & Maurer, K. (1995a). When and how does schizophrenia produce social deficits? European Archives of Psychiatry and Clinical Neuroscience, 246, 17–28.
Häfner, H., Maurer, W., Löffler, B. et al. (1995b). Onset and early course of schizophrenia. In H. Häfner & W. F. Gattaz. (eds.), Causes of Schizophrenia, vol. III. New York: Springer, pp. 43–66.
Häfner, H., Maurer, K., Ruhrmann, S. et al. (2004). Are early detection and secondary prevention feasible? Facts and visions. European Archives of Psychiatry and Clinical Neuroscience, 254, 117–28.
Haroun, N., Dunn, L., Haroun, A. & Cadenhead, K. S. (2006). Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophrenia Bulletin, 32, 166–78.
Harrigan, S. M., McGorry, P. D. & Krstev, H. (2003). Does treatment delay in first-episode psychosis really matter? Psychological Medicine, 33, 97–110.
Harris, M. G., Henry, L. P., Harrigan, S. M. et al. (2005). The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophrenia Research, 79, 85–93.
Hawkins, K. A., McGlashan, T. H., Quinlan, D. et al. (2004). Factorial structure of the Scale of Prodromal Symptoms. Schizophrenia Research, 68, 339–47.
Huber, G. & Gross, G. (1989). The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recent Progress in Medicine, 80, 646–52.
International Early Psychosis Association Writing Group (2005). International clinical practice guidelines for early psychosis. British Journal of Psychiatry, 187(Suppl 48), s120–4.
Jablensky, A. & Eaton, W. W. (1995). Schizophrenia. In A. Jablensky (eds.), Epidemiological Psychiatry. London: Baillière Tindall, pp. 283–306.
Jablensky, A. Sartorius, N., Ernberg, G. et al. (1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine – Monograph Supplement, 20, 1–97.
Jayaram, M. B., Hosalli, P. & Stroup, S. (2006). Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews, 2, CD005237.
Johns, L. C. & van Os, J. (2001). The continuity of psychotic experiences in the general population. Clinical Psychology Review, 21, 1125–41.
Kane, J. M. (2004). Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. Journal of Clinical Psychiatry, 65(Suppl 9), 16–20.
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–9.
Kingdon, D. & Turkington, D. (1994). Cognitive–Behavioural Therapy for Schizophrenia. Hove, England: Lawrence Erlbaum.
Kinon, B. J., Kaiser, C. J., Ahmed, S., Rotelli, M. D. & Kollack-Walker, S. (2005). Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. Journal of Clinical Psychopharmacology, 25, 255–8.
Klosterkötter, J., Hellmich, M., Steinmeyer, E. M. & Schultze-Lutter, F. (2001). Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry, 58, 158–64.
Larsen, T. K. (2002). The transition from the premorbid period to psychosis: how can it be described? Acta Psychiatrica Scandinavica, 106(Suppl 413), S10–11.
Lencz, T., Smith, C. W., Auther, A., Correll, C. U. & Cornblatt, B. A. (2003). The assessment of ‘prodromal schizophrenia’: unresolved issues and future directions. Schizophrenia Bulletin, 29, 717–28.
Lieberman, J. A., Tollefson, G. D., Schulz, C. et al. For the HGDH Study Group (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62, 361–70.
Manji, H. K., Moore, G. J. & Chen, G. (2000). Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic–depressive illness. Biological Psychiatry, 48, 740–54.
Margolese, H. C., Chouinard, G., Kolivakis, T. T. et al. (2005). Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Canadian Journal of Psychiatry, 50, 703–14.
Mason, O., Startup, M., Halpin, S. et al. (2004). Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophrenia Research, 71, 227–37.
McFarlane, W. R., Dixon, L., Lukens, E. & Lucksted, A. (2003). Family psychoeducation and schizophrenia: a review of the literature. Journal of Marital and Family Therapy, 29, 223–45.
McGlashan, T. H. (2001). Psychosis treatment prior to psychosis onset: ehical issues. Schizophrenia Research, 51, 47–54.
McGlashan, T. H., Zipursky, R. B., Perkins, D. et al. (2003). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design. Schizophrenia Research, 61, 7–18.
McGlashan, T. H., Zipursky, R. B., Perkins, D. et al. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry, 163, 790–9.
McGorry, P. D. (2005). Early intervention in psychotic disorders: beyond debate to solving problems. British Journal of Psychiatry, 187(Suppl 48), s108–10.
McGorry, P. D., Yung, A. R. & Phillips, L. J. (2001). Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophrenia Research, 51, 17–29.
McGorry, P. D., Yung, A. R., Phillips, L. J. et al. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59, 921–8.
Meichenbaum, D. H. (1975). Self-instructional methods. In F. H. Kanfer & Goldstein, A. P. (eds.), Helping People Change: A Textbook of Methods. New York: Pergamon, pp. 357–91.
Meyer, S. E., Bearden, C. E., Lux, S. R., et al. (2005). The psychosis prodrome in adolescent patients viewed through the lens of DSM-IV. Journal of Child and Adolescent Psychopharmacology, 15, 434–51.
Miller, L. J., O'Connor, E. & DiPasquale, T. (1993). Patients' attitudes toward hallucinations. American Journal of Psychiatry, 150, 584–8.
Miller, T. J., McGlashan, T. H., Rosen, J. L. et al. (2002). Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry, 159, 863–5.
Miller, T. J., Zipursky, R. B., Perkins, D. et al. (2003a). The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II Baseline characteristics of the ‘prodromal’ sample. Schizophrenia Research, 61, 19–30.
Miller, T. J., McGlashan, T. H., Rosen, J. L. et al. (2003b). Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin, 29, 703–15. [Erratum in Schizophrenia Bulletin (2004) 30, 217f.]
Miller, W. R. & Rollnick, S. (1991). Motivational Interviewing: Preparing People to Change Addictive Behaviour. New York: Guilford Press.
Morrison, A. P. (2001). The interpretation of intrusions in psychosis: an integrative cognitive approach to hallucinations and delusions. Behavioural and Cognitive Psychotherapy, 29, 257–76.
Morrison, A. P., French, P., Walford, L. et al. (2004). Cognitive therapy for the prevention of psychosis in people at ultra- high risk. British Journal of Psychiatry, 185, 291–7.
Morrison, A. P., Gumley, A. I., Schwannauer, M. et al. (2005). The beliefs about paranoia scale: preliminary validation of a metacognitive approach to conceptualising paranoia. Behavioural and Cognitive Psychotherapy, 33, 153–64.
Morrison, A. P., French, P., Parker, S. et al. (2007). Three year follow-up of a randomised controlled trial of cognitive therapy for the prevention of psychosis in people at ultra-high risk. Schizophrenia Bulletin, 33, 682–7.
Nemeroff, C. B. (2005). Use of atypical antipsychotics in refractory depression and anxiety. Journal of Clinical Psychiatry, 66, 13–21.
Newcomer, J. W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19(Suppl 1), 1–93.
Norman, R. M. G., Lewis, S. W. & Marshall, M. (2005). Duration of untreated psychosis and its relationship to clinical outcome. British Journal of Psychiatry, 187(Suppl 48), s19–23.
O'Reilly, T., Dunbar, R. & Bentall, R. (2001). Schizotypy and creativity: an evolutionary connection? Personality and Individual Differences, 31, 1067–78.
Ost, L. G. (1987). Applied relaxation: description of a coping technique and review of controlled studies. Behaviour Research and Therapy, 25, 397–410.
Phillips, L. J. & Francey, S. M. (2004). Changing PACE: psychological interventions in the pre-psychotic phase. In J. F. M Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis: A Practical Treatment Handbook. Chichester, UK: John Wiley, pp. 23–40.
Phillips, L. J., McGorry, P. D., Yuen, H. P. et al. (2007). Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research, 96, 25–33.
Post, S. G. (2001). Preventing schizophrenia and Alzheimer disease: comparative ethics. Schizophrenia Research, 51, 103–8.
Ramel, W., Goldin, P. R., Carmona, P. E. & McQuaid, J. R. (2004). The effects of mindfulness meditation on cognitive processes and affect in patients with past depression. Cognitive Therapy and Research, 28, 433–55.
Read, J. & Harre, N. (2001). The role of biological and genetic causal beliefs in the stigmatisation of ‘mental patients’. Journal of Mental Health, 10, 223–35.
Read, J. & Haslam, H. (2004). Public opinion: bad things happen and can drive you crazy. In J. Read, L. R. Mosher & R. P. Bentall (eds.), Models of Madness: Psychological, Social and Biological Approaches to Schizophrenia. Hove, UK: Brunner-Routledge, pp. 133–45.
Roemer, L. & Orsillo, S. M. (2002). Expanding our conceptualization of and treatment for generalized anxiety disorder: integrating mindfulness/acceptance-based approaches with existing cognitive-behavioral models. Clinical Psychology: Science and Practice, 9, 54–68.
Ruhrmann, S., Schultze-Lutter, F. & Klosterkötter, J. (2003). Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry, 36(Suppl 3), S162–7.
Ryle, A. & Kerr, I. B. (2002). Introducing Cognitive Analytic Therapy: Principles and Practice, Chichester, UK: John Wiley.
Sachdev, P. S. (2005). Neuroleptic-induced movement disorders: an overview. Psychiatric Clinics of North America, 28, 255–74.
Siddle, R. & Haddock, G. (2004). Cognitive-behavioural therapy for acute and recent-onset psychosis. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions in Early Psychosis. Chichester, UK: John Wiley, pp. 41–62.
Stathis, S., Martin, G. & McKenna, J. G. (2005). A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center. Journal of Clinical Psychopharmacology, 25, 539–44.
Sullivan, H. S. (1927; reprinted 1994). The onset of schizophrenia. American Journal of Psychiatry, 151, 135–9.
Svirkis, T., Korkeila, J., Heinimaa, M. et al. (2005). Axis I disorders and vulnerability to psychosis. Schizophrenia Research, 75, 439–46.
Tarrier, N., Harwood, S., Yusopoff, L., Beckett, R. & Baker, S. (1990). Coping strategy enhancement (CSE): a method of treating residual schizophrenic symptoms. Behavioural Psychotherapy, 18, 283–93.
Valmaggia, L. R., van der Gaag, M., Tarrier, N., Pijnenborg, M. & Slooff, C. J. (2005). Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. British Journal of Psychiatry, 186, 324–30.
Warner, R. (1985). Recovery from Schizophrenia: Psychiatry and Political Economy. New York: Routledge & Kegan Paul.
Warner, R. (2003). How much of the burden of schizophrenia is alleviated by treatment? British Journal of Psychiatry, 183, 375–6.
Warner, R. (2005). Problems with early and very early intervention in psychosis. British Journal of Psychiatry, 187(Suppl 48), s104–7.
Woods, S., Zipursky, R., Perkins, D. et al. (2002). Olanzapine vs. placebo for prodromal symptoms. Acta Psychiatrica Scandinavica, 106(Suppl 413), 43.
Woods, S. W., Breier, A., Zipursky, R. B. et al. (2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 54, 453–64.
Wykes, T. & van der Gaaz, M. (2001). Is it time to develop a new cognitive therapy for psychosis: cognitive remediation therapy (CRT). Clinical Psychology Review, 21, 1227–56.
Yung, A. R. & McGorry, P. D. (1996). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophrenia Bulletin, 22, 353–70.
Yung, A. R. & McGorry, P. D. (2003). Keeping an open mind: investigating options for treatment options of the pre-psychotic phase. Journal of Mental Health, 12, 341–3.
Yung, A. R., Phillips, L. J. & McGorry, P. D. (2004). Treating Schizophrenia in the Prodromal Phase. London: Taylor & Francis.
Yung, A. R., Phillips, L. J., Yuen, H. P. et al. (2003). Psychosis prediction: 12 month follow-up of a high risk (‘prodromal’) group. Schizophrenia Research, 60, 21–32.
Yung, A. R., Yuen, H. P., McGorry, P. D. et al. (2005). Mapping the onset of psychosis: the Comprehensive Assessment of At Risk Mental States (CAARMS). Australian and New Zealand Journal of Psychiatry, 39, 964–71.
Zimmermann, G., Favrod, J., Trieu, V. H. & Pomini, V. (2005). The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia-spectrum disorders: a meta-analysis. Schizophrenia Research, 77, 1–9.
Zubin, J. & Spring, B. (1977). Vulnerability: a new view of schizophrenia. Journal of Abnormal Psychology, 86, 103–26.

Reference Title: References

Reference Type: reference-list

Addington, J., van Mastrigt, S. & Addington, D. (2004). Duration of untreated psychosis: impact on 2-year outcome. Psychological Medicine, 34, 277–84.
Barnes, T., Hutton, S. B., Chapman, M. J. et al. (2000). West London first-episode study of schizophrenia. Clinical correlates of duration of untreated psychosis. British Journal of Psychiatry, 177, 207–11.
Beiser, M., Erickson, D., Fleming, J. A. E. & Iacono, W. G. (1993). Establishing the onset of psychotic illness. American Journal of Psychiatry, 150, 1349–54.
Biostat. Comprehensive Meta-Analysis Version 1.0.23. Englewood, NJ: Biostat. http//www.Meta-Analysis.com (accessed 13 February 2004).
Black, K., Peters, L., Rui, Q. et al. (2001). Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophrenia Research, 47, 215–22.
Bottlender, R., Strauss, A. & Moller, H. (2000). Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. Schizophrenia Research, 44, 145–50.
Bottlender, R., Sato, T., Jager, M. et al. (2002). The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. European Archives of Psychiatry and Clinical Neuroscience, 252, 226–31.
Bottlender, R., Sato, T., Jager, M. et al. (2003). The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophrenia Research, 62, 37–44.
Browne, S., Larkin, C. & O'Callaghan, E. (1999). Outcome studies in schizophrenia. Irish Journal of Psychological Medicine, 16, 140–4.
Browne, S., Clarke, M., Gervin, M. et al. (2000). Determinants of quality of life at first presentation with schizophrenia. British Journal of Psychiatry, 176, 173–6.
Cannon-Spoor, H. E., Potkin, S. G. & Wyatt, R. J. (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin, 8, 470–84.
Carbone, S., Harrigan, S., McGorry, P., Curry, C. & Elkins, K. (1999). Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatrica Scandinavica, 100, 96–104.
Chong, S., Mythily, Lum, A., Chan, Y. H. & McGorry, P. (2005). Determinants of duration of untreated psychosis and the pathway to care in Singapore. International Journal of Social Psychiatry, 51, 55–62.
Craig, T., Bromet, E. J., Fennig, S., Tanenberg-Karant, M., Lavelle, J. & Galambos, N. (2000). Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? American Journal of Psychiatry, 157, 60–6.
de Haan, L., Linszen, D. H., Lenior, M. E., de Win, E. D. & Gorsira, R. (2003). Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophrenia Bulletin, 29, 341–8.
Department of Health (2000). The NHS Plan. A Plan For Investment, A Plan For Reform. London: Department of Health.
Drake, R. J., Haley, C. J., Akhtar, S. & Lewis, S. W. (2000). Causes and consequences of duration of untreated psychosis in schizophrenia. British Journal of Psychiatry, 177, 511–15.
Edwards, J. & McGorry, P. D. (2002). Multi-component early intervention: models of good practice. In J. Edwards & P. D. McGorry (eds.), Implementing Early Intervention in Psychosis. London: Martin Dunitz, pp. 63–84.
Fresan, A., Apiquian, R., Ulloa, R. E. et al. (2003). Premorbid functioning by gender and its relationship with duration of untreated psychosis in first psychotic episode. Actas Españolas de Psiquiatría, 31, 53–8.
Friis, S., Melle, I., Larsen, T. K. et al. (2004). Does duration of untreated psychosis bias study samples of first-episode psychosis? Acta Psychiatrica Scandinavica, 110, 286–91.
Fuchs, J. & Steinert, T. (2004). Duration of untreated psychosis (DUP): a useful predictor of outcome in schizophrenia? Fortschritte der Neurologie-Psychiatrie, 72, 79–87.
Haas, G. & Sweeney, J. A. (1992). Premorbid and onset features of first-episode schizophrenia. Schizophrenia Bulletin, 18, 373–86.
Häfner, H., Riecher-Rossler, A., Hambrecht, M. et al. (1992). IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research, 6, 209–23.
Häfner, H., Maurer, K., Loffler, W. & Riecher-Rossler, A. (1993). The influence of age and sex on the onset and early course of schizophrenia. British Journal of Psychiatry, 162, 80–6.
Harrigan, S. M., McGorry, P. D. & Krstev, H. (2003). Does treatment delay in first-episode psychosis really matter? Psychological Medicine, 33, 97–110.
Ho, B. & Andreasen, N. C. (2001). Long delays in seeking treatment for schizophrenia. Lancet, 357, 898–9.
Ho, B., Andreasen, N. C., Flaum, M., Nopoulos, P. & Miller, D. (2000). Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. American Journal of Psychiatry, 157, 808–15.
Huber, G., Gross, G. & Schuttler, R. (1975). A long-term follow-up study of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatrica Scandinavica, 52, 49–57.
Kalla, O., Aaltonen, J., Wahlstrom, J. et al. (2002). Duration of untreated psychosis and its correlates first-episode psychosis in Finland and Spain. Acta Psychiatrica Scandinavica, 106, 265–75.
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–76.
Keshavan, K. S. & Schooler, N. R. (1992). First-episode studies in schizophrenia: criteria and characterization. Schizophrenia Bulletin, 18, 491–513.
Keshavan, M. S., Haas, G., Miewald, J. et al. (2003). Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. Schizophrenia Bulletin, 29, 757–69.
Larsen, T. K., McGlashan, T. J. & Moe, L. C. (1996). First-episode schizophrenia: I. Early course parameters. Schizophrenia Bulletin, 22, 241–56.
Larsen, T. K., Moe, L. C., Vibe-Hansen, L. & Johannessen, J. O. (2000). Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophrenia Research, 45, 1–9.
Larsen, T. K., McGlashan, T. H., Johannessen, J. O. et al. (2001). Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment. American Journal of Psychiatry, 158, 1917–19.
Lincoln, C. & McGorry, P. D. (1999). Pathways to care in early psychosis: clinical and consumer perspectives. In P. D. McGorry & H. J. Jackson (eds.), The Recognition and Management of Early Psychosis: A Preventive Approach. Cambridge, UK: Cambridge University Press, pp. 51–79.
Loebel, A. D., Lieberman, J. A., Alvir, J. M. et al. (1992). Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry, 149, 1183–8.
Malla, A. K., Norman, R. M. G., Manchanda, R. et al. (2002). One year outcome in first episode psychosis: influence of DUP and other predictors. Schizophrenia Research, 54, 231–42.
Marshall, M., Lockwood, L., Bradley, C. et al. (2000). Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia? British Journal of Psychiatry, 176, 249–53.
Maurer, K. & Häfner, H. (1995). Methodological aspects of onset assessment in schizophrenia. Schizophrenia Research, 15, 265–76.
McGlashan, T. H. (1998). Early detection and intervention of schizophrenia: rationale and research. British Journal of Psychiatry, 172, 3–6.
McGorry, P., Copolov, D. & Singh, B. (1990a). Royal Park Multidiagnostic Instrument for Psychosis: Part 1. Rationale and review. Schizophrenia Bulletin, 16, 501–15.
McGorry, P. D., Dossetor, C. R., Kaplan, I. et al. (1990). The Royal Park Multidiagnostic Instrument for Psychosis: Glossary and Guidelines for Administration. Melbourne, Australia: Royal Park Hospital. Available from Professor P. D. McGorry, Department of Psychiatry, University of Melbourne.
McGorry, P. D., Edwards, J., Mihalopoulos, C., Harrigan, S. M. & Jackson, H. J. (1996). EPPIC: an evolving system of early detection and optimal management. Schizophrenia Bulletin, 22, 305–26.
McGorry, P. D., Singh, B. S., Copolov, D. L. et al. (1990b). The Royal Park Multidiagnostic Instrument for Psychosis: Part II. Development, reliability and validity. Schizophrenia Bulletin, 16, 517–36.
Melle, I., Larsen, T. K., Haahr, U. et al. (2004). Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Archives of General Psychiatry, 61, 143–50.
Norman, R. & Malla, A. K. (2001). Duration of untreated psychosis: a critical examination of the concept and its importance. Psychological Medicine, 31, 381–400.
Norman, R., Townsend, L. & Malla, A. (2001). Duration of untreated psychosis and cognitive functioning in first-episode patients. British Journal of Psychiatry, 179, 340–5.
Perkins, D. O., Leserman, J., Jarskog, L. F. et al. (2000). Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophrenia Research, 44, 1–10.
Perkins, D. O., Gu, H., Boteva, K. & Lieberman, J. A. (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry, 162, 1785–804.
Robinson, D. G., Woerner, M. G., Alvir, J. A. J. et al. (1999a). Predictors of relapse following response from a first-episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241–7.
Robinson, D. G., Woerner, M. G., Alvir, J. A. J. et al. (1999b). Predictors of treatment response from a first-episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 156, 544–9.
Sheitman, B. & Lieberman, J. A. (1998). The natural history and pathophysiology of treatment resistant schizophrenia. Journal of Psychiatric Research, 32, 143–50.
Singh, S. P., Cooper, J. E., Fisher, H. L. et al. (2005). Determining the chronology and components of psychosis onset: the Nottingham Onset Schedule (NOS). Schizophrenia Research, 80, 117–30.
Szymanski, S., Cannon, T. D., Gallacher, F., Erwin, R. J. & Gur, R. E. (1996). Course of treatment response in first-episode and chronic schizophrenia. American Journal of Psychiatry, 153, 519–25.
Tirupati, N. S., Rangaswamy, T. & Raman, P. (2004). Duration of untreated psychosis and treatment outcome in schizophrenia patients untreated for many years. Australian and New Zealand Journal of Psychiatry, 38, 339–43.
Ucok, A., Polat, A., Genc, A., Cakir, S. & Turan, N. (2004). Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. Journal of Psychiatric Research, 38, 163–8.
Verdoux, H., Bergey, C., Assens, F. et al. (1998). Prediction of duration of psychosis before first admission. European Psychiatry, 13, 346–52.
Verdoux, H., Liraud, F., Gonzales, B. et al. (1999). Short-term outcome in first admission for psychosis. Encephale, 25, 213–20.
Verdoux, H., Liraud, F., Bergey, C. et al. (2001). Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophrenia Research, 49, 231–41.
Wiersma, D., Nienhuis, F., Slooff, C. J. & Giel, R. (1998). Natural course of schizophrenic disorders: a 15-year follow up of a Dutch incidence cohort. Schizophrenia Bulletin, 24, 75–85.
Wunderink, A., Nienhuis, F. J., Sytema, S. & Wiersma, D. (2006). Treatment delay and response rate in first episode psychosis. Acta Psychiatrica Scandinavica, 113, 332–9.
Wyatt, R. (1991). Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophrenia Research, 5, 201–2.
Wyatt, R. & Henter, I. (2001). Rationale for the study of early intervention. Schizophrenia Research, 51, 69–76.

Reference Title: References

Reference Type: reference-list

Addington, J., van Mastrigt, S., Hutchinson, J. & Addington, D. (2002). Pathways to care: help seeking behaviour in first episode psychosis. Acta Psychiatrica Scandinavica, 106, 358–64.
Angermeyer, M. C. & Matschinger, H. (1999). Social representations of mental illness among the public. In J. Guimon, W. Fischer & N. Sartorius (eds.), The Image of Madness: The Public Facing Mental Illness and Psychiatric Treatment. Basel: Karger, pp. 20–8.
Angermeyer, M. C. & Matschinger, H. (2004). Public attitudes towards psychotropic drugs: have there been any changes in recent years? Pharmacopsychiatry, 37, 152–6.
Angermeyer, M. C. & Matschinger, H. (2005). Have there been any changes in the public's attitudes towards psychiatric treatment? Results from representative population surveys in Germany in the years 1990 and 2001. Acta Psychiatrica Scandinavica, 111, 68–73.
Angermeyer, M. C., Däumer, R. & Matschinger, H. (1993). Benefits and risks of psychotropic medication in the eyes of the general public: results of a survey in the Federal Republic of Germany. Pharmacopsychiatry, 26, 114–20.
Battaglia, J., Coverdale, J. H. & Bushong, C. P. (1990). Evaluation of a mental illness awareness week program in public schools. American Journal of Psychiatry, 147, 324–9.
Bertolote, J. & McGorry, P. D. (2005). Early intervention and recovery for young people with early psychosis: consensus statement. British Journal of Psychiatry, 187(Suppl), s116–19.
Caldwell, T. M. & Jorm, A. F. (2000). Mental health nurses' beliefs about interventions for schizophrenia and depression: a comparison with psychiatrists and the public. Australian and New Zealand Journal of Psychiatry, 34, 602–11.
Chong, S. A., Mythily, S. & Verma, S. (2005). Reducing the duration of untreated psychosis and changing help-seeking behaviour in Singapore. Social Psychiatry and Psychiatric Epidemiology, 40, 619–21.
de Haan, L., Welborn, K., Krikke, M. & Linszen, D. H. (2004). Opinions of mothers on the first psychotic episode and the start of treatment of their child. European Psychiatry, 19, 226–9.
Fischer, W., Goerg, D., Zbinden, E. & Guimon, J. (1999). Determining factors and the effects of attitudes towards psychotropic medication. In J. Guimon, W. Fischer & N. Sartorius (eds.), The Image of Madness: The Public Facing Mental Illness and Psychiatric Treatment. Basel: Karger, pp. 162–86.
Furnham, A. & Chan, E. (2004). Lay theories of schizophrenia: a cross-cultural comparison of British and Hong Kong Chinese attitudes, attributions and beliefs. Social Psychiatry and Psychiatric Epidemiology, 39, 543–52.
Green, L. W. & Kreuter, M. W. (1999). Health Promotion Planning: An Educational and Ecological Approach, 3rd edn. Mountain View, CA: Mayfield.
Häfner, H., Maurer, K., Trendler, G. et al. (2005). Schizophrenia and depression: challenging the paradigm of two separate diseases: a controlled study of schizophrenia, depression and healthy controls. Schizophrenia Research, 77, 11–24.
Harris, M. G., Henry, L. P., Harrigan, S. M. et al. (2005). The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophrenia Research, 79, 85–93.
Janz, N. K. & Becker, M. H. (1984). The health belief model: a decade later. Health Education Quarterly, 11, 1–47.
Johannessen, J. O., McGlashan, T. H., Larsen, T. K. et al. (2001). Early detection strategies for untreated first-episode psychosis. Schizophrenia Research, 51, 39–46.
Jorm, A. F., Korten, A. E., Jacomb, P. A. et al. (1997a). ‘Mental health literacy’: a survey of the public's ability to recognize mental disorders and their beliefs about the effectiveness of treatment. Medical Journal of Australia, 166, 182–6.
Jorm, A. F., Korten, A. E., Jacomb, P. A. et al. (1997b). Helpfulness of interventions for mental disorders: beliefs of health professionals compared to the general public. British Journal of Psychiatry, 171, 233–7.
Jorm, A. F., Angermeyer, M. C. & Katschnig, H. (2000). Public knowledge of and attitudes to mental disorders: a limiting factor in the optimal use of treatment services. In G. Andrews & S. Henderson (eds.), Unmet Need in Psychiatry: Problems, Resources, Responses. Cambridge, UK: Cambridge University Press, pp. 399–413.
Jorm, A. F., Kitchener, B. A., O'Kearney, R. & Dear, K. B. G. (2004). Mental health first aid training of the public in a rural area: a cluster randomized trial. BMC Psychiatry, 4, 33.
Jorm, A. F., Nakane, Y., Christensen, H. et al. (2005a). Public beliefs about treatment and outcome of mental disorders: a comparison of Australia and Japan. BMC Medicine, 3, 12.
Jorm, A. F., Blewitt, K. A., Griffiths, K. M., Kitchener, B. A. & Parslow, R. A. (2005b). Mental health first aid responses of the public: results from an Australian national survey. BMC Psychiatry, 5, 9.
Jorm, A. F., Christensen, H. & Griffiths, K. M. (2006). The public's ability to recognize mental disorders and their beliefs about treatment: changes in Australia over 8 years. Australian and New Zealand Journal of Psychiatry, 40, 36–41.
Kitchener, B. A. & Jorm, A. F. (2002a). Mental Health First Aid Manual. Canberra: Centre for Mental Health Research.
Kitchener, B. A. & Jorm, A. F. (2002b). Mental health first aid training for the public: evaluation of effects on knowledge, attitudes and helping behavior. BMC Psychiatry, 2, 10.
Kitchener, B. A. & Jorm, A. F. (2004). Mental health first aid training in a workplace setting: a randomized controlled trial. BMC Psychiatry, 4, 23.
Kitchener, B. A. & Jorm, A. F. (2006). Mental health first aid training: review of evaluation studies. Australian and New Zealand Journal of Psychiatry, 40, 6–8.
Lauber, C., Nordt, C., Falcato, L. & Rössler, W. (2003). Do people recognize mental illness? Factors influencing mental health literacy. European Archives of Psychiatry and Clinical Neuroscience, 253, 248–51.
Lauber, C., Ajdacic-Gross, V., Fritschi, N., Stulz, N. & Rossler, W. (2005a). Mental health literacy in an educational elite: an online survey among university students. BMC Public Health, 5, 44.
Lauber, C., Nordt, C. & Rössler, W. (2005b). Recommendations of mental health professionals and the general population on how to treat mental disorders. Social Psychiatry and Psychiatric Epidemiology, 40, 835–43.
Lincoln, C., Harrigan, S. & McGorry, P. D. (1998). Understanding the topography of the early psychosis pathways: an opportunity to reduce delays in treatment. British Journal of Psychiatry, 172(Suppl), S21–5.
Magliano, L., Fiorillo, A., De Rosa, C., Malangone, C. & Maj, M. (2004). Beliefs about schizophrenia in Italy: a comparative nationwide survey of the general public, mental health professionals, and patients' relatives. Canadian Journal of Psychiatry, 49, 322–30.
Malla, A., Norman, R., Scholten, D., Manchanda, R. & McLean, T. (2005). A community intervention for early identification of first episode psychosis: impact of duration of untreated psychosis (DUP) and patient characteristics. Social Psychiatry and Psychiatric Epidemiology, 40, 337–44.
Marshall, M., Lewis, S., Lockwood, A. et al. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry, 62, 975–83.
Melle, I., Larsen, T. K., Haahr, U. et al. (2004). Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Archives of General Psychiatry, 61, 143–50.
Norman, R. M. G., Malla, A. K., Verdi, M. B., Hassall, L. D. & Fazekas, C. (2004). Understanding delay in treatment for first-episode psychosis. Psychological Medicine, 34, 255–66.
Pearce, K., Rickwood, D. & Beaton, S. (2003). Preliminary evaluation of a university-based suicide intervention project: impact on participants. Australian e-Journal for the Advancement of Mental Health, 2. www.auseinet.com/journal/vol2iss1/Pearce.pdf.
Perkins, D. O., Nieri, J. M., Bell, K. & Lieberman, J. A. (1999). Factors that contribute to delay in the initial treatment of psychosis. Schizophrenia Research, 36, 52.
Pinfold, V., Toulmin, H., Thornicroft, G. et al. (2003). Reducing psychiatric stigma and discrimination: evaluation of educational interventions in UK secondary schools. British Journal of Psychiatry, 182, 342–6.
Rickwood, D., Cavanagh, S., Curtis, L. & Sakrouge, R. (2004). Educating young people about mental health and illness: evaluating a school-based programme. International Journal of Health Promotion, 6, 23–32.
Riedel-Heller, S. G., Matschinger, H. & Angermeyer, M. C. (2005). Mental disorders: who and what might help? Help-seeking and treatment preferences of the lay public. Social Psychiatry and Psychiatric Epidemiology, 40, 167–74.
Wright, A., Harris, M. G., Wiggers, J. H. et al. (2005). Recognition of depression and psychosis by young Australians and their beliefs about treatment. Medical Journal of Australia, 183, 18–23.
Wright, A., McGorry, P. D., Harris, M. G., Jorm, A. F. & Pennell, K. (2006). Development and evaluation of a youth mental health community awareness campaign: the Compass Strategy, BMC Public Health, 6, 215–28.

Reference Title: References

Reference Type: reference-list

Addington, J., van Mastrigt, S., Hutchinson, J. & Addington, D. (2002). Pathways to care: help seeking behaviour in first-episode psychosis. Acta Psychiatrica Scandinavica, 106, 358–64.
Amaddeo, F., Zambello, F., Tansella, M. & Thornicroft, G. (2001). Accessibility and pathways to psychiatric care in a community-based mental health system. Social Psychiatry and Psychiatric Epidemiology, 36, 500–7.
Amador, X. F., Strauss, D. H., Yale, S. A. & Gorman, J. M. (1991). Awareness of illness in schizophrenia. Schizophrenia Bulletin, 17, 113–32.
Balestrieri, M., Bon, M. G., Rodriguez-Sacristan, A. & Tansella, M. (1994). Pathways to psychiatric care in South-Verona, Italy. British Journal of Psychiatry, 24, 641–9.
Barnes, T. R., Hutton, S. B., Chapman, M. J. et al. (2000). West London first episode study of schizophrenia: clinical correlates of duration of untreated psychosis. British Journal of Psychiatry, 177, 207–11.
Beiser, M., Erickson, D., Fleming, J. A. E. & Iacono, W. G. (1993). Establishing the onset of psychotic illness. American Journal of Psychiatry, 150, 1349–54.
Bhugra, D., Corridan, B., Rudge, S., Leff, J. & Mallett, R. (1999). Early manifestations, personality traits and pathways to care for Asian and white first-onset cases of schizophrenia. Social Psychiatry and Psychiatric Epidemiology. 34, 595–9.
Birchwood, M., Smith, J., Cochrane, R., Wetton, S. & Copestake, S. (1990). The Social Functioning Scale. The development and validation of a new scale of social development for use in family intervention programmes with schizophrenic patients. British Journal of Psychiatry, 157, 853–9.
Black, K., Peters, L., Rui, Q. et al. (2001). Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophrenia Research, 47, 215–22.
Burnett, R., Mallett, R., Bhugra, D. et al. (1999). The first contact of patients with schizophrenia with psychiatric services: social factors and pathways to care in a multi-ethnic population. Psychological Medicine, 29, 475–83.
Chen, E. Y-H., Dunn, E. L-W., Miao, M. Y-K. et al. (2005). The impact of family experience on the duration of untreated psychosis (DUP) in Hong Kong. Social Psychiatry and Psychiatric Epidemiology, 40, 350–6.
Chong, S-A., Mythily, S., Lum, A., Chan, Y. H. & McGorry, P. D. (2005a). Determinants of duration of untreated psychosis and the pathway to care in Singapore. International Journal of Social Psychiatry, 51, 55–62.
Chong, S-A., Mythily, S. & Verma, S. (2005b). Reducing the duration of untreated psychosis and changing help-seeking behaviour in Singapore. Social Psychiatry and Psychiatric Epidemiology, 40, 619–21.
Christiana, J. M., Gilman, S. E., Guardino, M. et al. (2000). Duration between onset and time of obtaining initial treatment among people with anxiety and mood disorders: an international survey of members of mental health patient advocate groups. Psychological Medicine, 30, 693–703.
Cohen, R. Z., Gotowiec, A. & Seeman, M. V. (2000). Duration of pretreatment phases in schizophrenia: women and men. Canadian Journal of Psychiatry, 45, 544–7.
Cole, E., Leavey, G., King, M., Johnson-Sabine, E. & Hoar, A. (1995). Pathways to care for patients with a first episode of psychosis: a comparison of ethnic groups. British Journal of Psychiatry, 167, 770–6.
Compton, M. T., Kaslow, N. J. & Walker, E. F. (2004). Observations on parent/family factors that may influence the duration of untreated psychosis among African American first-episode schizophrenia patients. Schizophrenia Research, 68, 373–85.
Cougnard, A., Kalmi, E., Desage, A. et al. (2004a). Pathways to care of first-admitted subjects with psychosis in South-Western France. Psychological Medicine, 34, 267–76.
Cougnard, A., Kalmi, E., Desage, A. et al. (2004b). Factors influencing compulsory admission in first episode subjects with psychosis. Social Psychiatry and Psychiatric Epidemiology, 39, 804–9.
de Haan, L., Peters, B., Dingemans, P., Wouters, L. & Linszen, D. (2002). Attitudes of patients toward the first psychotic episode and the start of treatment. Schizophrenia Bulletin, 28, 431–42.
de Haan, L., Welborn, K., Krikke, M. & Linszen, D. (2004). Opinions of mothers on the first psychotic episode and the start of treatment of their child. European Psychiatry, 19, 226–9.
Drake, R. J., Haley, C. J., Akhtar, S. & Lewis, S. W. (2000). Causes and consequences of duration of untreated psychosis in schizophrenia. British Journal of Psychiatry, 177, 511–15.
Erikson, D. H., Beiser, M., Iacono, W. G., Fleming, J. A. & Lin, T. (1989). The role of social relationships in the course of first-episode schizophrenia and affective psychosis. American Journal of Psychiatry, 146, 1456–61.
Erikson, D. H., Beiser, M. & Iacono, W. G. (1998). Social support predicts 5-year outcome in first-episode schizophrenia. Journal of Abnormal Psychology, 107, 681–5.
Etheridge, K., Yarrow, L. & Peet, M. (2004). Pathways to care in first episode psychosis. Journal of Psychiatric and Mental Health Nursing, 11, 125–8.
Friis, S., Vaglum, P., Haahr, U. et al. (2005). Effect of an early detection programme on duration of untreated psychosis: part of the Scandinavian TIPS study. British Journal of Psychiatry, 187(Suppl 48), s29–32.
Fuchs, J. & Steinert, T. (2004). Patients with a first episode of schizophrenia spectrum psychosis and their pathways to psychiatric hospital care in South Germany. Social Psychiatry and Psychiatric Epidemiology, 39, 375–80.
Gallo, J. J., Ford, S. M. & Anthony, J. C. (1995). Filters on the pathway to mental healthcare, II. Sociodemographic factors. Psychological Medicine, 25, 1149–60.
Garety, P. A. & Rigg, A. (2001). Early psychosis in the inner city: a survey to inform service planning. Social Psychiatry and Psychiatric Epidemiology, 36, 537–44.
Gater, R. & Goldberg, D. (1991). Pathways to psychiatric care in Manchester. British Journal of Psychiatry, 159, 90–6.
Gundez-Bruce, H., McMeniman, M., Robinson, D. G. et al. (2005). Duration of untreated psychosis and time to treatment response for delusions and hallucinations. American Journal of Psychiatry, 162, 1966–9.
Haley, C. J., Drake, R. J., Bentall, R. P. & Lewis, S. W. (2003). Health beliefs link to duration of untreated psychosis and attitudes to later treatment in early psychosis. Social Psychiatry and Psychiatric Epidemiology, 38, 311–16.
Hambrecht, M. (1995). A second case of schizophrenia in the family: is it observed differently? European Archives of Psychiatry and Clinical Neuroscience, 245, 267–9.
Harrigan, S. M., McGorry, P. D. & Krstev, H. (2003). Does treatment delay in first-episode psychosis really matter? Psychological Medicine, 33, 97–110.
Helgason, L. (1990). Twenty years follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatrica Scandinavica, 81, 231–5.
Ho, B-C. & Andreasen, N. C. (2001). Long delays in seeking treatment for schizophrenia. Lancet, 157, 898–900.
Jenike, M. A. (2004). Obsessive – compulsive disorder. New England Journal of Medicine, 350, 259–65.
Johannessen, J. O., Larsen, T. K. & McGlashan, T. (1999). Duration of untreated psychosis: an important target for intervention in schizophrenia? Nordic Journal of Psychiatry, 53, 275–83.
Johannessen, J. O., McGlashan, T. H., Larsen, T. K. et al. (2001). Early detection strategies for untreated first-episode psychosis. Schizophrenia Research, 51, 39–46.
Johnstone, E. C., Crow, T. C., Johnson, A. L. & MacMillan, J. F. (1986). The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems related to admission. British Journal of Psychiatry, 148, 115–20.
Kalla, O., Aaltonen, J., Wahlstrom, J. et al. (2002). Duration of untreated psychosis and its correlates in first episode psychosis in Finland and Spain. Acta Psychiatrica Scandinavica, 106, 265–75.
Kelly, B. D., Clark, M., Browne, S. et al. (2004). Clinical predictors of admission status in first-episode schizophrenia. European Psychiatry, 19, 67–71.
Kessler, D., Lloyd, K., Lewis, G. & Gray, D. P. (1999). Cross sectional study of symptom attribution and recognition of depression and anxiety in primary care. British Medical Journal, 318, 136–40.
Krstev, H., Carbone, S., Harrigan, S. M. et al. (2004). Early intervention in first-episode psychosis: the impact of a community development campaign. Social Psychiatry and Psychiatric Epidemiology, 39, 711–19.
Larsen, T. K., McGlashan, T. H. & Moe, L. C. (1996). First episode schizophrenia: I. Early course parameters. Schizophrenia Bulletin, 22, 241–56.
Larsen, T. K., Johannessen, J. O. & Opjordsmoen, S. (1998). First episode schizophrenia with long duration of untreated psychosis: pathways to care. British Journal of Psychiatry, 172(Suppl 3), s45–52.
Larsen, T. K., McGlashan, T. H., Johannessen, J. O. et al. (2001). Shortened duration of untreated first episode of psychosis: change in patient characteristics at treatment. American Journal of Psychiatry, 158, 1917–19.
Lieberman, J. A. & Fenton, W. S. (2000). Delayed detection of psychosis: causes, consequences, and effect on public health. American Journal of Psychiatry, 157, 1727–30.
Lincoln, C. V. & McGorry, P. D. (1995). Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Psychiatric Services, 46, 1166–71.
Lincoln, C. V., Harrigan, S. & McGorry, P. D. (1998). Understanding the topography of the early psychosis pathway. British Journal of Psychiatry, 172(Suppl 33), s21–5.
Loebel, A. D., Lieberman, J. A., Alvir, J. M. J. et al. (1992). Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry, 149, 1183–8.
Malla, A. K. & Norman, R. M. G. (2001). Treating psychosis: is there more to early intervention than intervening early? Canadian Journal of Psychiatry, 46, 645–8.
Malla, A. K. & Norman, R. M. G. (2002). Early intervention in schizophrenia and related disorders: advantages and pitfalls. Current Opinion in Psychiatry, 15, 17–23.
Malla, A. K., Norman, R. M. G. & Voruganti, L. P. (1999). Improving outcome in schizophrenia: the case for early intervention. Canadian Medical Association Journal, 160, 843–6.
Malla, A. K., Takhar, J. J., Norman, R. M. G. et al. (2002). Negative symptoms in first episode non-affective psychosis. Acta Psychiatrica Scandinavica, 105, 431–9.
Malla, A. K., Norman, R. M. G., McLean, T. S. et al. (2004). Determinants of quality of life in first episode psychosis. Acta Psychiatrica Scandinavica, 109, 46–54.
Malla, A. K., Norman, R. M. G., Scholten, D., Manchanda, R. & McLean, T. (2005). A community intervention for early identification of first-episode psychosis: impact on duration of untreated psychosis (DUP) and patient characteristics. Social Psychiatry and Psychiatric Epidemiology, 40, 337–44.
Marshall, M., Lewis, S., Lockwood, A. et al. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. Archives of General Psychiatry, 62, 975–83.
McGlashan, T. H. (1999). Duration of untreated psychosis in first episode schizophrenia: marker or determinant of course? Biological Psychiatry, 46, 899–907.
McGorry, P. D. (2000). Evaluating the importance of reducing the duration of untreated psychosis. Australian and New Zealand Journal of Psychiatry, 34(Suppl), s145–9.
McGorry, P. D., Edwards, J., Mihalopoulos, C., Harrigan, S. M. & Jackson, H. J. (1996). EPPIC: an evolving system of early detection and optimal management. Schizophrenia Bulletin, 22, 305–26.
McGorry, P. D., Krstev, H. & Harrigan, S. (2000). Early detection and treatment delay: implications for outcomes in early psychosis. Current Opinion in Psychiatry, 13, 37–43.
Melle, I., Larsen, T. K., Haahr, U. et al. (2004). Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Archives of General Psychiatry, 61, 143–50.
Miller, T. J., McGlashan, T. H., Woods, S. W. et al. (1999). Symptom assessment in schizophrenia prodromal states. Psychiatric Quarterly, 70, 273–87.
Moller, P. (2000). First-episode schizophrenia: do grandiosity, disorganization, and acute initial development reduce duration of untreated psychosis? An exploratory naturalistic case study. Comprehensive Psychiatry, 41, 184–90.
Moller, P. (2001). Duration of untreated psychosis: are we ignoring the model of initial development? Psychopathology, 34, 8–14.
Norman, R. M. G. & Malla, A. K. (2001). Duration of untreated psychosis: a critical examination of the concept and its importance. Psychological Medicine, 31, 381–400.
Norman, R. M. G. & Malla, A. K. (2002). Examining adherence to medication and substance abuse as possible confounds of duration of untreated psychosis. Journal of Nervous and Mental Disease, 190, 331–4.
Norman, R. M. G., Malla, A. K., Verdi, M. B., Hassall, L. D. & Fazekas, C. (2004). Understanding delay in treatment for first-episode psychosis. Psychological Medicine, 34, 255–66.
Norman, R. M. G., Lewis, S. W. & Marshall, M. (2005a). Duration of untreated psychosis and its relationship to clinical outcome. British Journal of Psychiatry, 187(Suppl 48), s19–23.
Norman, R. M. G., Malla, A. K., Manchanda, R. et al. (2005b). Social support and three-year symptom and admission outcomes for first episode psychosis. Schizophrenia Research, 80, 227–34.
Norman, R. M. G., Malla, A. K., Manchanda, R., Harricharan, R. & Northcott, S. (2007). Delay in treatment for psychosis: Its relation to family history. Social Psychiatry and Psychiatric Epidemiology, 42, 507–12.
Peralta, V., Cuesta, M. J., Matinez-Larrea, A., Serrano, J. E. & Langarica, M. (2005). Duration of untreated psychotic illness: the role of premorbid social support networks. Social Psychiatry and Psychiatric Epidemiology, 40, 345–9.
Perkins, D. O., Nieri, J. M., Bell, K. & Lieberman, J. A. (1999). Factors that contribute to delay in the initial treatment of psychosis. Schizophrenia Research, 36, 52.
Perkins, D. O., Gu, H., Boteva, K. & Lieberman, J. A. (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry, 162, 1785–804.
Phillips, L., Yung, A. R., Hearn, N. et al. (1999). Preventive mental healthcare: accessing the target population. Australian and New Zealand Journal of Psychiatry, 33, 912–17.
Preda, A., Miller, T. J., Rosen, J. L. et al. (2002). Treatment histories of patients with a syndrome putatively prodromal to schizophrenia. Psychiatric Services, 53, 342–4.
Singh, S. P. & Grange, T. (2006). Measuring pathways to care in first episode psychosis: a systematic review. Schizophrenia Research, 81, 75–82.
Skeate, A., Jackson, C., Birchwood, M. & Jones, C. (2002). Duration of untreated psychosis and pathways to care in first episode psychosis: investigation of help-seeking behaviour in primary care. British Journal of Psychiatry, 181(Suppl 43), s73–7.
Thompson, A., Hunt, C. & Issakidis, C. (2004). Why wait? Reasons for delay and prompts to seek help for mental health problems in an Australian clinical sample. Social Psychiatry and Psychiatric Epidemiology, 39, 810–17.
Verdoux, H., Bergey, C., Assens, F. et al. (1998). Prediction of duration of psychosis before first admission. European Psychiatry, 13, 346–52.
Verdoux, H., Liraud, F., Bergey, C. et al. (2001). Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophrenia Research, 49, 231–41.
Wells, J. E., Robins, L. N., Bushnell, J. A. et al. (1994). Perceived barriers to care in St. Louis (USA) and Christchurch (NZ): reason for not seeking help for psychological distress. Social Psychiatry and Psychiatric Epidemiology, 29, 155–64.
Wyatt, R. J. (1991). Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17, 325–51.
Yamazawa, R., Mizuno, M., Nemoto, T. et al. (2004). Duration of untreated psychosis and pathways to psychiatric services in first-episode schizophrenia. Psychiatry and Clinical Neurosciences, 58, 76–81.

Reference Title: References

Reference Type: reference-list

Allen, M. H., Currier, G. W., Hughes, D. H., Reyes-Harde, M. & Docherty, J. P. (2001). The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgraduate Medicine, 1–88.
Allison, D. B., Mentore, J. L., Heo, M. et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 1686–96.
APA. (1980). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Press.
APA. (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
APA. (2004a). Practice guideline for the treatment of patients with schizophrenia (second edition). In American Psychiatric Association, Practice Guidelines for the Treatment of Psychiatric Disorders. Compendium 2004, Washington, DC: American Psychiatric Press, pp. 249–440.
APA. (2004b) Practice guideline for the treatment of patients with bipolar disorder (second edition). In American Psychiatric Association, Practice Guidelines for the Treatment of Psychiatric Disorders. Compendium 2004, Washington, DC: American Psychiatric Press, pp. 525–612.
APA. (2004c). Practice guideline for the treatment of patients with major depressive disorder (second edition). In American Psychiatric Association, Practice Guidelines for the Treatment of Psychiatric Disorders. Compendium 2004, Washington, DC: American Psychiatric Press, pp. 440–524.
Arendt, M., Rosenberg, R., Foldager, L., Perto, G. & Munk-Jorgensen, P. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. British Journal of Psychiatry, 187, 510–15.
Arseneault, L., Cannon, M., Poulton, R. et al. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal, 325, 1212–13.
Barnes, T. R., Mutsatsa, S. H., Hutton, S. B., Watt, H. C. & Joyce, E. M. (2006). Comorbid substance use and age at onset of schizophrenia. British Journal of Psychiatry, 188, 237–42.
Bechdolf, A., Pukrop, R., Kohn, D. et al. (2005). Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophrenia Research, 79, 137–43.
Bilder, R. M., Goldman, R. S., Robinson, D. et al. (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. American Journal of Psychiatry, 157, 549–59.
Carlsson, R., Nyman, H., Ganse, G. & Cullberg, J. (2006) Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosis. Acta Psychiatrica Scandinavica, 113, 102–11.
Coldham, E. L., Addington, J. & Addington, D. (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica, 106, 286–90.
Conus, P., Abdel-Baki, A., Harrigan, S., Lambert, M. & McGorry, P. D. (2004). Schneiderian first rank symptoms predict poor outcome within first episode manic psychosis. Journal of Affective Disorders, 81, 259–68.
Correll, C. U., Leucht, S. & Kane, J. M. (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. American Journal of Psychiatry, 161, 414–25.
Day, J. C., Bentall, R. P., Roberts, C. et al. (2005). Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Archives of General Psychiatry, 62, 717–24.
de Haan, L., Welborn, K., Krikke, M. & Linszen, D. H. (2004). Opinions of mothers on the first psychotic episode and the start of treatment of their child. European Psychiatry, 19, 226–9.
Drake, R. E., McHugo, G. J., Xie, H. et al. (2006). Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin, 32, 464–73.
Edwards, J. & McGorry, P. (2002). Implementing Early Intervention in Psychosis. London: Martin Dunitz.
Emsley, R. A. (1999). Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophrenia Bulletin, 25, 721–9.
Emsley, R. A., Rabinowitz, J. & Medori, R. (2006). Time course for antipsychotic treatment response in first-episode schizophrenia. American Journal of Psychiatry, 163, 743–5.
Faulkner, G., Soundy, A. A. & Lloyd, K. (2003). Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatrica Scandinavica, 108, 324–32.
Flyckt, L., Mattsson, M., Edman, G., Carlsson, R. & Cullberg, J. (2006). Predicting 5-year outcome in first-episode psychosis: construction of a prognostic rating scale. Journal of Clinical Psychiatry, 67, 916–24.
Fountoulakis, K. N., Nimatoudis, I., Iacovides, A. & Kaprinis, G. (2004). Off-label indications for atypical antipsychotics: a systematic review. Annual General Hospital Psychiatry, 3, 1–10.
Gearon, J. S. & Bellack, A. S. (1999). Women with schizophrenia and co-occurring substance use disorders: an increased risk for violent victimization and HIV. Community Mental Health Journal, 35, 401–19.
Goodwin, G. M. for the Consensus Group of the British Association of Psychopharmacology (2003). Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 17, 149–73.
Gray, R., Wykes, T. & Gournay, K. (2002). From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. Journal of Psychiatry and Mental Health Nursing, 9, 277–84.
Green, M. F., Kern, R. S, Braff, D. L. & Mintz J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘right stuff’? Schizophrenia Bulletin, 26, 119–36.
Gunduz-Bruce, H., McMeniman, M., Robinson, D. G. et al. (2005). Duration of untreated psychosis and time to treatment response for delusions and hallucinations. American Journal of Psychiatry, 162, 1966–9.
Hamann, J., Leucht, S. & Kissling W. (2003). Shared decision making in psychiatry. Acta Psychiatrica Scandinavica, 107, 403–9.
Hamann, J., Cohen, R., Leucht, S., Busch, R. & Kissling W. (2005). Do patients with schizophrenia wish to be involved in decisions about their medical treatment? American Journal of Psychiatry, 162, 2382–4.
Hawton, K., Sutton, L., Haw, C., Sinclair, J. & Deeks, J. J. (2005). Schizophrenia and suicide: systematic review of risk factors. British Journal of Psychiatry, 187, 9–20.
Huq, Z. U. For the RIS-GBR-32 Investigators (2004). A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. Journal of Clinical Psychopharmacology, 24, 220–4.
International Early Psychosis Association Writing Group (2005). International clinical practice guidelines for early psychosis. British Journal of Psychiatry, 187(Suppl 48), s120–4.
Jarbin, H., Ott, Y. & von Knorring, A. L. (2003). Adult outcome of social function in adolescent-onset schizophrenia and affective psychosis. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 176–83.
Jones, P., Rodgers, B., Murray, R. & Marmot, M. (1994). Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet, 19, 1398–402.
Joyce, E. M., Hutton, S. B., Mutsatsa, S. H. & Barnes, T. R. (2005). Cognitive heterogeneity in first-episode schizophrenia. British Journal of Psychiatry, 187, 516–22.
Keefe, R. S., Seidman, L. J., Christensen, B. K. et al. (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry, 161, 985–95.
Kim-Cohen, J., Caspi, A., Moffitt, T. E. et al. (2003). Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Archives of General Psychiatry, 60, 709–17.
Kopala, L. C., Good, K. P., Milliken, H. et al. (2006). Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophrenia Research, 81, 29–39.
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G. & Jeste, D. V. (2002). Prevalence of and risk factors for medication non-adherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry, 63, 892–909.
Lambert, M. & Naber, D. (2004a). Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs, 18(Suppl 2), 5–17.
Lambert, M. & Naber, D. (2004b). Current Schizophrenia. London: Science Press.
Lambert, M., Conus, P., Lambert, T. & McGorry, P. D. (2003a). Pharmacotherapy of first-episode schizophrenia. Expert Opinion on Pharmacotherapy, 4, 717–51.
Lambert, M., Holzbach, R., Moritz, S. et al. (2003b). Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. International Clinical Psychopharmacology, 18, 251–60.
Lambert, M., Conus, P., Lubman, D. I. et al. (2005a). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica, 112, 141–8.
Lambert, M., Conus, P., Schimmelmann, B. et al. (2005b). Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry, 38, 206–13.
Lambert, M., Conus, P., Schimmelmann, B., Naber, D. & McGorry, P. D. (2005c). Olanzapine in patients with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone. International Journal of Psychiatry in Clinical Practice, 9, 244–50.
Lambert, M., Schimmelmann, B., Naber, D. et al. (2006). Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. Journal of Clinical Psychiatry, 67, 1690–7.
Lambert, M., Naber, D., Eich, F. X. et al. (2007). Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatrica Scandinavica 115, 106–13.
Larsen, T. K., Friis, S., Haahr, U. et al. (2004). Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. British Journal of Psychiatry, 185, 108–15.
Law, C. W., Chen, E. Y., Cheung, E. F. et al. (2005). Impact of untreated psychosis on quality of life in patients with first-episode schizophrenia. Quality of Life Research, 14, 1803–11.
Lencz, T., Smith, C. W., Auther, A., Correll, C. U. & Cornblatt, B. (2004). Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophrenia Research, 68, 37–48.
Leucht, S., Pitschel-Walz, G., Abraham, D. & Kissling, W. (1999). Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51–68.
Lieberman, J. A., Tollefson, G., Tohen, M. et al. For the HGDH Study Group (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry, 160, 1396–404.
Maki, P., Veijola, J., Jones, P. B. et al. (2005). Predictors of schizophrenia: a review. British Medical Bulletin, 73–74, 1–15.
Malla, A., Norman, R., Scholten, D. et al. (2004). A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. Psychiatry Research, 129, 159–69.
Malla, A., Norman, R., Schmitz, N. et al. (2006). Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychological Medicine, 36, 649–58.
Manchanda, R., Norman, R. M., Malla, A. K., Harricharan, R. & Northcott, S. (2005). Persistent psychoses in first episode patients. Schizophrenia Research, 80, 113–16.
Marder, S. R., Essock, S. M., Miller, A. L. et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 1334–49.
Marshall, M., Lewis, S., Lockwood, A. et al. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry, 62, 975–83.
Mattsson, M., Lawoko, S., Cullberg, J. et al. (2005). Background factors as determinants of satisfaction with care among first-episode psychosis patients. Social Psychiatry and Psychiatric Epidemiology, 40, 749–54.
McEvoy, J. P., Hogarty, G. E. & Steingard, S. (1991). Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry, 48, 7397–45.
McEvoy, J. P., Meyer, J. M., Goff, D. C. et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19–32.
McEvoy, J. P., Johnson, J., Perkins, D. et al. (2006). Insight in first-episode psychosis. Psychological Medicine, 36, 1385–93.
McGorry, P. D. (1999). Recommended haloperidol and risperidone doses in first-episode psychosis. Journal of Clinical Psychiatry, 60, 794–5.
McGorry, P. D., Copolov, D. L. & Singh, B. S. (1990a). Royal Park Multidiagnostic Instrument for Psychosis: Part I. Rationale and review. Schizophrenia Bulletin, 16, 501–15.
McGorry, P. D., Singh, B. S., Copolov, D. L. et al. (1990b). Royal Park Multidiagnostic Instrument for Psychosis: Part II. Development, reliability, and validity. Schizophrenia Bulletin, 16, 517–36.
McIntyre, R. S., Konarski, J. Z., Soczynska, J. K. et al. (2006). Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatric Services, 57, 1140–4.
Merlo, M. C., Hofer, H., Gekle, W. et al. (2002). Risperidone, 2 mg/d vs. 4 mg/d, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. Journal of Clinical Psychiatry, 63, 885–91.
Mueser, K. T. & McGurk, S. R. (2004). Schizophrenia. Lancet, 363, 2063–72.
NICE. (2002). Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Clinical Guideline 1. London: National Collaborating Centre for Mental Health.
Newcomer J W. (2006). Medical risk in patients with bipolar disorder and schizophrenia. Journal of Clinical Psychiatry, 67(Suppl 9), 25–30.
Olsen, K. A. & Rosenbaum, B. (2006a). Prospective investigations of the prodromal state of schizophrenia: assessment instruments. Acta Psychiatrica Scandinavica, 113, 273–82.
Olsen, K. A. & Rosenbaum, B. (2006b). Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatrica Scandinavica, 113, 247–72.
Oosthuizen, P., Emsley, R. A., Turner, J. & Keyter, N. (2001). Determining the optimal dose of haloperidol in first-episode psychosis. Journal of Psychopharmacology, 15, 251–5.
Perkins, D., Lieberman, J., Gu, H. et al. For the HGDH Research Group (2004). Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. British Journal of Psychiatry, 185, 18–24.
Perlis, R. H. (2005). The role of pharmacologic treatment guidelines for bipolar disorder. Journal of Clinical Psychiatry, 66(Suppl 3), 37–47.
Petersen, L., Jeppesen, P., Thorup, A. et al. (2005). A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. British Medical Journal 331, 602–10.
Power, P. & McGorry, P. D. (1999). Initial assessment in first-episode psychosis. In P. D. McGorry & H. J. Jackson (eds.), The Recognition and Management of Early Psychosis. A Preventive Approach. Cambridge, UK: Cambridge University Press, pp. 155–84.
Poyurovsky, M., Fuchs, C. & Weizman, A. (1999). Obsessive–compulsive disorder in patients with first-episode schizophrenia. American Journal of Psychiatry, 156, 1998–2000.
Remington, G. (2005). Rational pharmacotherapy in early psychosis. British Journal of Psychiatry, 48(Suppl), s77–84.
Robinson, D. G., Woerner, M. G., Alvir, J. M. et al. (1999a). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 156, 544–9.
Robinson, D. G., Woerner, M. G., Alvir, J. M. et al. (1999b). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241–7.
Robinson, D. G., Woerner, M. G., Alvir, J. M. et al. (2002). Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research, 57, 209–19.
Robinson, D. G., Woerner, M. G., Delman, H. M. & Kane, J. M. (2005). Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin, 31, 705–22.
Rosen, J. L., Miller, T. J., D'Andrea, J. T., McGlashan, T. H. & Woods, S. W. (2006). Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophrenia Research, 85, 124–31.
Royal Australian and New Zealand College of Psychiatrists (2004). Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Australian and New Zealand Journal of Psychiatry, 38, 280–305.
Royal Australian and New Zealand College of Psychiatrists (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39, 1–30.
Sanger, T. M., Lieberman, J. A., Tohen, M. et al. (1999). Olanzapine versus haloperidol treatment in first-episode psychosis. American Journal of Psychiatry, 156, 79–87.
Schimmelmann, B., Conus, P., Edwards, J., McGorry, P. D. & Lambert, M. (2005a). Diagnostic stability 18-month after a first diagnosis of psychosis. Journal of Clinical Psychiatry, 66, 1239–46.
Schimmelmann, B., Paulus, S., Tilgner, C. et al. (2005b). Side effects, subjective distress and subjective well-being in first admitted adolescents with early onset psychosis treated with atypical antipsychotics. Journal of Child and Adolescent Psychopharmacology, 15, 249–58.
Schimmelmann, B., Conus, P., Schacht, M., McGorry, P. D. & Lambert, M. (2006). Predictors of service disengagement in first admitted adolescents with psychosis. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 990–9.
Schooler, N., Rabinowitz, J., Davidson, M. et al. For the Early Psychosis Global Working Group (2005). Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. American Journal of Psychiatry, 162, 947–53.
Schwartz, J. E., Fennig, S., Tanenberg-Karant, M. et al. (2000). Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Archives of General Psychiatry, 57, 593–600.
Sim, K., Swapna, V., Mythily, S. et al. (2004). Psychiatric comorbidity in first episode psychosis: the Early Psychosis Intervention Programme (EPIP) experience. Acta Psychiatrica Scandinavica, 109, 23–9.
Sim, K., Chua, T. H., Chan, Y. H., Mahendran, R. & Chong, S. A. (2006). Psychiatric comorbidity in first episode schizophrenia: a 2 year, longitudinal outcome study. Journal of Psychiatry Research, 40, 656–63.
Thorup, A., Petersen, L., Jeppesen, P. et al. (2005). Integrated treatment ameliorates negative symptoms in first episode psychosis: results from the Danish OPUS trial. Schizophrenia Research, 79, 95–105.
Townsend, L. A. & Norman, R. M. (2004). Course of cognitive functioning in first episode schizophrenia spectrum disorders. Expert Review of Neurotherapeutics, 4, 61–8.
Ventura, J., Liberman, R. P., Green, M. F., Shaner, A. & Mintz, J. (1998). Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Research, 15, 163–73.
Wade, D., Harrigan, S., Edwards, J. et al. (2006). Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry, 189, 229–34.
WHO (1992). International Classification of Diseases, 10th edn. Geneva: World Health Organization.
Yap, H. L., Mahendran, R., Lim, D. et al. (2001). Risperidone in the treatment of first-episode psychosis. Singapore Medical Journal, 42, 170–3.
Zalsman, G., Carmon, E., Martin, A. et al. (2003). Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. Journal of Children and Adolescent Psychopharmacology, 13, 319–27.
Zhang-Wong, J., Zipursky, R. B., Beiser, M. & Bean G. (1999). Optimal haloperidol dosage in first-episode psychosis. Canadian Journal of Psychiatry, 44, 164–7.

Reference Title: References

Reference Type: reference-list

Addington, J. (2003). An integrated treatment approach to substance abuse in an early psychosis program. In H. Graham, K. Mueser, M. Birchwood & A. Copello (eds.), Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery. Chichester, UK: John Wiley, pp. 121–35.
Addington, J. & Addington, D. (2006). Phase specific group treatment in an early psychosis program. In J. O. Johannessen, B. Martindale & J. Cullberg (eds.), Evolving Psychosis: Different Stages Different Treatments. London: Brunner-Routledge, pp. 124–38.
Addington, J. & Burnett, P. (2004). Working with families in the early stages of psychosis. In J. F. M. Gleeson & P. D. McGorry (eds.), Psychological Interventions for Early Psychosis. Chichester, UK: John Wiley, pp. 99–116.
Addington, J. & Gleeson, J. (2005). Implementing cognitive behaviour therapy for first episode psychosis, British Journal of Psychiatry, 187(Suppl 48), s272–6.
Addington, J., Leriger, E. & Addington, D. (2003a). Symptom outcome one year after admission to an early psychosis program. Canadian Journal of Psychiatry, 48, 204–7.
Addington, J., Young, J. & Addington, D. (2003b). Social outcome in early psychosis. Psychological Medicine, 33, 1119–24.
Addington, J., Brooks, B. & Addington, D. (2003c). Cognitive functioning in first episode psychosis: initial presentation. Schizophrenia Research, 62, 59–64.
Addington, J., Collins, A., McCleery, A. & Addington, D. (2005a). The role of family work in early psychosis. Schizophrenia Research, 79, 77–83.
Addington, J., McCleery, A. & Addington, D. (2005b). Three year outcome of family work in an early psychosis program. Schizophrenia Research, 79, 107–16.
Addington, J., Saeedi, H. & Addington, D. (2005c). The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome. Schizophrenia Research, 78, 35–43.
Addington, J., Chaves, A. C. & Addington, D. (2006). Diagnostic stability over one year in first episode psychosis. Schizophrenia Research, 86, 71–5.
Albiston, D. J., Francey, S. M. & Harrigan, S. M. (1998). Group programmes for recovery from early psychosis. British Journal of Psychiatry, 172(Suppl 33), s117–21.
APA (2000). Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (text revision), 4th edn [DSM-IV]. Washington, DC: American Psychiatric Press.
Andreasen, N. C., Carpenter, W. T., Jr, Kane, J. M., et al. (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry, 162, 441–9.
Anthony, W. A. (2000). A recovery-oriented service system: setting some system level standards. Psychiatric Rehabilitation Journal, 24, 159–69.
Arvindakshan, M., Ghate, M., Ranjekar, P. K., Evans, D. R. & Mahadik, S. P. (2003). Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research, 62, 195–204.
Barnes, T. R. E. & McEvedy, C. J. B. (1996). Pharmacological treatment strategies in the non-responsive schizophrenic patient. International Clinical Psychopharmacology, 11, 67–71.
Birchwood, M., Todd, P. & Jackson, C. (1998). Early intervention in psychosis: the critical period hypothesis. British Journal of Psychiatry, 172(Suppl 33), s53–9.
Bond, W. S. & Hussar, D. A. (1991). Detection methods and strategies for improving medication compliance. American Journal of Hospital Pharmacy, 48, 1978–88.
Brenner, H. D., Dencker, S. J., Goldstein, M. J. et al. (1990). Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin, 16, 551–61.
Buckley, P. F. & Shendarkar, N. (2005). Treatment-refractory schizophrenia. Current Opinion in Psychiatry, 18, 165–73.
Canadian Psychiatric Association (2005). Clinical practice guidelines for schizophrenia. Canadian Journal of Psychiatry, 50(Suppl 1).
Chadwick, P., Birchwood, M. & Trower, P. (1996). Cognitive Therapy for Delusions, Voices and Paranoia. New York: John Wiley.
Chanpattana, W. & Kramer, B. A. (2004). Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvement in psychopathology, quality of life and social outcomes. Schizophrenia Research, 66, 177–81.
Chanpattana, W., Chakrabhand, M. L., Kongaskon, R., Techakasem, P. & Buppanharun, W. (1999). Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia. Journal of ECT, 15, 129–39.
Coldham, E. L., Addington, J. & Addington, D. (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica, 106, 286–90.
Conley, R. R. & Buchanan, R. W. (1997). Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin, 23, 663–74.
Conley, R. R., Carpenter, W. R. J. & Taminga, C. A. (1997). Time to response and response-dose in a 12-month clozapine trial. American Journal of Psychiatry, 154, 1243–7.
Corrigan, P. W. & Watson, A. C. (2002). The paradox of self-stigma and mental illness. Clinical Psychology, Science and Practice, 9, 35–53.
Cramer, J. A. & Rosenheck, R. (1998). Compliance with medication regimens for mental and physical disorders. Psychiatric Services, 49, 196–201.
Drake, R., Becker, D. & Bond, G. (2003). Recent research on vocational rehabilitation for persons with severe mental illness. Current Opinion in Psychiatry, 16, 451–5.
Early Psychosis Prevention and Intervention Centre (EPPIC) (2000). Early Psychosis Manuals, 3: Working with Groups in Early Psychosis. Melbourne, Australia: Psychiatric Services Branch, Victoria Health Service.
Edwards, J., Maude, D., McGorry, P. D., Harrigan, S. M. & Cocks, J. T. (1998). Prolonged recovery in first-episode psychosis. British Journal of Psychiatry, 172(Suppl 33), s107–16.
Edwards, J., McGorry, P., Waddell, F. & Harrigan, S. (1999). Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. Schizophrenia Research, 40, 147–58.
Edwards, J., Harris, M. G. & Bapat, S. (2005). Developing services for first episode psychosis and the critical period. British Journal of Psychiatry, 187(Suppl 48), s91–7.
Fowler, D., Garety, P. & Kuipers, E. (1995). Cognitive Behavior Therapy for Psychosis. Chichester, UK: John Wiley.
Garety, P. A., Fowler, D. & Kuipers, E. (2000). Cognitive-behavioral therapy for medication-resistant symptoms. Schizophrenia Bulletin, 26, 73–86.
Grant, C., Addington, J., Addington, D. & Konnert, C. (2001). Social functioning in first- and multi-episode schizophrenia. Canadian Journal of Psychiatry, 46, 746–9.
Green, A. I., Tohen, M. F., Hamer, R. M. et al. for the HGDH Research Group (2004). First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research, 66, 125–35.
Green, M. F., Kern, R. S. & Heaton, R. K. (2004). Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Research, 72, 41–51.
Gumley, A. & Schwannauer, M. (2006). Staying Well After Psychosis: A Cognitive Interpersonal Approach to Recovery and Relapse Prevention. Chichester, UK: John Wiley.
Gupta, S., Andreasen, N. C., Arndt, S. et al. (1997). The Iowa longitudinal study of recent onset psychosis: one-year follow-up of first episode patients. Schizophrenia Research, 23, 1–13.
Häfner, H., Loffler, W., Maurer, K., Hambrecht, M. & an der Heiden, W. (1999). Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatrica Scandinavica, 100, 105–18.
Harrigan, S. M., McGorry, P. D. & Krstev, H. (2003). Does treatment delay in first-episode psychosis really matter? Psychological Medicine, 33, 97–110.
Harrison, G., Croudace, T., Mason, P., Glazebrook, C. & Medley, I. (1996). Predicting the long-term outcome of schizophrenia. Psychological Medicine, 26, 697–705.
Harvey, P. D., Meltzer, H., Simpson, G. M. et al. (2004). Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia, Schizophrenia Research, 66, 101–13.
Hermann-Doig, T., Maude, D. & Edwards, J. (2003). Systematic Treatment of Persisting Psychosis (STOPP): A Guide for Facilitating Recovery From First Episode Psychosis. London: Martin Dunitz.
Ho, B. C., Nopoulos, P., Flaum, M., Arndt, S. & Andreasen, N. C. (1998). Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. American Journal of Psychiatry, 155, 1196–201.
Ho, B. C., Alicata, D., Ward, J. et al. (2003). Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. American Journal of Psychiatry, 160, 142–8.
Hofer, A., Hummer, M., Kemmler, G. et al. (2003). The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. International Journal of Neuropsychopharmacology, 6, 201–6.
Hunt, G. E., Bergen, J. & Bashir, M. (2002). Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival four years after a relapse. Schizophrenia Research, 54, 253–64.
Jackson, C. & Birchwood, M. (1996). Early intervention in psychosis: opportunities for secondary prevention. British Journal of Clinical Psychology, 35, 487–502.
Jackson, H., Edwards, J., Hulbert, C. & McGorry, P. D. (1999). Recovery from psychosis. In P. McGorry & H. J. Jackson (eds.), The Recognition and Management of Early Psychosis: A Preventive Approach. Cambridge, UK: Cambridge University Press, pp. 265–307.
Jackson, H., McGorry, P., Henry, L. et al. (2001). Cognitively oriented psychotherapy for early psychosis (COPE): a 1 year follow-up. British Journal of Clinical Psychology, 40, 57–70.
Jackson, H. J., McGorry, P. D., Killackey, E. et al. (2008). Acute phase and 1-year follow-up results of a randomized controlled trial of CBT versus befriending for first-episode psychosis: the ACE project. Psychological Medicine, 38, 725–35.
Kampman, O., Laippala, P., Vaananen, J. et al. (2002). Indicators of medication compliance in first-episode psychosis. Psychiatry Research, 110, 39–48.
Kemp, R., Hayward, P., Applewhaite, G., Everitt, B. & David, A. (1996). Compliance therapy in psychotic patients: randomised controlled trial. British Medical Journal, 312, 345–9.
Killackey, E. (2004). Psychosocial treatment. In M. Lambert & D. Naber (eds.), Current Schizophrenia. London: Science Press, pp. 65–74.
Killackey, E., Jackson, H. J. & McGorry, P. D. (2008). Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. British Journal of Psychiatry, 193, 114–20.
Kingdon, D. G. & Turkington, D. (2002). The Case Study Guide to Cognitive Behaviour Therapy of Psychosis. Chichester, UK: John Wiley.
Kingdon, D. G. & Turkington, D. (2005). Cognitive-Behavioral Therapy of Schizophrenia. London: Guilford Press.
Koreen, A. R., Siris, S. G., Chakos, M. et al. (1993). Depression in first-episode schizophrenia. American Journal of Psychiatry, 150, 1643–8.
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G. & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry, 63, 892–909.
Lambert, M., Conus, P., Lambert, T. & McGorry, P. D. (2003a). Pharmacotherapy of first-episode psychosis. Expert Opinion in Pharmacotherapy, 4, 717–50.
Lambert, M., Conus, P., Lubman, D. I. et al. (2005). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica, 112, 141–8.
Lambert, T. (2006). Selecting patients for long-acting novel antipsychotic therapy. Australasian Psychiatry, 14, 38–42.
Lambert, T. & Castle, D. (2003) Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia, 178 (9 Suppl), S57–61.
Lambert, T. J., Cock, N., Alcock, S. J., Kelly, D. L. & Conley, R. R. (2003b). Measurement of antipsychotic-induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacology, 18, 405–11.
Lambert, T. J., Brennan, A., Castle, D., Kelly, D. L. & Conley, R. R. (2003c) Perception of depot antipsychotics by mental health professionals. Journal of Psychiatric Practice, 9, 252–60.
Lambert, T. J., Chapman, L. H. for the Consensus Working Group (2004). Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Medical Journal of Australia, 181, 544–8.
Lehman, A. F., Kreyenhuhl, J., Buchanan, R. W., et al. (2004). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin, 30, 193–217.
Lewis, S., Tarrier, N., Haddock, G. et al. (2002). Randomised controlled trial of cognitive–behavioral therapy in early schizophrenia: acute-phase outcomes. British Journal of Psychiatry, 181(Suppl), s91–7.
Lieberman, J., Alvir, J., Woerner, M. et al. (1992). Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophrenia Bulletin, 18, 351–71.
Lieberman, J., Jody, D., Geisler, S. et al. (1993). Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry, 50, 369–76.
Lieberman, J. A., Sheitman, B., Chakos, M. et al. (1998). The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. Journal of Clinical Psychopharmacology, 18(Suppl), S20–4.
Lieberman, J. A., Chakos, M., Wu, H. et al. (2001). Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry, 49, 487–99.
Lincoln, C. V. & McGorry, P. (1995). Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Psychiatric Services, 46, 1166–71.
Linzsen, D. H., Dingemans, P. M., Lenior, M. E. et al. (1994). Relapse criteria in schizophrenic disorders: different perspectives. Psychiatry Research, 54, 273–81.
Little, K. Y., Gay, T. L. & Vore, M. (1989). Predictors of response to high dose antipsychotics in chronic schizophrenics. Psychiatry Research, 30, 1–9.
Malla, A. K., Norman, R. M. G., McLean, T. S. & McIntosh, E. (2001). Impact of phase-specific treatment of first episode of psychosis on Wisconsin Quality of Life Index (client version). Acta Psychiatrica Scandinavica, 103, 355–61.
Manchanda, R., Norman, R. M., Malla, A. K., Harricharan, R. & Northcott, S. (2005). Persistent psychoses in first episode patients. Schizophrenia Research, 80, 113–16.
Marshall, M., Lewis, S., Lockwood, A. et al. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archives of General Psychiatry, 62, 975–83.
Marwaha, S. & Johnson, S. (2004). Schizophrenia and employment: a review. Social Psychiatry and Psychiatric Epidemiology, 39, 337–49.
McGlashan, T. H., Docherty, J. P. & Siris, S. (1976). Integrative and sealing-over recoveries from schizophrenia: distinguishing case studies. Psychiatry, 39, 325–38.
McGlashan, T. H., Wadeson, H. S. & Carpenter, W. T. (1977). Art and recovery style from psychosis. Journal of Nervous and Mental Disease, 164, 182–90.
McGorry, P. D. (2002). The detection and optimal management of early psychosis. In J. Lieberman & R. M. Murray (eds.), Comprehensive Care of Schizophrenia. London: Martin Dunitz, pp. 153–66.
McGorry, P. D., Edwards, J., Mihalopoulos, C., Harrigan, S. M. & Jackson, H. J. (1996). EPPIC: an evolving system of early detection and optimal management. Schizophrenia Bulletin, 22, 305–26.
Meltzer, H. Y., Lee, M. & Cola, P. (1998). The evolution of treatment resistance: biologic implications. Journal of Clinical Psychopharmacology, 18(Suppl 1), S5–11.
Miller, A. L., Hall, C. S., Buchanan, R. W. et al. (2004). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry, 65, 500–8.
Morrison, A. P. (ed.) (2002). A Casebook of Cognitive Therapy For Psychosis. New York: Taylor & Francis.
Murphy, B. P., Chung, Y. C., Park, T. W. & McGorry, P. D. (2006). Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophrenia Research, 88, 5–25.
Myin-Germeys, I., Delespaul, P. & van Os, J. (2005). Behavioural sensitization to daily life stress in psychosis. Psychological Medicine, 35, 733–41.
Nelson, H. (1997). Cognitive Behavioral Therapy with Schizophrenia. Cheltenham, UK: Nelson Thornes.
Nosé, M., Barbui, C. & Tansella, M. (2003). How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine, 33, 1149–60.
Pantelis, C. & Barnes, T. R. (1996). Drug strategies and treatment-resistant schizophrenia. Australian and New Zealand Journal of Psychiatry, 30, 20–37.
Pantelis, C. & Lambert, T. J. (2003). Managing patients with ‘treatment-resistant’ schizophrenia. Medical Journal of Australia, 178(Suppl), S62–6.
Penn, D. L., Waldheter, E. J., Perkins, D. O., Mueser, K. T. & Lieberman, J. A. (2005). Psychosocial treatment for first-episode psychosis: a research update. American Journal of Psychiatry, 162, 2220–32.
Perkins, D. O. (1999). Adherence to antipsychotic medications. Journal of Clinical Psychiatry, 60(Suppl 21), 25–30.
Perkins, D. O. (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry, 63, 1121–8.
Perkins, D. O., Johnson, J. L., Hamer, R. M. et al. for the HGDH Research Group (2006). Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research, 83, 53–63.
Petersen, L., Jeppesen, P., Thorup, A. et al. (2005). A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. British Medical Journal, 331, 602.
Peuskens, J. (1999). The evolving definition of treatment resistance. Journal of Clinical Psychiatry, 60(Suppl 12), 4–8.
Power, P., Elkins, K., Adlard, S. et al. (1998). Analysis of the initial treatment phase in first-episode psychosis. British Journal of Psychiatry, 172(Suppl), s71–6.
Priebe, S., Roeder-Wanner, U. & Kise, W. (2000). Quality of life in first admitted schizophrenia patients: a follow-up study. Psychological Medicine, 30, 225–30.
Resnick, S. G., Rosenheck, R. A. & Lehman, A. F. (2004). An exploratory analysis of correlates of recovery. Psychiatric Services, 55, 540–7.
Resnick, S. G., Fontana, A., Lehman, A. F. & Rosenheck, R. A. (2005). An empirical conceptualization of the recovery orientation. Schizophrenia Research, 75, 119–28.
Rinaldi, M., McNeil, K., Firn, M. et al. (2004). What are the benefits of evidence-based supported employment for patients with first-episode psychosis? Psychiatric Bulletin, 28, 281–4.
Robinson, D., Woerner, M. G., Alvir, J. M. et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241–7.
Robinson, D. G., Woerner, M. G., Alvir, J. M. et al. (2002). Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research, 57, 209–19.
Robinson, D. G., Woerner, M. G., Delman, H. M. & Kane, J. M. (2005). Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin, 31, 705–22.
Ropcke, B. & Eggers, C. (2005). Early-onset schizophrenia: a 15-year follow-up. European Child and Adolescent Psychiatry, 14, 341–50.
Rosenberg, P. P. (1984). Support groups. Small Group Behavior, 15, 173–86.
Royal Australian and New Zealand College of Psychiatrists (2005). Clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39, 1–30.
Schooler, N., Rabinowitz, J., Davidson, M. et al. (2005). Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. American Journal of Psychiatry, 162, 947–53.
Sheitman, B. B. & Lieberman, J. A. (1998). The natural history and pathophysiology of treatment resistant schizophrenia. Journal of Psychiatric Research, 32, 143–50.
Svedberg, B., Mesterton, A. & Cullberg, J. (2001). First-episode non-affective psychosis in a total urban population: a 5-year follow-up. Social Psychiatry and Psychiatric Epidemiology, 36, 332–7.
Tait, L., Birchwood, M. & Trower, P. (2003). Predicting engagement with services for psychosis: insight, symptoms and recovery style. British Journal of Psychiatry, 182, 123–8.
Tarrier, N. & Wykes, T. (2004). Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? Behaviour Research and Therapy, 42, 1377–401.
Tarrier, N., Lewis, S., Haddock, G. et al. (2004) Cognitive-behavioral therapy in first-episode and early schizophrenia. British Journal of Psychiatry, 184, 231–9.
Thompson, K. N., McGorry, P. D. & Harrigan, S. M. (2003). Recovery style and outcome in first-episode psychosis. Schizophrenia Research, 62, 31–6.
Tohen, M., Strakowski, S. M., Zarate, C. Jr et al. (2000). The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and non-affective psychosis. Biological Psychiatry, 48, 467–76.
Ucok, A., Polat, A., Cakir, S. & Genc, A. (2000). One year outcome in first episode schizophrenia: predictors of relapse. European Archives of Psychiatry and Clinical Neuroscience, 256, 37–43.
van Os. J., Burns, T., Cavallaro, R. et al. (2006). Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica, 113, 91–5.
Velligan, D. I., Lam, F., Ereshefsky, L. & Miller, A. L. (2003). Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatric Services, 54, 665–7.
Voges, M. & Addington, J. (2005). The association between social anxiety and social functioning in first episode psychosis. Schizophrenia Research, 76, 287–92.
Wade, D., Harrigan, S., Edwards, J. et al. (2005). Patterns and predictors of substance use disorders and daily tobacco use in first-episode psychosis. Australian and New Zealand Journal of Psychiatry, 39, 892–8.
Wahlbeck, K., Cheine, M., Essali, A. & Adams, C. (1999). Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry, 156, 990–9.
Zipursky, R. B. (2001). Optimal pharmacologic management of the first episode of schizophrenia. In R. B. Zipursky & S. C. Schulz (eds.), The Early Stages of Schizophrenia. Washington, DC: American Psychiatric Press, pp. 81–106.
Zygmunt, A., Olfson, M., Boyer, C. A. & Mechanic, D. (2002). Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry, 159, 1653–64.

Reference Title: References

Reference Type: reference-list

Akiskal, H. S. (1981). Subaffective disorders: dysthymic, cyclothymic and bipolar II disorders in the ‘borderline’ realm. Psychiatric Clinics of North America, 4, 25–46.
Akiskal, H. S. (1999). Bipolarity: beyond classic mania. Psychiatric Clinics of North America, 22, 512–703.
Akiskal, H. S., Downs, J., Jordan, P. et al. (1985). Affective disorders in referred children and younger siblings of manic depressives. Mode of onset and prospective course. Archives of General Psychiatry, 42, 996–1003.
Akiskal, H. S., Hantouche, E. G., Azorin, J. M. et al. (2003). Clinical characterization acute mania: data in 1090 patients – ‘EPIMAN-II’. Bipolar Disorders, 5(Suppl 1), 27.
APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
APA (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry, 159, 4–50.
Angst, J. (1985). Switch from depression to mania: a record study over decades between 1920 and 1982. Psychopathology, 18, 140–54.
Angst, J., Felder, W. & Lohmeyer, B. (1980). Course of schizoaffective psychoses: results of a followup study. Schizophrenia Bulletin, 6, 579–85.
Baethege, C., Smolka, M. N., Grushka, P. et al. (2003). Does prophylaxis-delay in bipolar disorder influence outcome? Results from a long-term study of 147 patients. Acta Psychiatrica Scandinavica, 107, 260–7.
Baldessarini, R. J., Tondo, L. & Hennen, J. (2003). Treatment latency and previous episodes: relationship to pretreatment morbidity and response to maintenance treatment in bipolar I and II disorders. Bipolar Disorders, 5, 169–79.
Basco, M. R. & Rush, A. J. (1995). Compliance with pharmacology in mood disorders. Psychiatric Annals, 25, 269–79.
Bellivier, F., Golmard, J. L., Rietschel, M. et al. (2003). Age at onset in bipolar I affective disorder: further evidence for three subgroups. American Journal of Psychiatry, 160, 999–1001.
Berk, M. & Dodd, S. (2005). Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Medical Hypotheses, 65, 39–43.
Berk, M., Malhi, G. S., Mitchell, P. B. et al. (2004). Scale matters: the need for a Bipolar Depression Rating Scale (BDRS). Acta Psychiatrica Scandinavica, 422(Suppl), 39–45.
Berk, M., Berk, L., Moss, K., Dodd, S. & Malhi, G. S. (2006). Diagnosing bipolar disorder: how can we do it better? Medical Journal of Australia, 184, 459–62.
Berk, M., Malhi, G. S., Cahill, C. et al. (2007). The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disorder, 9, 571–9.
Burke, K. C., Burke, J. D., Regier, D. A., Rae, D. S. (1990). Age at onset of selected mental disorders in five community populations. Archives of General Psychiatry, 47, 511–18.
Carlson, G. A., Bromet, E. J. & Sievers, S. (2000). Phenomenology and outcome of subjects with early- and adult-onset psychotic mania. American Journal of Psychiatry, 157, 213–19.
Chang, K., Karchemskiy, A., Barnea-Goraly, N. et al. (2005). Reduced amygdala gray matter volume in familial pediatric bipolar disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 565–73.
Cochran, S. D. (1984). Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. Journal of Consulting and Clinical Psychology, 52, 873–8.
Colom, F., Vieta, E., Martinez-Aran, A. et al. (2003). A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrence in bipolar patients whose disease is in remission. Archives of General Psychiatry, 60, 402–7.
Conus, P. & McGorry, P. D. (2002). First episode mania: a neglected priority for early intervention. Australian and New Zealand Journal of Psychiatry, 36, 158–72.
Conus, P., Abdel-Baki, A., Harrigan, S., Lambert, M. & McGorry, P. D. (2004). Schneiderian first rank symptoms predict poor outcome within first episode manic psychosis. Journal of Affective Disorders, 81, 259–68.
Conus, P., Cotton, S., Abdel-Baki, A. & McGorry, P. D. (2006a). Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. Bipolar Disorders, 8, 221–31.
Conus, P., Berk, M. & McGorry, P. D. (2006b). Pharmacological treatment in the early phase of bipolar disorders: what stage are we at? Australian and New Zealand Journal of Psychiatry, 40, 199–207.
Conus, P., Berk, M., Hallam, K., Lucas, N. & Ward, J. (2006c). The prodrome to first episode psychotic mania: results of a retrospective study. Schizophrenia Research, 86(Suppl), 37.
Coryell, W., Scheftner, W., Keller, M. et al. (1993). The enduring psychosocial consequences of mania and depression. American Journal of Psychiatry, 150, 720–7.
Craig, T. J., Grossman, S., Mojtabai, R. et al. (2004). Medication use patterns and 2-year outcome in first-admission bipolar disorders with psychotic features. Bipolar Disorders, 6, 406–15.
Dion, G. L., Tohen, M., Anthony, W. A. & Waternaux, C. S. (1988). Symptoms and functioning of patients with bipolar disorder six months after hospitalisation. Hospital and Community Psychiatry, 39, 652–7.
Egeland, J. A., Blumenthal, R. L., Nee, J., Sharpe, L. & Eddincott, J. (1987). Reliability and relationship of various ages of onset criteria for major affective disorders. Journal of Affective Disorders, 12, 159–65.
Egeland, J. A., Hostetter, A. M., Pauls, D. L. & Sussex, J. N. (2000). Prodromal symptoms before onset of manic–depressive disorder suggested by first hospital admission histories. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 1245–52.
Ernst, C. L. & Goldberg, J. F. (2004). Clinical features related to age at onset in bipolar disorder. Journal of Affective Disorders, 82, 21–7.
Frank, E., Swartz, H. A., Mallinger, A. G. et al. (1999). Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. Journal of Abnormal Psychology, 108, 579–87.
Geller, B., Tillman, R., Craney, J. L. & Bolhofner, K. (2004). Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Archives of General Psychiatry, 61, 459–67.
Ghaemi, S. N., Ko, J. Y. & Goodwin, F. K. (2002). ‘Cade's disease’ and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder.Canadian Journal of Psychiatry, 47, 125–34.
Goldberg, J. F. & Ernst, C. L. (2002). Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. Journal of Clinical Psychiatry, 63, 985–91.
Gonzalez-Pinto, A., Gonzalez, C., Enjuto, S. et al. (2004). Psychoeducation and cognitive-behavioral therapy in bipolar disorder: an update. Acta Psychiatrica Scandinavica, 109, 83–90.
Goodwin, F. K. & Jamison, K. R. (1990). Manic–Depressive Illness. New York: Oxford University Press.
Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, revised. [DHEW Publication No. (ADM) 76–338.] Rockville MD: National Institute of Mental Health.
Harrow, M., Goldberg, J. F., Grossman, L. S. & Meltzer, H. Y. (1990). Outcome in manic disorders. Archives of General Psychiatry, 47, 665–71.
Hennion, J. P., el-Masri, M. A., Huff, M. O. & el-Mailakh, R. S. (2002). Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disorders, 4, 201–6.
Hirschfeld, R. M., Calabrese, J. R., Weissman, M. M. et al. (2003a). Screening for bipolar disorder in the community. Journal of Clinical Psychiatry, 64, 53–9.
Hirschfeld, R. M., Lewis, L. & Vornik, L. A. (2003b). Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic Depressive Association 2000 Survey of Individuals with Bipolar Disorder. Journal of Clinical Psychiatry, 64, 161–74.
Huxley, N. A., Parikh, S. V. & Baldessarini, R. J. (2000). Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harvard Review of Psychiatry, 8, 126–40.
International Early Psychosis Association Writing Group (2005). International clinical practice guidelines for early psychosis.British Journal of Psychiatry, 187(Suppl. 48), 120–4.
Jones, S. (2004). Psychotherapy of bipolar disorder: a review. Journal of Affective Disorders, 80, 101–14.
Jones, S. H., Sellwood, W. & McGovern, J. (2005). Psychological therapies for bipolar disorder: the role of model-driven approaches to therapy integration. Bipolar Disorders, 7, 22–32.
Joyce, P. R. (1984). Age of onset in bipolar affective disorder and misdiagnosis as schizophrenia. Psychological Medicine, 14, 145–9.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry, 59, 530–7.
Keck, P. E., McElroy, S. L., Strakowski, S. M. et al. (1996). Factors associated with pharmacological noncompliance in patients with mania. Journal of Clinical Psychiatry, 57, 292–7.
Keck, P. E., McElroy, S. L., Strakowski, S. M. et al. (1998). 12-month outcome of patients with bipolar disorder following hospitalisation for a manic or mixed episode. American Journal of Psychiatry, 155, 646–52.
Keck, P. E., McElroy, S. L. & Strakowski, S. M. (2000). Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Journal of Clinical Psychiatry, 61(Suppl 4), 33–8.
Kraepelin, E. (1919). Dementia Praecox. New York: Churchill Livingstone.
Kukopulos, A., Reginaldi, D., Laddomada, P. et al. (1980). Course of the manic–depressive cycle and changes caused by treatments. Pharmacopsychiatric Neuropsychopharmakologie 13, 156–67.
Lam, D. H., Watkins, R., Hayward, P. et al. (2003). A randomised controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Archives of General Psychiatry, 60, 145–52.
Lambert, M., Conus, P., Lambert, T. & McGorry, P. D. (2003). Pharmacotherapy of first-episode psychosis. Expert Opinion on Pharmacotherapy, 4, 717–50.
Lambert, M., Conus, P., Eide, P. et al. (2005). Treatment of early psychosis with olanzapine or risperidone (TEPOR study): a medical record review study in 367 non-affective and affective first-episode psychosis patients admitted to the Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne Australia between 1998–2000. Pharmacopsychiatry, 38, 1–8.
Lieberman, J. A., Tollefson, G. D., Charles, C. et al. for the HGDH Study Group (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry, 62, 361–70.
Lish, J. D., Dime-Meenan, S., Whybrow, P. C., Price, R. A. & Hirschfeld, R. M. (1994). The National Depressive and Manic–depressive Association (DMDA) survey of bipolar members. Journal of Affective Disorders, 31, 281–94.
Macneil, C. (2004). Cognitive behavioural therapy with bipolar disorder: theory and reality with a first episode population. Schizophrenia Research, 70(Suppl 1), 92.
Mahli, G. S., Berk, M., Bourin, M. et al. (2005). Atypical mood stabilizers: a ‘typical’ role for atypical antipsychotics. Acta Psychiatrica Scandinavica, 426, 29–38.
Malla, A. M. & Norman, R. M. (2001). Treating psychosis: is there more to early intervention than intervening early? Canadian Journal of Psychiatry, 46, 645–8.
McGlashan, T. H. (1988). Adolescent versus adult onset of mania. American Journal of Psychiatry, 145, 221–3.
McGorry, P. D. (1995a). A treatment relevant classification of psychotic disorders. Australian and New Zealand Journal of Psychiatry, 29, 555–8.
McGorry, P. D. (1995b). Psychoeducation in first episode psychosis: a therapeutic process. Psychiatry, 58, 313–28.
McGorry, P. D. & Jackson, H. J. (1999). The Recognition and Management of Early Psychosis: A Preventive Approach. Cambridge, UK: Cambridge University Press.
Mensink, G. J. R. & Sloof, C. J. (2004). Novel antipsychotics in bipolar and schizoaffective mania. Acta Psychiatrica Scandinavica, 109, 405–19.
Monkul, E. S., Malhi, G. S. & Soares, J. C. (2005). Anatomical MRI abnormalities in bipolar disorder: do they exist and do they progress? Australian and New Zealand Journal of Psychiatry, 39, 222–6.
National Early Psychosis Project (1998). Australian Guidelines for Early Psychosis. Melbourne: University of Melbourne.
Perry, A., Tarrier, N., Morriss, R., McCarthy, E. & Limb, K. (1999). Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. British Medical Journal, 318, 149–53.
Perugi, G., Micheli, C., Akiskal, H. S. et al. (2000). Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients. Comprehensive Psychiatry, 41, 13–18.
Post, R. M. (1992). Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. American Journal of Psychiatry, 149, 999–1010.
Post, R. M., Leverich, G. S., Altshuler, L. et al. (2003). An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disorders, 5, 310–19.
Prien, R. F. & Potter, W. Z. (1990). NIMH workshop report on treatment of bipolar disorder. Psychopharmacology Bulletin, 26, 409–27.
Remington, G., Kapur, S. & Zipursky, R. B. (1998). Pharmacotherapy of first-episode schizophrenia. British Journal of Psychiatry, 172, 66–70.
Royal Australian and New Zealand College of Psychiatrists (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39, 1–30.
Roy-Byrne, P., Post, R. M., Uhde, T. W., Porcu, T. & Davis, D. (1985). The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatrica Scandinavica, 317(Suppl), 1–34.
Scott, J. & Gutierrez, M. J. (2004). The current status of psychological treatments in bipolar disorders: a systematic review of relapse prevention. Bipolar Disorders, 6, 498–503.
Scott, J. & Tacchi, M. J. (2002). A pilot study of concordance therapy for individuals with bipolar disorders who are non-adherent with lithium prophylaxis. Bipolar Disorders, 4, 386–92.
Scott, J., Paykel, E., Morriss, R. et al. (2006). Cognitive–behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. British Journal of Psychiatry, 188, 313–20.
Sernyak, M. J., Griffin, R. A., Johnson, R. M. et al. (1994). Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptics. American Journal of Psychiatry, 151, 133–5.
Strakowski, S. M., Keck, P. E., McElroy, S. L. et al. (1998). Twelve-month outcome after first hospitalisation for affective psychosis. Archives of General Psychiatry, 55, 49–55.
Strober, M. & Carlson, G. (1982). Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Archives of General Psychiatry, 39, 549–55.
ten Have, M., Vollebergh, W., Bijl, R. & Nolen, W. A. (2002). Bipolar disorder in the general population in the Netherlands (prevalence, consequences and care utilisation): results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Journal of Affective Disorder, 68, 203–13.
Thompson, K. N., Conus, P., Ward, J. L. et al. (2003). The initial prodrome to bipolar affective disorder: prospective case studies. Journal of Affective Disorder, 77, 79–85.
Tohen, M., Waternaux, C. M. & Tsuang, M. T. (1990a). Outcome in mania. Archives of General Psychiatry, 47, 1106–11.
Tohen, M., Waternaux, C. M., Tsuang, M. T. & Hunt, A. T. (1990b). Four-year follow-up of twenty-four first-episode manic patients. Journal of Affective Disorders, 19, 79–86.
Tohen, M., Stoll, A. L., Strakowski, S. M. et al. (1992). The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome. Schizophrenia Bulletin, 18, 273–82.
Tohen, M., Strakowski, S. M., Zarate, C. et al. (2000a). The McLean–Harvard First-Episode Project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biological Psychiatry, 48, 467–76.
Tohen, M., Hennen, J., Zarate, C. et al. (2000b). Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. American Journal of Psychiatry, 157, 220–8.
Tohen, M., Marneros, A., Bowden, C. L. et al. (2003a). Olanzapine vs. lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Bipolar Disorders, 5(Suppl 1), 89.
Tohen, M., Bowden, C. L., Calabrese, J. R. et al. (2003b). Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind, placebo-controlled 12-month clinical trial. Bipolar Disorders, 5(Suppl 1), 89.
Tohen, M., Chengappa, K., Suppes, T. et al. (2004). Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. British Journal of Psychiatry, 184, 337–45.
Tohen, M., Greil, W., Calabrese, J. R. et al. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry, 162, 1281–90.
Tryer, S. P. & Brittlebank, A. D. (1993). Misdiagnosis of bipolar affective disorder as personality disorder. Canadian Journal of Psychiatry, 38, 587–9.
Tsuang, M. T., Woolson, R. F. & Fleming, J. A. (1979). Long term outcome of major psychoses: I schizophrenia and affective disorders compared with psychiatrically symptom-free surgical controls. Archives of General Psychiatry, 36, 1295–301.
Verdoux, H., Gonzales, B., Takei, N. & Bourgeois, M. (1996). Survey of prescribing practice of antipsychotic maintenance treatment for manic–depressive outpatients. Journal of Affective Disorders, 38, 81–7.
Wozniak, J., Biederman, J. & Richards, J. A. (2001). Diagnostic and therapeutic dilemmas in the management of pediatric-onset bipolar disorder. Journal of Clinical Psychiatry, 62(Suppl 14), 10–15.
Yatham, L. N., Kennedy, S. H., O'Donovan, C. et al. for the Canadian Network for Mood and Anxiety Treatments. (2005) Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders, 7(Suppl 3), 5–69.
Yung, A. R., Phillips, L. J., Yuen, H. P. et al. (2003). Psychosis prediction: 12-month follow up of a high-risk (‘prodromal’) group. Schizophrenia Research, 60, 21–32.
Zarate, C. A., Tohen, M., Land, M. & Cavanagh, S. (2000). Functional impairment and cognition in bipolar disorder. Psychiatric Quarterly, 71, 309–29.
Zis, A. P., Grof, P., Webster, M. & Goodwin, F. K. (1980). Prediction of relapse in recurrent affective disorder. Psychopharmacological Bulletin, 16, 47–9.

Reference Title: References

Reference Type: reference-list

Addington, J. & Addington, D. (2001). Impact of an early psychosis programme on substance use. Psychiatric Rehabilitation Journal, 25, 60–7.
Andreasson, S., Allebeck, P., Engstrom, A. & Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, ü, 1483–6.
Arndt, S., Tyrrell, G., Flaum, M. & Andreasen, N. C. (1992). Comorbidity of substance abuse and schizophrenia: the role of premorbid adjustment. Psychological Medicine, 22, 379–88.
Arendt, M., Rosenberg, R., Foldager, L., Perto, G. & Munk-Jorgensen, P. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. British Journal of Psychiatry, 187, 510–15.
Arseneault, L., Cannon, M., Poulton, R. et al. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal, 325, 1212–13.
Arseneault, L., Cannon, M., Witton, J. & Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry, 184, 110–17.
Baker, A., Lewin, T., Reichler, H. et al. (2002). Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatrica Scandinavica, 106, 233–40.
Baker, A., Bucci, S. & Kay-Lambkin, F. (2004). Intervention for Alcohol, Cannabis and Amphetamine Use among People with a Psychotic Illness. [NDARC Technical Report No. 193.] Sydney: National Drug and Alcohol Research Centre.
Baker, A., Bucci, S., Lewin, T. J. et al. (2006a). Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. British Journal of Psychiatry, 188, 439–48.
Baker, A., Richmond, R., Haile, M. et al. (2006b). Randomised controlled trial of a smoking cessation intervention among people with a psychotic disorder. American Journal of Psychiatry, 163, 1934–42.
Barrowclough, C., Haddock, G., Tarrier, N. et al. (2001) Randomized controlled trial of motivational interviewing, cognitive behaviour therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry, 158, 1706–13.
Blanchard, J. J., Squires, D., Henry, T. et al. (1999). Examining an affect regulation model of substance abuse in schizophrenia: the role of traits and coping. Journal of Nervous and Mental Disease, 187, 72–9.
Blanchard, J. J., Brown, S. A., Horan, W. P. & Sherwood, A. R. (2000). Substance use disorders in schizophrenia: review, integration, and a proposed model. Clinical Psychology Review, 20, 207–34.
Brown, S., Barraclough, B. & Inskip, H. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–17.
Cantwell, R., Brewin, J., Glazebrook, C. et al. (1999). Prevalence of substance misuse in first-episode psychosis. British Journal of Psychiatry, 174, 150–3.
Caspi, A., Moffitt, T. E., Cannon, M. et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biological Psychiatry, 57, 1117–27.
Chambers, R. A., Krystal, J. H. & Self, D. W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50, 71–83.
Coldham, E. L., Addington, J. & Addington, D. (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica, 106, 286–90.
Degenhardt, L. & Hall, W. (2001). The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-being. Psychological Medicine, 31, 659–68.
Degenhardt, L., Hall, W. & Lynskey, M. (2003). Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence, 71, 37–48.
DeLisi, L. E., Boccio, A. M., Riordan, H. et al. (1991). Familial thyroid disease and delayed language development in first admission patients with schizophrenia. Psychiatry Research, 38, 39–50.
Dervaux, A., Bayle, F. J., Laqueille, X. et al. (2001). Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? American Journal of Psychiatry, 158, 492–4.
Dixon, L., Haas, G., Weiden, P. J., Sweeney, J. & Frances, A. J. (1991). Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry, 148, 224–30.
Drake, R. E., Mueser, K. T., Brunette, M. F. & McHugo, G. J. (2004). A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabilitation Journal, 27, 360–74.
Edwards, J., Hinton, M., Elkins, K. & Athanasopoulos, O. (2003). Cannabis and first-episode psychosis: the CAP project. In H. L. Graham, A. Copello, M. J. Birchwood & K. T. Mueser (eds.), Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery. Chichester, UK: John Wiley, pp. 283–304.
Edwards, J., Elkins, K., Hinton, M. et al. (2006). Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatrica Scandinavica, 114, 109–17.
Evins, A. E., Mays, V. K., Rigotti, N. A. et al. (2001). A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine and Tobacco Research, 3, 397–403.
Fergusson, D. M., Horwood, L. J. & Swain-Campbell, N. R. (2003). Cannabis dependence and psychotic symptoms in young people. Psychological Medicine, 33, 15–21.
George, T. P., Ziedonis, D. M., Feingold, A. et al. (2000). Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry, 157, 1835–42.
George, T. P., Vessicchio, J. C., Termine, A. et al. (2002). A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry, 52, 53–61.
Gleeson, J, Jackson, H. J., Stavely, H. & Burnett, P. (1999). Family intervention in early psychosis. In P. D. McGorry & H. J. Jackson (eds.), The Recognition and Management of Early Psychosis. Cambridge, UK: Cambridge University Press, pp. 376–406.
Graham, H. L., Copello, A., Birchwood, M. J. et al. (2004). Cognitive-behavioural Integrated Treatment (C-BIT): A Treatment Manual for Substance Misuse in People with Severe Mental Health Problems. Chichester, UK: John Wiley.
Green, B., Kavanagh, D. & Young, R. M. (2004). Reasons for cannabis use in men with and without psychosis. Drug and Alcohol Review, 23, 445–53.
Gut-Fayand, A., Dervaux, A., Olie, J. et al. (2001). Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Research, 102, 65–72.
Haddock, G., Barrowclough, C., Tarrier, N. et al. (2003). Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry, 183, 418–26.
Hambrecht, M. & Häfner, H. (1996). Substance abuse and the onset of schizophrenia. Biological Psychiatry, 40, 1155–63.
Hambrecht, M. & Häfner, H. (1998). Are symptoms observed differently in male and female first-episode patients? Schizophrenia Research, 29, 186.
Hamera, E., Schneider, J. K. & Deviney, S. (1995). Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. Journal of Nervous and Mental Disease, 183, 559–65.
Henquet, C., Murray, R., Linszen, D. & van Os, J. (2005). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin, 31, 608–12.
Hercus, M., Lubman, D. I. & Hellard, M. (2005). Blood borne viral and sexually transmissible infections among psychiatric populations: what are we doing about them? Australian and New Zealand Journal of Psychiatry, 39, 849–55.
Hides, L., Lubman, D. & Dawe, S. (2004). Models of co-occurring substance misuse and psychosis: are personality traits the missing link? Drug and Alcohol Review, 23, 425–32.
Hides, L., Dawe, S., Kavanagh, D. J. & Young, R. M. (2006). Psychotic symptom and cannabis relapse in recent-onset psychosis: a prospective study. British Journal of Psychiatry, 189, 137–43.
Hinton, M., Elkins, K., Edwards, J. & Donovan, K. (2002). Cannabis and Psychosis: An Early Psychosis Treatment Manual. Melbourne: Early Psychosis Prevention and Intervention Centre.
James, W., Preston, N. J., Koh, G. et al. (2004). A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychological Medicine, 34, 983–90.
Jeffery, D. P., Ley, A., McLaren, S. & Siegfried N. (2000). Psychosocial treatment programmes for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews, 2, CD001088. [DOI: 10.1002/14651858.CD001088].
Kavanagh, D. J., Mueser, K. T. & Baker, A. (2003a). Management of comorbidity. In M. Teesson & H. Proudfoot (eds.), Comorbid Mental Disorders and Substance Use Disorders: Epidemiology, Prevention and Treatment. Canberra: Commonwealth of Australia, pp. 78–120.
Kavanagh, D. J., Young, R., White, A. et al. (2003b). Start over and survive: a brief intervention for substance misuse in early psychosis. In H. L. Graham, A. Copello, M. J. Birchwood & K. T. Mueser (eds.), Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery. Chichester, UK: John Wiley, pp. 244–58.
Kavanagh, D. J., Young, R., White, A. et al. (2004). A brief motivational intervention for substance misuse in recent-onset psychosis. Drug and Alcohol Review, 23, 151–5.
Kay-Lambkin, F. J., Baker, A. L. & Lewin, T. J. (2004). The ‘co-morbidity roundabout’: a framework to guide assessment and intervention strategies and engineer change among people with comorbid problems. Drug and Alcohol Review, 23, 407–23.
Kemp, R., Kirov, G., Everitt, B., Hayward, P. & David, A. (1998). Randomised controlled trial of compliance therapy: 18-month follow-up. British Journal of Psychiatry, 172, 413–19.
Khantzian, E. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry, 142, 1259–64.
Lachman, H. M., Papolos, D. F., Saito, T. et al. (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6, 243–50.
Lambert, M., Conus, P., Lubman, D. I. et al. (2005). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica, 112, 141–8.
Lewis, S. W., Tarrier, N. & Drake, R. J. (2005). Integrating non-drug treatments in early schizophrenia. British Journal of Psychiatry, 187, 65–71.
Linszen, D. H., Dingemans, P. M. & Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51, 273–9.
Liraud, F. & Verdoux, H. (2000). Which temperamental characteristics are associated with substance use in subjects with psychotic and mood disorders? Psychiatry Research, 93, 63–72.
Martino, S., Carroll, K. M., O'Malley, S. S. & Rounsaville, B. J. (2000). Motivational interviewing with psychiatrically ill substance abusing patients. American Journal on Addictions, 9, 88–91.
McGorry, P. D. (1995). Psychoeducation in first-episode psychosis: a therapeutic process. Psychiatry, 58, 313–28.
McGorry, P., Killackey, E., Elkins, K., Lambert, M. & Lambert, T. (2003). Summary: Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australasian Psychiatry, 11, 136–47.
McHugo, G. J., Drake, R. E., Burton, H. L. & Ackerson, T. H. (1995). A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. Journal of Nervous and Mental Disease, 182, 164–7.
Miller, W. & Rollnick, S. (2002). Motivational Interviewing: Preparing People for Change. New York: Guilford Press.
Mueser, K. T. & Drake, R. E. (2003). Integrated dual disorder treatment in New Hampshire (USA). In H. L. Graham, A. Copello, M. J. Birchwood & K. T. Mueser (eds.), Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery. Chichester, UK: John Wiley, pp. 93–105.
Mueser, K. T., Drake, R. E. & Wallach, M. A. (1998). Dual diagnosis: a review of aetiological theories. Addictive Behaviours, 23, 717–34.
Mueser, K. T., Rosenberg, S. D., Drake, R. E. et al. (1999). Conduct disorder, antisocial personality disorder and substance use disorders in schizophrenia and major affective disorders. Journal of Studies on Alcohol, 60, 278–84.
Nordentoft, M., Jeppesen, P., Abel, M. et al. (2002). OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis – one-year follow-up of a randomised controlled trial. British Journal of Psychiatry, 181, 98–106.
Norman, R. M. G. & Malla, A. K. (2002). Examining adherence to medication and substance use as possible confounds of duration of untreated psychosis. Journal of Nervous and Mental Disease, 190, 331–4.
Osher, F. C. & Kofoed, L. L. (1989). Treatment of patients with psychiatric and psychoactive substance use disorders. Hospital and Community Psychiatry, 40, 1025–30.
Rabinowitz, J., Bromet, E. J., Carlson, L. G., Kovasznay, B. & Schwartz, J. E. (1998). Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine, 28, 1411–19.
Regier, D. A., Farmer, M. E., Rae, D. S. et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. Journal of the American Medical Association, 264, 2511–18.
Robinson, D., Woerner, M. G., Alvir, J. M. J. et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241–7.
Rollnick, S., Heather, N., Gold, R. & Hall, W. (1992). Development of a short ‘readiness to change’ questionnaire for use in brief, opportunistic interventions among excessive drinkers. British Journal of Addiction, 87, 743–54.
Rosenberg, S. D., Drake, R., Wolford, G. L. et al. (1998). Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. American Journal of Psychiatry, 155, 232–8.
Saunders, J. B., Aasland, O. G., Babor, T. F., de le Fuente, J. R. & Grant, M. (1993). Development of the alcohol use disorders identification test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption. Addiction, 88, 791–804.
Semple, D. M., McIntosh, A. M. & Lawrie, S. M. (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology, 19, 187–94.
Sevy, S., Robinson, D. G., Holloway, S. et al. (2001). Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatrica Scandinavica, 104, 367–74.
Sorbara, F., Liraud, F., Assens, F., Abalan, F. & Verdoux, H. (2003). Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. European Psychiatry, 18, 133–6.
Spencer, C., Castle, D. & Michie, P. T. (2002). Motivations that maintain substance use among individuals with psychotic disorders. Schizophrenia Bulletin, 28, 233–47.
Strakowski, S. M., Keck, P. E., McElroy, S. L. et al. (1998). Twelve-month outcome after a first hospitalization for affective psychosis. Archives of General Psychiatry, 55, 49–55.
Swanson, A. J., Pantalon, M. V. & Cohen, K. R. (1999). Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. Journal of Nervous and Mental Disease, 187, 630–5.
Van Mastrigt, S., Addington, J. & Addington, D. (2004). Substance misuse at presentation to an early psychosis program. Social Psychiatry and Psychiatric Epidemiology, 39, 69–72.
Verdoux, H., Liraud, F., Gonzales, B. et al. (2001). Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatrica Scandinavica, 103, 347–54.
Verma, S. K., Subramaniam, M., Chong, S. A. & Kua, E. H. (2002). Substance abuse in schizophrenia: a Singapore perspective. Social Psychiatry and Psychiatric Epidemiology, 37, 326–8.
Voruganti, L. N. P., Slomka, P., Zabel, P., Mattar, A. & Awad, A. G. (2001). Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research Neuroimaging, 107, 173–7.
Wade, D., Harrigan, S., Edwards, J. et al. (2005). Patterns and predictors of substance use disorders and daily tobacco use in first-episode psychosis. Australian and New Zealand Journal of Psychiatry, 39, 892–8.
Wade, D., Harrigan, S., Edwards, J. et al. (2006a). Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophrenia Research, 81, 145–50.
Wade, D., Harrigan, S., Edwards, J. et al. (2006b). Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry, 189, 229–34.
WHO ASSIST Working Group (2002). The alcohol, smoking, and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction, 97, 1183–94.
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I. & Lewis, G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal, 325, 1199–204.

Reference Title: References

Reference Type: reference-list

Addington, D., Addington, J. & Patten, S. (1998). Depression in people with first-episode schizophrenia. British Journal of Psychiatry, 172(Suppl 33), s90–2.
Addington, J., Williams, J., Young, J. & Addington, D. (2004). Suicide behaviour in early psychosis. Acta Psychiatrica Scandinavica, 109, 116–20.
Adlard, S. (1997). An Analysis of Health Damaging Behaviours in Young People at High Risk of Psychosis. Fellowship dissertation, Royal College and New Zealand College of Psychiatrists, Melbourne.
Amador, X. F., Freidman, J. H., Kasapis, C. et al. (1996). Suicidal behaviour in schizophrenia and its relationship to awareness of illness. American Journal of Psychiatry, 153, 1185–8.
Andriessen, K. (2006). On ‘intention’ in the definition of suicide. Suicide and Life-Threatening Behaviour, 36, 533–8.
Appleby, L., Shaw, J., Sherratt, J. et al. (2001). Safety First: Five-year Report of the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. London: The Stationary Office.
Appleby, L., Shaw, J., Kapur, N. et al. (2006). Avoidable Deaths: Five Year Report into the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. London: The Stationary Office.
Apter, A., Bleich, A., Plutchik, R., Mendelsohn, S. & Tyano, S. (1988). Suicidal behaviour, depression and conduct disorder in hospitalised adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 696–9.
Aquilar, E. J., Haas, G., Manzanera, F. G. et al. (1997). Hopelessness and first-episode psychosis: a longitudinal study. Acta Psychiatrica Scandinavica, 96, 25–30.
Asberg, M., Traskman, L. & Thoren, P. (1976). 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Archives of General Psychiatry, 33, 1193–7.
Australian Institute for Suicide Research and Prevention (2003). International Suicide Rates: Recent Trends and Implications for Australia. Canberra: Australian Government Department of Health and Ageing.
Barak, Y., Mirecki, I., Knobler, H. Y., Natan, Z. & Aizenberg, D. (2004). Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology, 175, 215–19.
Beck, A., Schuyler, D. & Herman, I. (1974a). Development of suicidal intent scales. In A. T. Beck, H. C. P. Resnik & D. Lettieri (eds.), The Prediction of Suicide. Bowie, MD: Charles Press, pp. 5445–56.
Beck, A., Weissman, A., Lester, D. & Trexler, L. (1974b). The measurement of pessimism: the Hopelessness Scale. Journal of Consulting and Clinical Psychology, 44, 861–5.
Beck, A. T. (1996). Foreword. In T. E. Ellis & C. F. Newman (eds.), Chosing to Live. Oakland, CA: New Harbinger, pp. ix–xi.
Beck, A. T., Kovacs, M. & Weissman, A. (1979). Assessment of suicidal ideation: the Scale for Suicide Ideation. Journal of Consulting and Clinical Psychology, 47, 343–52.
Bertelsen, M., Jeppesen, P., Petersen, L. et al. (2007). Suicidal behaviour and mortality in 547 first-episode psychotic patients: the OPUS trial. British Journal of Psychiatry, 51(Suppl), s140–6.
Birchwood, M., Iqbal, Z., Chadwick, P. & Trower, P. (2000). Cognitive approach to depression and suicidal thinking in psychosis: ontogeny of post-psychotic depression. British Journal of Psychiatry, 177, 516–21.
Blumenthal, S. (1990). Youth suicide: risk factors, assessment, and treatment of adolescent and young adult suicidal patients. Psychiatric Clinics of North America, 13, 511–56.
Brady, J. (2006). The association between alcohol misuse and suicidal behaviour. Alcohol and Alcoholism, 41, 473–8.
Brent, D. A. & Mann, J. J. (2005). Family genetic studies, suicide, and suicidal behaviour. American Journal of Medical Genetics: Seminars in Medical Genetics, 133, 13–24.
Bronisch, T. (1996). The relationship between suicidality and depression. Archives of Suicide Research, 2, 235–54.
Brown, S. (1997). Excess mortality of schizophrenia: a meta-analysis. British Journal of Psychiatry, 171, 502–8.
Burgess, P., Pirkis, J., Morton, J. & Croke, E. (2000). Lessons from a comprehensive clinical audit of users of psychiatric services who committed suicide. Psychiatric Services, 51, 1555–60.
Chance, S. (1997). Stronger than Death: When Suicide Touches Your Life. New York: W. W. Norton.
Clarke, M., Whitty, P., Browne, S. et al. (2006). Suicidality in first episode psychosis. Schizophrenia Research, 86, 221–5.
Coppen, A. (1994). Depression as a lethal disease: prevention strategies. Journal of Clinical Psychiatry, 55(Suppl), 37–45.
Craig, T. J., Ye, Q. & Bromet, E. J. (2006). Mortality among first-admission patients with psychosis. Comprehensive Psychiatry, 47, 246–51.
Dahlsgaard, K. K., Beck, A. T. & Brown, G. K. (1998). Inadequate response to therapy as a predictor of suicide. Suicide and Life-Threatening Behaviour; 28, 197–204.
Davidson, M. W. & Range, L. M. (1999). Are teachers of children and young adolescents responsive to suicide prevention training modules? Yes. Death Studies, 23, 61–71.
De Hert, M., McKenzie, K. & Peuskens, J. (2001). Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophrenia Research, 47, 127–34.
Desai, R. A., Dausey, D. J., Rosenhack, R. A. (2005). Mental health service delivery and suicide risk: the role of individual patient and facility factors. American Journal of Psychiatry, 162, 311–18.
Drake, R. E., Gates, C., Cotton, P. G. & Whitaker, A. (1984). Suicide among schizophrenics: who is at risk? Journal of Nervous and Mental Disease, 172, 613–17.
Drury, V., Birchwood, M., Cochrane, R. & MacMillan, F. (1996). Cognitive therapy and recovery from acute psychosis: a controlled trial: I. Impact on psychotic symptoms. British Journal of Psychiatry, 169, 593–601.
Ellis, T. E. & Newman, C. F. (1996). Choosing to Live. Oakland, CA: New Harbinger.
Evans, E., Hawton, K., Rodham, K. & Deeks, J. (2005). The prevalence of suicidal phenomena in adolescents: a systematic review of population-based studies. Suicide and Life-Threatening Behaviour, 35, 239–50.
Fennig, S., Horesh, N., Aloni, D., Apter, A., Weizman, A. & Fennig, S. (2005). Life events and suicidality in adolescents with schizophrenia. European Child and Adolescent Psychiatry, 14, 454–460.
Fenton, W. & McGlashan, T. (1991). Natural history of schizophrenia subtypes. Archives of General Psychiatry, 48, 969–77.
Fenwick, C. D., Vassilas, C. A., Carter, H. & Haque, M. S. (2004). Training health professionals in the recognition, assessment and management of suicide risk. International Journal of Psychiatry in Clinical Practice, 8, 117–21.
Freeman, A. & Reinecke, M. A. (1993). Cognitive Therapy of Suicide Behaviour: A Manual for Treatment. New York: Springer.
Goldston, D. (2000). Assessment of Suicidal Behaviours and Risk Among Children and Adolescents. [Technical Report submitted to NIMH under Contract No 263-MD-909995. Bethesda, MB: National Institutes of Mental Health.
Green, G. & Gask, L. (2005). The development, research and implementation of STORM (Skills-based Training on Risk Management). Primary Care Mental Health, 3, 207–13.
Gupta, R. D. & Guest, J. F. (2002). Annual cost of bipolar disorder to UK society. British Journal of Psychiatry, 180, 227–33.
Hansen, L. & Kingdom, D. (2006). Akathisia as a risk factor for suicide. British Journal of Psychiatry, 188, 192.
Harkavy-Friedman, J. M. (2006). Can early detection of psychosis prevent suicidal behaviour? American Journal of Psychiatry, 163, 768–70.
Harkavy-Friedman, J. M., Restifo, K., Malaspina, D. et al. (1999). Suicidal behaviour in schizophrenia: characteristics of individuals who had and had not attempted suicide. American Journal of Psychiatry, 156, 1276–8.
Harvey, S. B., Dean, K., Morgan, C. et al. (2006). How often does deliberate self-harm precipitate first presentation to services with psychosis? Findings from the AESOP Study, Schizophrenia Research, 86, S56–7.
Hawton, K., Sutton, L., Haw, C., Sinclair, J. & Deeks, J. (2005a). Schizophrenia and suicide: systematic review of risk factors. British Journal of Psychiatry, 187, 9–20.
Hawton, K., Sutton, L., Haw, C., Sinclair, J. & Harris, L. (2005b). Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. Journal of Clinical Psychiatry, 66, 693–704.
Heilä, H. (1999). Suicide in schizophrenia: a review. Psychiatria Fennica, 30, 47–57.
Heilä, H. & Lönnqvist, J. (2003). The clinical epidemiology of suicide in schizophrenia. In R. M. Murray, P. B. Jones, E. Susser, J. Van Os & M. Cannon (eds.), The Epidemiology of Schizophrenia. Cambridge, UK: Cambridge University Press, pp. 288–316.
Hiroeh, U., Appleby, L., Mortensen, P. & Dunn, G. (2001). Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet, 358, 2110–12.
Hunt, I. M., Kapur, N., Windfuhr, K. et al. (2006). Suicide in schizophrenia: findings from a national clinical survey. Journal of Psychiatric Practice, 12, 139–47.
Inskip, H., Harris, E. C. & Barraclough, B. (1998). Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. British Journal of Psychiatry, 172, 35–7.
Jackson, H., McGorry, P., Henry, L. et al. (2001). Cognitively-oriented psychotherapy for early psychosis. British Journal of Clinical Psychology, 40, 57–70.
Kemp, R., Hayward, P., Applewhaite, G., Everitt, B. & David, A. (1996). Compliance therapy in psychotic patients: randomised controlled trial. British Medical Journal, 312, 345–9.
Kerkhof, A. J. & Diekstra, R. F. (1995). How to evaluate and deal with acute suicide risk. In R. F. Diekstra, W. Gulbinat, I. Kienhorst & D. de Leo (eds.), Preventive Strategies on Suicide. Leiden: E. J. Brill, pp. 97–119.
Kerwin, R. W. & Bolonna, A. A. (2004). Is clozapine antisuicidal? Expert Review of Neurotherapeutics, 4, 187–90.
Kienhorst, C. W. M., deWilde, E. J., van den Bout, J. et al. (1990). Self-report suicidal behaviour in Dutch secondary education students. Suicide and Life Threatening Behaviour, 20, 101–12.
Kirkbride, J. B., Fearon, P., Morgan, C. et al. (2006). Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AESOP study. Archives of General Psychiatry, 63, 250–8.
Korn, M. L., Brown, S. L., Kotler, M., Gordon, M. & Van Praag, H. M. (1995). Biological aspects of suicide. In R. F. Diekstra, W. Gulbinat, I. Kienhorst & D. de Leo (eds.), Preventive Strategies on Suicide. Leiden: E. J. Brill, pp. 311–37.
Kramer, M., Vogel, W. & Dijohnson, C. (1989). Antidepressants in ‘depressed’ schizophrenic inpatients. A controlled trial. Archives of General Psychiatry, 46, 922–8.
Krausz, M., Muller-Thomsen, T. & Maasen, C. (1995). Suicide among schizophrenic adolescents in the long-term course of illness. Psychopathology, 28, 95–103.
Lester, D. (1989). Questions and Answers about Suicide. Philadelphia, PA: Charles Press.
Linehan, M., Goodstein, J., Nielsen, S. & Chiles, J. (1983). Reasons for staying alive when you are thinking of killing yourself: the Reasons for Living Inventory. Journal of Consulting and Clinical Psychology, 51, 276–86.
Lipschitz, A. (1995). Suicide prevention in young adults (age 18–30). Suicide Prevention: Toward the Year 2000, 25, 155–70.
Mann, J. J., Apter, A., Bertolote, J. et al. (2005). Suicide prevention strategies: a systematic review. Journal of the American Medical Association, 294, 2064–74.
Mann, J. J., Currier, D., Stanley, B. et al. (2006). Can biological tests assist prediction of suicide in mood disorders? International Journal of Neuropsychopharmacology, 9, 465–74.
Martin, G. (1995). Youth Assessment Checklist. Bedford, South Australia: Flinders Medical Centre, Child and Adolescent Mental Health Service.
McGorry, P. D., Chanen, A., McCarthy, E. et al. (1991). Post-traumatic stress disorder following recent-onset psychosis: an unrecognized post-psychotic syndrome. Journal of Nervous and Mental Disease, 179, 253–8.
McGorry, P. J., Henry, L. & Power, P. (1998). Suicide in early psychosis: could early intervention work? In R. Kosky & H. Eshkevari (eds.), Suicide Prevention: The Global Context. New York: Plenum Press, pp. 103–10.
McKenzie, N., Landau, S., Kapur, N. et al. (2005). Clustering of suicides among the mentally ill: suicide may be contagious. British Journal of Psychiatry. 187, 476–80.
Melle, I., Johannesen, J. O., Friis, S. et al. (2006). Early detection of the first episode of schizophrenia and suicidal behaviour. American Journal of Psychiatry, 163, 800–4.
Meltzer, H. Y. (2005). Suicidality in schizophrenia: pharmacologic treatment. Clinical Neuropsychiatry: Journal of Treatment Evaluation, 2, 76–83.
Meltzer, H. & Okayli, G. (1995). The reduction of suicidality during clozapine treatment in neuroleptic resistant schizophrenics. American Journal of Psychiatry, 152, 183–90.
Micallef, J., Fakra, E. & Blin, O. (2006). Intérêt des antidépresseurs chez le patient schizophrène présentant un syndrome dépressif. [Use of antidepressant drugs in schizophrenic patients with depression; Abstract in English.] L'Encéphale, 32, 263–9.
Milne, S., Matthews, K. & Ashcroft, G. W. (1994). Suicide in Scotland 1988–1989. Psychiatric and physical morbidity according to primary care case notes. British Journal of Psychiatry, 165, 541–4.
Mortensen, P. & Juel, K. (1993). Mortality and causes of death in first admitted schizophrenic patients. British Journal of Psychiatry, 163, 183–9.
Mukherjee, S., Sackeim, H. & Schur, D. (1994). Electroconvulsive therapy of acute manic episodes: a review of 50 years experience. American Journal of Psychiatry, 151, 169–76.
Munk, J. P. (1999). Has deinstitutionalization gone too far? European Archives of Psychiatry and Clinical Neuroscience, 249, 136–43.
Nordentoft, M., Jeppesen, P., Abel, M. et al. (2002). OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial. British Journal of Psychiatry, 181(Suppl 43), s98–106.
O'Carrol, P., Berman, A., Maris, M. et al. (1996). Beyond the tower of Babel: a nomenclature for suicidology. Suicide and Life-Threatening Behaviour, 26, 237–52.
Orvaschel, H., Puig-Antich, J., Chambers, W. J., Tabrizi, M. A. & Johnson, R. (1982). Retrospective assessment of pre-pubertal major depression with the Kiddie-SADS-E. Journal of the American Academy of Child and Adolescent Psychiatry, 21, 392–7.
Palmer, B. A., Pankratz, V. S. & Bostwick, J. M. (2005). The lifetime risk of suicide in schizophrenia: a reexamination. Archives of General Psychiatry, 62, 247–53.
Parker, G., Roy, K., Hadzi-Pavlovic, D. & Pedic, F. (1992). Psychotic depression: a meta-analysis of physical treatments. Journal of Affective Disorders, 24, 17–24.
Pearce, C. & Martin, G., (1994). Predicting suicide attempts among adolescents. Acta Psychiatrica Scandinavica, 90, 324–8.
Perälä, J., Suvisaari, J., Saarni, S. I. et al. (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry, 64, 19–28.
Perris, C. (1994). Cognitive therapy in the treatment of patients with borderline personality disorders. Acta Psychiatrica Scandinavica, 89 (Suppl), 69–72.
Power, P. (1999). Outpatient Commitment: Is it Effective. MD Thesis, University of Melbourne.
Power, P. (2004). Suicide prevention in first episode psychosis. In P. McGorry & J. Gleeson (eds.), Psychological Interventions in Early Psychosis. Chichester: John Wiley, pp. 175–89.
Power, P., Elkins, E., Adlard, S. et al. (1998). An analysis of the initial treatment phase of first episode psychosis. British Journal of Psychiatry, 172 (Suppl 33), s71–7.
Power, P., Bell, R., Mills, R. et al. (2003). Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Australian and New Zealand Journal of Psychiatry, 37, 414–20.
Power, P., McGuire, P., Iacoponi, E. et al. (2007). Early intervention in the real world: Lambeth Early Onset (LEO) and Outreach and Support in South London (OASIS) service. Early Intervention in Psychiatry, 1, 97–103.
Proctor, S. E., Mitford, E. & Paxton R. (2004). First episode psychosis: a novel met